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BREAST CANCER
Breast Cancer Epidemiology
Globally, cancer is a major health problem amongst men and women with 
incidence rates of 205 and 165 per 100,000 individuals, respectively. In women, 
breast cancer (BC) is the most common cancer type and is responsible for 25% 
of the cancer incidence rate with an estimated 1.67 million new cases diagnosed 
in 2012 worldwide. Concerning mortality, BC is the 5th cause of cancer related 
death worldwide (1). In 2012, BC incidence and mortality were 13,895 and 3,163, 
respectively, in the Netherlands (2).
BC Screening and Diagnosis
In view of the high incidence rate of BC and in attempt to decrease mortality 
rate, mammography was introduced as a screening method for early detection. 
Mammography applies low energy x-rays to detect abnormal breast lesions. In 
the Netherlands, women between the age of 50-75 years are invited for screening 
by mammography biennially since 1988. Multiple studies reported a decrease in 
BC mortality due to screening mammography programs (3,4). However, mammo-
graphy has several limitations leading to a significant amount of false positive 
and false negative findings. False positive and false negative rates ranging from 
65.2-121.2 and 1.0-1.5 per 1,000 women depending on age, respectively, were 
reported (5). Major limiting factors include higher breast density, younger age 
and pre-menopausal status, which all lead to an increased risk of false positive 
and particularly false negative findings. Especially high breast density is associ-
ated with increased risk of false negative diagnoses. False positive results lead 
to unnecessary additional tests, which apart from costs may cause psychological 
harm (6,7). False negative results on the other hand can cause delay in diagnosis 
and treatment, negatively impacting the course of the disease (6). When a suspi-
cious lesion is detected by mammography, additional imaging is required such as 
ultrasound (US) and/or magnetic resonance imaging (MRI).
US uses high frequency sound waves to acquire an image of the breast. Previous 
studies have shown that supplemental US is more sensitive for lesion detection 
in women with dense breast tissue compared to mammography alone (3-4.6 more 
lesions are detected per 1000 supplemental US examinations) (8). Furthermore, 
US is often used to distinguish fluid filled (e.g. cysts) from solid lesions.
MRI uses radiofrequency waves in a strong magnetic field to create a detailed 
image of tissue structures inside the body, including the breasts. Breast MRI is 
nowadays incorporated in daily breast radiology. One indication for breast MRI is 
screening of women with high risk of developing BC, due to a genetic predisposi-
tion or due to chest radiation received at young age (9). The sensitivity of MRI 
is independent of the breast density and about twice as high as the sensitivity of 
mammography (10).
Although the above imaging methods are used for early detection of BC, diagnosis 
is based on histopathologic examination. Detected breast lesions are biopsied and 
the retrieved tissue is examined for the presence of malignancy.
BC Subtypes
BC is a very heterogeneous disease and consists of multiple biological subtypes. 
Four major BC subtypes are identified based on gene expression patterns: luminal 
A, luminal B, human epidermal growth factor receptor 2 (HER2)-driven and basal 
like tumors (11-14). Amongst other molecular factors, these subtypes can to 
some extent be identified by estrogen receptor (ER), progesterone receptor (PR) 
and HER2 expression, markers that majorly impact the treatment and prognosis 
of the disease. 
Next to the subtype specific treatments for BC that will be discussed below, local 
therapies in the form of surgery and radiation therapy are therapeutic methods 
applied independent of the BC subtypes. Clinically the presence or absence of 
subtype specific markers, determined by immunostaining and/or in situ hybridi-
zation, is used as a surrogate in order to identify BC subtypes after diagnosis.
Luminal BCs account for ±70% of all BCs and are ER- and/or PR-positive, with 
luminal A tumors having higher ER/PR expression than luminal B tumors. 
Furthermore, luminal A tumors are HER2-negative, while luminal B tumors have 
variable HER2 expression. In addition, luminal B tumors have a higher prolifera-
tion index rate, assessed by Ki-67, and often have a higher histological grade. 
In comparison to the other subtypes, this BC subtype has the best prognosis. 
Luminal A tumors are treated with endocrine treatment, while luminal B tumors 
may benefit more from a combination of endocrine treatment and chemotherapy 
(anti-HER2 antibodies such as Trastuzumab in case of HER2-positivity). HER2-
driven BCs are usually ER- and/or PR-negative and always HER2-positive. 
Before the availability of HER2 blocking therapies, this BC subtype had a worse 
prognosis than that of luminal BCs. However, the prognosis of HER2-driven BCs 
has improved since the incorporation of anti-HER2 antibodies, resulting in a 
prognosis similar to that of luminal BCs. Basal-like tumors, accounting for 15% of 
the BCs, are the most aggressive subtype. These tumors are ER-, PR- and HER2-
negative and generally have a high proliferation rate and differentiation grade. 
Treatment usually consists of chemotherapy, as there are no other (targeted) 
therapy options. An overview of the BC subtypes is displayed in Figure 1.
Despite all available therapy modalities, 20-30% of the patients overall expe-
rience relapse which can consist of locoregional recurrence or metastatic disease 
(15). Unfortunately, metastatic disease is still incurable and an estimated 5-year 
survival rate of only 25% was reported for advanced disease (16). Approximately 
20% of ER-positive BC patients with metastatic disease show intrinsic resistance 
against first line anti-estrogen treatment and only 30-40% of patients respond 
to second and third line antihormonal therapy (17). Concerning Trastuzumab 
treatment, response rates of 11-26% have been reported for trastuzumab mono-
therapy in metastatic disease (18). Basal-like (or triple negative) BCs are more 
aggressive than other BCs and have an increased risk of distant recurrence and 
disease-associated mortality (19). Molecular targets for the latter-mentioned BC 
subtype are largely lacking and more research is needed to identify potential 
targets in order to develop more precise treatment strategies (20). 
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NUCLEAR MEDICINE-BASED IMAGING AND 
TREATMENT
Concepts Behind Nuclear Imaging and Treatment of Cancer
Since current imaging and therapy options for BC still have limitations, novel 
options are needed. One of the aims is to improve the survival rate by enhancing 
BC detection. Within nuclear medicine, systemically administered radiopharma-
ceuticals are used for imaging and treatment of various cancer types. These radio- 
pharmaceuticals are either radionuclides alone or radionuclides coupled to a 
targeting molecule. Photons emitted during radioactive decay of radionuclides 
within in the body can be detected for imaging purposes. For single-photon 
emission computer tomography (SPECT), single photons from γ-emitting radio-
nuclides are detected at multiple positions around the longitudinal axis of the 
patients by rotating scintillation cameras, equipped with parallel-hole or pin-hole 
collimators (22). The acquired data are reconstructed using an appropriate 
reconstruction algorithm of which several are available (23). Other than SPECT 
imaging, positron emission tomography (PET) applies positron-emitters. Pairs of 
photons (with an energy of 511 keV each) generated after annihilation of a positron 
and an electron are detected and used for image acquisition. These photons travel 
in opposite direction and are detected by a series of opposing detectors installed 
in a ring-like pattern (24). This mechanism of PET imaging allows the detection 
of a higher number of events, resulting in a higher sensitivity and spatial resolu-
tion than those retrieved by SPECT imaging (25). The events measured by the 
detectors during PET imaging are combined and used to reconstruct a 3D image. 
Both SPECT and PET imaging on their own provide very little information on 
Figure 1. Breast cancer subtypes and associated characteristics. Figure is adapted from (21).
anatomical reference and these methods are preferably and widely combined with 
computed tomography or MRI (26).
For nuclear imaging of BC, dedicated cameras have recently been developed 
which are currently under investigation (27). These dedicated cameras have a 
restricted field of view which results in a higher sensitivity, especially for small 
tumors, compared to whole body scanners (28). Dedicated cameras can however 
only visualize primary lesions (and in some cases regional lymph node metas-
tases), hence these cameras are not suitable for imaging of distant metastatic 
disease. 
Concerning therapy, in nuclear medicine therapeutic radionuclides can be used 
to eradicate cancer cells. Table 1 shows an overview of several radionuclides for 
SPECT and PET imaging and for radionuclide therapy.
Nuclear Medicine in BC
Concerning nuclear imaging of BC, multiple approaches are being applied. A 
few of these approaches are based on accumulation of radioactivity in cancer 
cells because of their high proliferation rate. 99mTc-Sestamibi, 201Tl and 99mTc- 
Tetrofosmin (of which 99mTc-Sestamibi is studied the most) accumulate in mito-
chondria, which are abundantly present in BC cells, and 18F-fludeoxyglucose 
(FDG) is taken up by cancer cells because of their high metabolic rates. These 
methods lack specificity however, which might lead to false positive scans. In the 
case of 99mTc-Sestamibi, false positive scans have e.g. been reported for sites of 
prior surgical intervention, inflammation and some benign breast diseases (31). 
18F-FDG PET scans may show increased uptake in non-cancerous lesions such 
as inflammatory and infectious lesions, brain, muscle and brown adipose tissue 
(32). In line with this, clinical studies evaluating the role of 99mTc-Sestamibi for 
BC imaging resulted in high sensitivity, but low specificity (33). Concerning 
18F-FDG breast scans, studies demonstrated high sensitivity and specificity for 
pT2 tumors, while a high rate of false negatives was reported for pT1 tumors 
(34). In agreement with this, sensitivity was low for small, non-invasive, low 
grade and non-palpable tumors (31,32,35).
A more specific method for cancer imaging is the use of molecular expression 
patterns for targeting of cancer cells. These targeted imaging methods are already 
successfully used for other cancer types and may be beneficial for BC as well.
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Targeted Nuclear Imaging and Therapy/Theranostics in Oncology
Targeted nuclear imaging and treatment of cancer is based on targeting of 
biomarkers overexpressed on cancer cells using radioligands. These radio-
ligands consist of a targeting agent (e.g. chemically synthesized peptide analog of 
a natural ligand, antibodies, nanobodies etc., with high affinity for the biomarker), 
which can be coupled to a chelator (directly or via a linker) that can stably 
complex a radionuclide (Figure 2A). Depending on the radionuclide that is incor-
porated in or coupled to the radioligand, targeted imaging and/or therapy can 
be performed using the same ligand, the so-called theranostic approach. With 
regard to radionuclides used for theranostic agents, 3 different classes can be 
used: radionuclides that emit both imaging photons and therapeutic particles, 
radionuclide pairs consisting of the same element or radionuclide pairs derived 
from different elements (Table 2). The use of theranostic agents offers a person-
alized approach for disease management by enabling diagnosis/staging, therapy, 
and monitoring of treatment response (Figure 2B). Hereby, only patients that 
show sufficient accumulation of radioligands in cancer lesions on scans are 
selected for therapy using the same ligand labeled with a therapeutic radio- 
nuclide. Besides, this enables treatment adjustment according to results of 
interim monitoring. Currently, targeted nuclear imaging and therapy is success-
fully used in the clinic for imaging and treatment of e.g. neuroendocrine tumors 
by targeting somatostatin receptors (SSTR) overexpressed on neuroendocrine 
tumor cells using SSTR-targeting radioligands, which are successfully used for 
imaging, therapy and response evaluation (36). Since biomarkers for nuclear 
targeting of BC have been identified, the application of radioligands for thera-
nostic purposes may have the potential to also improve BC patient care.
Table 1. Continued. 
Therapeutic radionuclides
α-emitting radionuclides
Radionuclide T1/2 (h) Decay mode 
(%)
Eα (keV) (%) Production Mode
213Bi 0.76 α (2)
β- (98)
5558 (0.18)
5875 (1.96)
225Ac/213Bi Generator
225Ac 240 α (100) 5637 (4.4)
5724 (3.1)
5732 (8.0)
5790.6 (8.6)
5792.5 (18.1)
5830 (50.7)
229Th/225Ac Generator
Cyclotron
T1/2=half-life, E=energy, IT=isomeric transition, EC=electron capture. 
Table is adapted from (29). Information on α radiation is based on (30).
SPECT radionuclides
Radionuclide T1/2 (h) Decay mode 
(%)
End-pointis Eγ 
(keV) (%)
Production Mode
99mTc 6.02 IT (100), γ 141 (91) 99Mo/99mTc generator
111In 67.9 EC (100)
Auger, γ
171 (90)
245 (94)
Cyclotron
67Ga 78.26 EC (100)
Auger, γ
93 (39)
185 (21)
300 (17)
Cyclotron
123I 13.2 EC (100), γ 159 (84)
27 (71)
31 (16)
Cyclotron
PET radionuclides
Radionuclide T1/2 (h) Decay mode 
(%)
End-point Eβ+ 
(keV) (%)
Production Mode
18F 1.83 β+ (97)
EC (3)
634 (97) Cyclotron
68Ga 1.13 β+ (89)
EC (11)
1.899 (88) 68Ge/68Ga generator
64Cu 12.7 β+ (19)
β- (40)
EC (41)
656 (18) Cyclotron
86Y 14.7 β+ (33)
EC (66)
1.221 (12)
1.314 (17)
1.409 (14)
1.474 (9)
1.545 (6)
1.988 (4)
2.242 (13)
Cyclotron
124I 99.6 EC (77)
β+ (23)
3.160 (24)
2.556 (25)
2.137 (11)
1.535 (12)
866 (11)
Cyclotron
Therapeutic radionuclides
β-emitting radionuclides
Radionuclide T1/2 (h) Decay mode 
(%)
End-point Eβ- 
(keV) (%)
Production Mode
90Y 64.1 β- (100) 2.280 (99.99) 90Sr/90Y generator
177Lu 161 β-, γ 498 (79)
385 (9)
177 (12)
Reactor
67Cu 61.9 β- (100), γ 392 (57)
484 (22)
577 (20)
Accelerator
Table 1. Overview of some clinically relevant radionuclides for SPECT, PET and radionuclide 
therapy
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TARGETED NUCLEAR IMAGING OF BC
Molecular Targets
Multiple targets have been identified for nuclear imaging of BC, including 
the SSTR subtype 2 (SSTR2), the gastrin releasing peptide receptor (GRPR), 
hormone receptors and HER2. In our review (Chapter 3) we discuss targets 
currently under investigation for nuclear imaging of BC as well as their potential. 
Figure 2. A) Representation of radioligands for targeted nuclear imaging and therapy. 
Biomarkers overexpressed on tumor cells are targeted using radioligands that contain a 
binding domain. This binding domain is in some cases coupled to a chelator, often via a 
linker. The chelator enables stable binding of a radionuclide. Depending on the radionuclide 
of choice, radioligands can be used for either imaging or treatment. B) The use of radioligands 
for theranostic purposes. Radiotracers coupled to imaging radionuclides are used to determine 
target expression and for diagnosis/disease staging. If tumor lesions are visualized, which 
demonstrates target expression, the same radiotracer coupled to therapeutic radionuclides 
can be used for therapy. Subsequently, treatment can be adjusted after interim monitoring 
which can be done by SPECT/PET scanning using the same radioligand coupled to imaging 
radionuclides.
Radionuclides that can be used for both imaging and therapy
Radionuclide T1/2 (d) Imaging
γ Energy
keV (%)
Therapy 
Therapeutic particle(s) 
(Average keV)
47Sc 3.35 159 (88) β- (162)
67Cu 2.58 186 (40) β- (141)
67Ga 3.26 93 (40)
184 (24)
296 (22)
15 Auger (0.04-9.5 ((572%))
10 CE (82-291 (30%)
111In 2.80 171 (91)
245 (94)
6 Auger (0.13-25.6 ((407%))
12 CE (144-245 (21%))
131I 8.0 365 (82) β- (182)
177Lu 6.71 208 (11)
113 (6.4)
β- (134)
Theranostic pairs consisting of different isotopes of the same element  
for imaging and therapy
Radionuclide 
Pair
T1/2 (d) Imaging
β+ Energy
keV (%)
Therapy 
Therapeutic particle(s) 
(Average keV)
44Sc/47Sc 2.4/3.35 511 (94) β- (162)
64Cu/67Cu 0.53/2.6 511 (35) β- (141)
68Ga/67Ga 0.05/3.26 511 (176) 15 Auger (0.04-9.5 ((572%))
10 CE (82-291 (30%)
86Y/90Y 0.61/2.7 511 (66) β- (935)
124I/131I 4.2/8.0 511 (44) β- (182)
Theranostic pairs consisting of radionuclides from different elements  
for imaging and therapy
Imaging radionuclide Therapeutic radionuclide
68Ga/111In 177Lu/90Y/213Bi
99mTc 186/188Re
Table 2. Examples of radionuclide (pairs) used for theranostic purposes
T1/2=half-life, CE= conversion electrons.
Part of the table is adapted from (37). Data on 177Lu is adapted from (30).
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Figure 3. A) Key functions of SSTRs, GRPR and CXCR4 in cancer cells. In contrast to 
GRPR and CXCR4 that elicit a pro-tumoral response (amongst other factors stimulating 
proliferation and survival) upon binding of their ligands, activation of SSTRs results in 
anti-tumoral response by inducing apoptosis and inhibiting proliferation and secretion of 
hormone such as growth factors. B) Organs in which SSTR, GRPR and CXCR4 malignancies 
commonly occur.
In this thesis the main focus will be on application of radioligands targeting SSTR2 
and GRPR for imaging and treatment of BC. In Chapters 2 and 3 the relevance of 
a third target, C-X-C chemokine receptor 4 (CXCR4), will be discussed as well.
SSTR
SSTRs are G protein-coupled receptors with 7 transmembrane spanning 
domains, of which 5 subtypes exist (SSTR1-5). They are differentially expressed 
throughout the central nervous system and the periphery (including kidneys, 
pancreas and gastrointestinal tract). Binding of SSTRs to their natural ligands, 
somatostatin (SST)-14 and SST-28, results in a broad range of biological effects 
including inhibition of endocrine and exocrine secretions (including growth 
hormone, thyroid stimulating hormone, gastrointestinal hormones, pancreatic 
enzymes and neuropeptides), and bowel motility and has an anti-proliferative 
effect (Figure 3A) (38,39). Although all SSTR subtypes can be found in several 
human cancers, SSTR2 is most widely expressed, followed by SSTR3 and SSTR4. 
Figure 3B shows an overview of the organs in which SSTR-expressing malignan-
cies commonly occur.
Since binding of SST to the SSTR results in an anti-proliferative effect, treatment 
with SST analogs became interesting for tumor targeting and multiple SST 
analogs were synthesized for this purpose (40). An example of such a SST analog 
is octreotide, which is currently approved by the U.S. Food and Drug Administra-
tion (FDA) for treatment of acromegaly, carcinoid tumors and vasoactive intes-
tinal peptide tumors. The observation that the success of SST analog treatment 
was dependent on the density of SSTRs, led to investigations with radiolabeled 
SST analogs for imaging purposes. The first radiolabeled SST analog tested for 
imaging in patients was 123I labelled Tyr3-octreotide (41). Since then, the success 
of radiolabeled SST analogs has led to major developments with the aim of 
improving this nuclear medicine based approach. An overview of the develop-
ments regarding SST radiotracers is described in a review by Theodoropoulou 
et al. (42) of which a summary is given here. Following 123I-Tyr3-octreotide, 
111In-DTPA-octreotide (also called 111In-pentetreotide or OctreoScan) was 
developed and FDA-approved for SPECT imaging of SSTR2-expressing malignan-
cies. 99mTc-depreotide, a 99mTc labeled SST analog was also developed for SPECT 
imaging. The use of 99mTc labeled SST analogs has a few advantages over 111In 
labeled SST analogs, since 99mTc is more ideal for imaging (the lower energy of 
99mTc enables higher dose administration, resulting in an increase in image quality 
and lesion detection), more readily available and more cost efficient compared 
to 111In. The next step in the development of SSTR radioligands was the use 
of the chelator, DOTA, resulting in radiotracers like 111In labeled DOTA-Tyr3- 
octreotide (DOTATOC), DOTA-lantreotide and DOTA-Tyr3-octreotate (DOTA-
TATE). The above-mentioned SST analogs are primarily focused on targeting 
of SSTR2. 111In-DOTA-1-Nal3-octreotide (DOTANOC), also used for SPECT 
imaging, is able to bind to SSTR2, SSTR3 and SSTR5, potentially yielding a 
higher tumor uptake, but also higher uptake in normal organs. The use of DOTA 
as a chelator, has offered the opportunity to label SST analogs with different 
radionuclides, such as 68Ga for PET imaging and 90Y or 177Lu for therapeutic 
Chapter 1 General Introduction and Thesis Outline
2322
1
purposes. Examples are 68Ga-DOTATATE and 177Lu-DOTATATE/90Y-DOTATOC 
that are widely used for PET imaging and radionuclide therapy, respectively. 
SSTR radioligands labeled to other PET radionuclides such as 18F are currently 
not yet available in the clinic but are being investigated preclinically. The above-
mentioned SST analogs are all receptor agonists, which are internalized upon 
binding to the target receptor. Recently, SST analogs with antagonistic proper-
ties have been developed for tumor targeting. Examples include 177Lu-DOTA-
JR11 and 177Lu-DOTA-BASS. Only few studies have been performed with these 
compounds yet, but the SSTR antagonists has been reported to be superior to the 
clinically used 177Lu-DOTATATE for tumor targeting (43,44). Figure 4 shows the 
mechanism of action of radiotracers with agonistic and antagonistic properties.
Overexpression of SSTR, mainly SSTR2, has been reported on 15-75% of BC 
cells (45). Following the success of SSTR-targeted imaging and treatment of 
neuroendocrine tumors, studies investigating SSTR-mediated nuclear imaging 
in BC have been performed in the past. Results of these studies were variable 
and a summary of these studies is reported in our second review in Chapter 5. 
To date, SSTR-mediated nuclear imaging is not used clinically in BC patients, 
because of the limited and variable evidence of clinical utility from clinical studies. 
However, since our understanding of BC as well as nuclear medicine techniques 
and radiotracers have improved remarkably over the past decades it is worth 
reinvestigating this biomarker as a target for nuclear imaging. Regarding therapy, 
radiolabeled SST analogs have been tested scarcely in patients with neuro- 
endocrine BCs (neuroendocrine BC is a type of BC with morphologic neuro-
endocrine features and tumor cells that express neuroendocrine markers) (46), 
but not in the remaining BC patients.
GRPR
The GRPR or BB2 is a G protein-coupled receptor with 7 transmembrane 
spanning domains. The receptor is part of the mammalian bombesin receptor 
family. When bound to its ligands, gastrin releasing peptide (GRP) and to a lesser 
extent neuromedin B, a signaling cascade is initiated which results in a broad 
spectrum of biological and pharmacological responses. These include release of 
neurotransmitters and hormones from various organs, smooth muscle contrac-
tion in the gastrointestinal tract and urogenital system, and movement of the 
digestive system (48). The GRPR can be found widely distributed across the 
central nervous system and peripheral tissues such as the gastrointestinal 
tract, the pulmonary, urogenital, reproductive and hematopoietic systems and 
on endocrine glands, and immune cells (49). Overexpression of the GRPR has 
been reported on a wide range of cancers such as breast, prostate and lung 
cancer, head and neck squamous cell carcinoma, cancer of the gastrointestinal 
tract, and brain and renal cancer (Figure 3B) (48). It was reported that activa-
tion of the GRPR in cancer cells affects growth and differentiation (Figure 3A). 
With regard to BC, according to literature approximately 62-74% of the breast 
tumors show high density GRPR expression, making this biomarker an attrac-
tive candidate for receptor targeted nuclear imaging and therapy (50-53). 
A substantial number of different GRPR radioligands with agonistic and anta-
gonistic properties have been developed over the years. These GRPR radioligands 
have mostly been studied for application in prostate cancer; these investigations 
expanded knowledge on these radiotracers and led to the development of tracers 
with improved targeting properties. A review by Sancho et al. (54) provides an 
overview of studies performed with GRPR radioligands, agonists as well as anta-
gonists. Different structures, linkers, spacers and chelators have been tested in 
order to develop compounds with optimal tumor targeting properties and optimal 
tumor to background ratios. Examples of GRPR radioligands that were evaluated 
clinically include the GRPR agonists and antagonists 99mTc-Demobesin 4, 99mTc-
HYNIC-[Lys3]-BN, 99mTc-RP527, 68Ga-NOTA-Aca-BBN(7-14), 64Cu-CB-TE2A-
AR06, 68Ga-RM2/68Ga-BAY 86-7548, 68Ga-SB3 and 68Ga-NeoBOMB1 (55-64) (the 
latter is a novel GRPR antagonist of which preclinical evaluation is described in 
Chapter 9 of this thesis). Clinical therapeutic studies using GRPR radioligands 
are limited but preclinical studies using 177Lu-JMV4168, 177Lu-DOTA-gluBBN and 
177Lu-RM2/177Lu-BAY 1017858 (65-67) reported promising results. Concerning 
therapy, a clinical study using the GRPR agonist 177Lu-AMBA reported side 
effects and thus for this purpose radiolabeled GRPR antagonists may be a much 
better choice (68). 
Figure 4. Mechanism of action of radiotracers with agonistic and antagonistic properties. 
Although radiotracers with agonistic properties are internalized resulting in accumulation of 
radioactivity in cells, it has been reported that radiotracers with antagonistic properties can 
target more binding sites resulting in enhanced tumor targeting (47).
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CXCR4
CXCR4/fusin or CD184 is an α-chemokine receptor expressed in a variety of 
organs e.g. lymphatic tissues, thymus, brain, spleen, stomach and the small 
intestine (69). Upon binding of its ligand, stromal derived factor 1 (SDF1) also 
called CXCL12, signaling pathways are activated resulting in various biological 
responses that influence cell survival, migration, proliferation, chemotaxis and 
adhesion (Figure 3A) (69). Overexpression of CXCR4 has been reported on a 
wide variety of cancers including BC (Figure 3B). This overexpression can poten-
tially be attributed to hypoxia or oncoprotein induced transcription, as well as 
other factors e.g. VEGF induced expression, and altered regulation of CXCR4 
independent of effects on transcription or translation such as post-translational 
ubiquitination (70). High levels of CXCR4 were found in primary breast tumors 
and regional and distant metastases but not in healthy breast tissue (71). In 
line with this, expression of CXCR4 and its ligand were positively associated 
with development of metastatic disease and poor prognosis (69). Based on this 
knowledge, targeting of CXCR4 with radiotracers for theranostic purposes can 
potentially benefit BC patients, especially those with aggressive or advanced 
disease. Multiple CXCR4-targeting radiotracers have been synthesized, including 
111In-DTPA-Ac-TZ14011, 99mTc-O2-AMD3100, 67Ga-AMD3100, 11C-AMD3465, 
68Ga-pentixafor and 68Ga-NOTA-NFB (72-77). 68Ga-pentixafor, the CXCR4 radio-
tracer studied most extensively, has been investigated in preclinical and clinical 
studies for imaging and therapeutic applications in acute myeloid leukemia, 
multiple myeloma, glioblastoma and small cell lung cancer patients (78-82).
The Potential of Targeted Nuclear Medicine Techniques in BC
Targeted-nuclear imaging is not suited for nationwide BC screening programs, 
as the success rate is dependent on sufficient target expression, the relatively 
high costs and the associated radiation burden. This imaging method, however, 
can offer a more sensitive and specific option for visualization of primary and 
metastatic BC lesions in other situations (Figure 5). Currently, mammography 
is the standard imaging method used for follow-up surveillance of BC patients 
with resected or treated tumors (83). With the knowledge that mammography 
has several limitations regarding BC detection, there is room for improvement. 
Tumor material (e.g. from biopsies routinely performed for diagnosis) can be used 
to determine target expression after which imaging can be performed to monitor 
disease recurrence. Furthermore, receptor positive tumors can be imaged pre- 
and post-therapy to select patients for therapy as well as to determine efficacy 
of treatment. Whole body SPECT or PET imaging can be used for BC staging. 
Concerning regional lymph node staging, sentinel lymph node biopsy has replaced 
axillary lymph node dissection in lymph node negative patients. Besides other 
adverse events, axillary lymph node dissection is still associated with substantial 
morbidity (84,85). Sentinel lymph node biopsy is associated with less adverse 
events than axillary lymph node dissection, but this method also has complica-
tions (86,87). Targeted nuclear imaging in patients with positive primary tumors 
might potentially identify malignant lesions in the lymph node in a non-invasive 
way, sparing sentinel lymph node biopsy and/or axillary lymph node dissection.
Radiotracers targeting biomarkers on BC can also be used to perform pre- 
operative imaging for the purpose of surgical planning. Another benefit of the use 
of radiotracers is the option to use the radiotracers for intra-operative guidance, 
whether or not in combination with optical imaging. After injection of the radio-
tracer, γ-probes can be used during surgery to detect radioactivity emitted from 
the tumor, which guide the surgeon towards the area where the lesion is localized. 
This can also be of benefit for intra-operative guidance during lymph node dissec-
tion, potentially resulting in sparing of unaffected lymph nodes.
Using the theranostic approach, if targeting of a tumor lesion results in a positive 
SPECT or PET scan, radiotracers labeled with therapeutic radionuclides can be 
applied for treatment of the disease. In this case expression of biomarkers for 
tumor targeting can be determined in a non-invasive way and therapy selection 
takes place in a personalized manner. Targeted radionuclide therapy can especially 
be beneficial for metastatic disease, since metastases are often not resectable 
and currently available systemic therapy options can cause severe side effects or 
are no longer available after multiple lines of therapy. Furthermore, response to 
therapy can be closely monitored and therapy can be adjusted according to patient 
needs.
Figure 5. Potential applications for radiotracers targeting the SSTR, GRPR and CXCR4 in 
breast cancer. 
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THESIS OUTLINE
This thesis described the application of radiopharmaceuticals for theranostic use 
in BC with the aim of improving imaging and treatment of the disease. Chapter 2 
reviews the targets currently under investigation for nuclear imaging of BC.
Since BC is a very heterogeneous disease characterized by different subtypes 
with distinctive molecular patterns, it is important to identify the subtypes of 
BC that may benefit from application of radiotracers targeting e.g. SSTR2, GRPR 
or CXCR4. In Chapter 3 we describe the clinical relevance of targeting SSTR2, 
GRPR and CXCR4 by measuring mRNA expression in primary breast tumors 
and correlated this with important clincopathologic and biological factors and 
prognosis. Since the application of these radiotracers might especially be benefi-
cial for metastatic disease, we also compared SSTR2, GRPR and CXCR4 mRNA 
expression in 60 primary breast tumors and paired regional or distant metas-
tases, as described in Chapter 4.
Chapter 5 reviews previous studies on SSTR2-mediated nuclear imaging and 
the potential benefit of developments in the field of nuclear medicine regarding 
SSTR-mediated imaging of BC. One such a development is the use of radiolabeled 
SSTR antagonists that showed enhanced tumor targeting for imaging purposes in 
neuroendocrine tumors compared to the clinically successfully used agonists. In 
Chapter 6 we describe the comparison of a radiolabeled SSTR agonist and anta-
gonist in human BC specimens and a BC mouse model to investigate whether 
the enhanced binding observed in neuroendocrine tumors can be of benefit for 
BC targeting as well. As a next step, the use of radiolabeled SSTR agonists and 
antagonists for therapeutic purposes was compared in an SSTR-expressing lung 
cancer mouse model to determine whether the observed enhanced binding could 
also be translated to therapeutic purposes, as described in Chapter 7.
In the next section, our research has focused on the application of radioligands 
targeting the GRPR. In Chapter 8, we describe the application of GRPR radio-
ligands for in vivo imaging and in vitro treatment of preclinical BC models. 
Chapter 9 describes the study of a novel GRPR radioligand that can be used for 
both imaging and treatment of GRPR-expressing tumors.
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ABSTRACT
Targeted nuclear imaging directed against molecular markers overexpressed on 
breast cancer (BC) cells offers a sensitive and specific method for BC imaging. 
Currently, a few targets such as estrogen receptor (ER), progesterone receptor 
(PR), human epidermal growth factor receptor 2 (HER2), somatostatin receptor 
(SSTR) and the gastrin releasing peptide receptor (GRPR) are being investigated 
for this purpose. Expression of these targets is BC subtype dependent and infor-
mation that can be gained from lesion visualization is dependent on the target; 
ER-targeting radiotracers e.g. can be used to monitor response to anti-estrogen 
treatment. Here we give an overview of the studies currently under investigation 
for targeted nuclear imaging of BC. Main findings of imaging studies are summa-
rized and (potential) purposes of lesion visualization by targeting these molecular 
markers are discussed. Since BC is a very heterogeneous disease and molecular 
target expression can vary per subtype, but also during disease progression or 
under influence of treatment, radiotracers for selected imaging purposes should 
be chosen carefully.
Keywords:
Breast cancer, Targeted Nuclear Imaging, SPECT, PET, GRPR, SSTR, ER, PR, 
HER2
INTRODUCTION
Breast cancer (BC) is the most common cancer in women worldwide. In 2012, 
167 million new BC cases were diagnosed and 522,000 people died of the disease 
(1). BC is highly heterogenic and comprises of multiple histological subtypes e.g. 
luminal A, luminal B, human epidermal growth factor 2 (HER2)-driven and basal-
like tumors (2). These histological subtypes are characterized by distinctive 
molecular patterns that play an important role in treatment and prognosis of the 
disease. The most important molecular tumor characteristics include estrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor 2 (HER2) expression (2). 
Our knowledge of BC has greatly expanded over the past years leading to new 
diagnostic and therapeutic methods, which positively influenced the mortality 
rate of the disease. The prognosis of metastatic BC is still poor, the estimated 
5-year survival being only 26% (3), and therefore early detection of the disease 
is essential. Although BC is finally diagnosed by histology, imaging methods are 
indispensable for detection of the disease. Mammography is used for nationwide 
screenings, in some cases supplemented with magnetic resonance imaging (MRI) 
or ultrasound. Unfortunately, these methods have limitations leading to false 
negatives and false positives (4,5). Concerning mammography, false positive and 
false negative rates ranging from 65.2-121.2 and 1.0-1.3 cases per 1,000 women 
per screening round have been reported, respectively (6). MRI and ultrasound 
have a higher sensitivity than mammography, but a low specificity was reported 
leading to a significant amount of false positives (7,8).
Imaging techniques that can provide information on molecular characteristics 
such as biomarker expression can have added value, especially in highly hetero-
geneous cancer types such as BC. To fulfill this purpose target-mediated nuclear 
imaging of BC is being investigated.
In nuclear medicine, such target-mediated imaging is successfully used in the 
clinical setting for imaging of e.g. neuroendocrine tumors (9,10). This approach 
uses the molecular expression pattern of tumors for targeting. Molecules 
(e.g. receptors, transporters and enzymes) overexpressed on cancer cells can 
be targeted with synthesized target ligands (e.g. peptide analogs, antibodies, 
affibodies and nanobodies) that bind to the target with high affinity and speci-
ficity (Figure 1A). 
Depending on the radionuclide that these peptide analogs are conjugated with, 
single-photon emission computed tomography (SPECT) or positron emission 
tomography (PET) can be performed. SPECT and PET are functional, highly 
sensitive nuclear imaging methods based on the detection of γ-photons directly 
or indirectly derived from γ-emitting (e.g. 111In) or positron emitting (e.g. 68Ga) 
radionuclides, respectively (Figure 1B+C). Combining SPECT or PET with 
computed tomography or MRI provides functional imaging information in combi-
nation with high resolution imaging of anatomical structures (11,12). In the 
review by Pattion et al. (13) and the paper by Ziegler et al. (14) the mechanisms 
of SPECT and PET imaging are described in more detail. With respect to BC 
imaging, dedicated SPECT and PET imaging devices have been developed that 
Chapter 2 Targeted Nuclear Imaging of Breast Cancer
3736
2
Figure 1. A) Schematic overview of targeted nuclear imaging. Ligands that can bind their 
targets overexpressed on BC cells can be coupled to a chelator, often via a linker. The chelator 
enables labeling with radionuclides that can be applied for imaging purposes. B+C) Drawing 
of the principles of radionuclides for SPECT and PET imaging. For SPECT imaging, 
γ-photons from radionuclides such as 111In are captured by detectors at multiple angles. For 
PET imaging positrons emitted from a radionuclide such as 68Ga interact with electrons 
which results in the production of 2 γ-photons. These photons are picked up at multiple angles 
by opposing detectors installed in a ring-like pattern. 
have a higher resolution and thus better diagnostic accuracy than whole body 
SPECT and PET systems (15,16).
In the past years a number of molecular targets for targeted nuclear imaging 
of BC have been identified and are currently under investigation: the somato-
statin receptor (SSTR), the gastrin releasing peptide receptor (GRPR), hormone 
receptors, HER2, folate receptor (FR), C-X-C chemokine receptor type 4 
(CXCR4), neuropeptide Y receptor Y1 (NPY1R), vascular endothelial growth 
factor A (VEGF-A) and vasoactive intestinal polypeptide receptor 1 (VIP-R1). 
In this review we describe these targets, discuss ongoing investigations and the 
prospects of BC targeted nuclear imaging. 
This review focuses on molecular targets mentioned above. Other radiotracers 
under investigation for nuclear imaging of BC including radiotracers that accumu-
late in cells due to (over)expression of functional transporters or higher metabo-
lism in BC cells are beyond the scope of this review.
SSTR-mediated BC Imaging
Receptor-mediated nuclear imaging is successfully used in neuroendocrine 
tumor patients by targeting SSTRs overexpressed on neuroendocrine tumor 
cells using SSTR binding radioligands. Next to neuroendocrine tumors, SSTR 
expression has also been reported on BC cells (17,18). Since radiolabeled peptide 
analogs targeting these receptors were available, several clinical studies have 
been performed targeting these receptors for imaging purposes. In our previous 
review we discussed earlier clinical studies (19-29) on SSTR-mediated imaging, 
showing very variable sensitivities and specificities ranging from 36-100% and 
22-100%, respectively (30). Limiting factors for successful BC targeting were low 
and heterogeneous SSTR expression, appropriate patient group selection, the 
use of radiolabeled peptide analogs with suboptimal receptor affinity and imaging 
equipment with low spatial resolution. For successful receptor-mediated imaging 
the expression of the target should be sufficient. Since low and heterogeneous 
SSTR expression was reported as a limiting factor for successful BC imaging, the 
question is whether SSTR is a suitable target for targeted nuclear BC imaging. 
However, another limiting factor of the previous studies was non-appropriate 
patient selection. Since BC is a very heterogeneous disease, SSTR expression 
between BC subtypes may vary. We and others showed higher SSTR expres-
sion in ER-positive BC compared to ER-negative BC, identifying ER-positive BC 
subtypes as the most suitable subtypes for SSTR-mediated imaging (31-34). If 
we only focus on these BC subtypes, which account for the majority of the breast 
tumors, SSTR-mediated BC imaging might be more successful. Furthermore, we 
studied SSTR expression of primary BCs versus SSTR expression of regional and 
distant metastases and demonstrated that these expression patterns are similar 
in the majority of cases (S. Dalm et. al., EANM annual meeting 2016, Barcelona 
Spain). Previous studies have been performed with radiolabeled octreotide, which 
has a lower SSTR affinity compared to the currently used radiolabeled somato-
statin analogs, including Tyr3-octreotate (35). In addition, lower spatial resolution 
planar imaging was used in earlier studies in comparison to currently available 
whole body and dedicated SPECT and PET techniques (11,15,16). Another 
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noteworthy recent development is the application of SSTR antagonists that 
have shown to be superior to SSTR agonists for neuroendocrine tumor targeting 
(36-40). This enhanced tumor targeting of SSTR antagonists was explained by the 
ability of receptor antagonists to bind more binding sites/receptors than receptor 
agonists (40). Since SSTR expression in BC was reported to be low and hetero-
geneous, the use of antagonists is promising in this respect. Cescato et al. (39) 
reported 11±4 times higher binding of an SSTR antagonist, 177Lu-DOTA-BASS, 
vs. the clinically used SSTR agonist 177Lu-DOTA-Tyr3-octreotate in 7 human BC 
specimens. We recently reported on enhanced binding of the SSTR antagonist 
DOTA-JR11 vs. the SSTR agonist DOTA-Tyr3-octreotate in 40 BC specimens as 
well as on superior imaging of a patient-derived xenograft mouse model using 
the radiolabeled receptor agonist vs. the antagonist (S. Dalm et.al., EANM annual 
meeting 2016, Barcelona Spain). 
Thus, previous studies on SSTR-mediated imaging in BC performed under 
suboptimal conditions were not convincing, but with recent improvements as 
mentioned above, this outcome might change. Additional studies that benefit 
from these recent developments are needed to investigate the true potential of 
SSTR-mediated BC imaging.
GRPR-mediated BC Imaging
The GRPR is a G-protein coupled receptor that is overexpressed on a high 
percentage of BCs. According to literature 62-96% of primary BCs express GRPR 
(41-44). Over the past years multiple GRPR targeting radioligands have been 
described to target GRPR-expressing cancers. Although the majority of these 
were studied in prostate cancer, these studies expanded our knowledge on prefer-
ential radioligand properties and uptake in other/background organs. One example 
is the preference for radiolabeled GRPR antagonist instead of agonists for tumor 
targeting, since similar to what was observed for SSTR radioligands, superior 
binding of GRPR antagonists vs. agonists was reported (45). Several preclinical 
studies have been performed demonstrating successful GRPR-mediated nuclear 
imaging using SPECT and PET in BC mouse models (44,46,47). In the study by 
Prignon et al. (46), GRPR-mediated imaging was compared to 18F-FDG PET for 
tumor visualization and disease monitoring after endocrine therapy, resulting in 
a preference for GRPR-mediated imaging. In line with this finding, we reported 
on high GRPR mRNA expression levels to be associated with improved progres-
sion free survival after first line tamoxifen (Nolvadex) treatment, indicating that 
GRPR has predictive value for response to tamoxifen treatment (31). In the same 
study we reported on higher GRPR expression in ER-positive tumors, identi-
fying specific BC patients suited for the application of radiotracers targeting this 
receptor. Furthermore, we recently reported that BC metastases from GRPR-
positive primary BCs also express GRPR, indicating that this imaging method 
can be applied in both primary and metastatic disease (S.Dalm et.al., EANM 
annual meeting 2016, Barcelona Spain). Although results obtained from pre- 
clinical studies are promising, to date only a few clinical studies have been 
performed on GRPR-mediated nuclear BC imaging. In a study by Maina et al. 
(48), 4/8 breast tumors were successfully visualized in patients with advanced 
disease using 68Ga-SB3, a radiolabeled GRPR antagonist. Scan outcomes were 
not related to ER expression in this study. Stoykow et al. (49) showed successful 
imaging in 13/18 patients with another 68Ga labeled GRPR-antagonist 68Ga-RM2. 
Positive imaging results were correlated with ER expression in accordance 
with our findings (31), confirming the potential of GRPR-mediated imaging in 
ER-positive patients.
Although more clinical studies on the application of GRPR radioligands for BC 
imaging are needed, current findings suggest that GRPR-targeted imaging might be 
used successfully for tumor detection and disease monitoring in ER-positive patients. 
Targeting of Hormone Receptors for Nuclear Imaging
The ER is not only interesting for therapeutic targeting options, but also for 
imaging. 18F-FES, a fluorinated estradiol (50), is the most extensively studied 
ER-targeting PET radioligand in clinical trials. Studies have focused on the 
potential of ER-mediated nuclear imaging for visualization of ER-positive primary 
and metastatic BC lesions as well as the ability of the radioligand to predict 
response to anti-estrogen treatment. Four clinical studies reported on sensitivity 
and specificity of the radiotracer for tumor visualization; 69-100% and 80-100%, 
respectively (51-54). Furthermore, 18F-FES imaging was used to predict response 
to anti-estrogen treatment prior to and in early phases of therapy. High uptake 
of 18F-FES prior to treatment indicates the presence of ER, which is necessary 
for a positive therapy response, while a decrease of 18F-FES uptake in early 
phases of treatment is an indication of successful treatment. Up to now positive 
and negative predictive values of 65% and 88%, respectively, were reported for 
pre-therapy scanning in relation to anti-estrogen treatment (55-58). Following 
these positive results, a substantial number of clinical trials using 18F-FES for 
BC imaging have started and are still ongoing. Combining current findings, the 
highest potential for 18F-FES use lies in determining ER expression of BC lesions 
(offering a less invasive method than immunostaining on biopsy material) and the 
use of the radiotracer to predict therapy response.
Because expression of the PR is an estrogen-regulated process, primary focus was 
on the development of ER-targeted radiotracers. However, ER-targeting radio-
tracers are not always efficient in patients treated with anti-estrogens since these 
molecules bind to the ER as well, rendering the receptor unavailable for radiotracer 
binding for e.g. interim monitoring of treatment efficacy. In this case PR-targeted 
radiotracers might be useful. Furthermore, similar to ER-status, PR-targeting radio-
tracers offer a less invasive method for determining PR status of breast lesions. 
A number of PR-targeting radiotracers have been synthesized and investigated 
in preclinical and clinical studies (59,60). The most successful PR-targeted radio-
tracer, 18F-FFNP, was used in a clinical pilot study successfully identifying 15/16 
PR-positive BCs (61). Previous research reported a decrease in PR expression 
after successful anti-estrogen treatment as a result of inhibition of ER activated 
pathways (62) and preclinical studies investigating the potential of 18F-FFNP PET 
imaging to predict response to anti-estrogen treatment have been performed with 
promising results (63,64). To date clinical data on PR-targeted nuclear imaging is 
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limited, but potential application of PR radioligands lies in the determination of PR 
expression and therapy assessment after endocrine treatment.
HER2-targeted Imaging
Similar to hormone receptors, HER2 expression in BC is not only of interest for 
therapeutic interventions but also for imaging. HER2 targeted nuclear imaging 
has been tested in preclinical and clinical studies using both radiolabeled mono-
clonal antibodies, radiolabeled affibodies and radiolabeled nanobodies. Mono-
clonal antibodies used for therapy of HER2-expressing BCs were radiolabeled 
with different radionuclides enabling both SPECT and PET imaging. Following 
positive results from preclinical studies, radiolabeled Trastuzumab was inves-
tigated in clinical studies for its ability to visualize HER2-positive BC lesions 
(65-71). The main purpose of studying HER2-targeted nuclear imaging was 
to predict response to treatment with Trastuzumab as well as other types of 
treatment, and to predict Trastuzumab related toxicity. The results of clinical 
studies were variable, limiting factors being poor visualization of liver metastases 
due to high background uptake in the liver and suboptimal imaging of HER2-
positive lesions if no unlabeled Trastuzumab was pre-administered. Furthermore, 
treatment of HER2 positive BC patients with a combination of Trastuzumab and 
paclitaxel or a heat shock protein 90 inhibitor NVP-AUY922 led to a decrease in 
uptake of radiolabeled Trastuzumab, indicating that the radiotracer can be used 
to assess response to these types of treatment (69,70). In contrast to antibodies, 
the smaller affibody molecules have relatively fast uptake and clearance rates, 
resulting in a lower radiation burden for patients and offering the opportunity to 
scan patients at earlier time points after administration of the radiotracer. Two 
clinical studies have been performed evaluating the use of radiolabeled HER2-
targeting affibodies in patients, which resulted in successful imaging of HER2-
positive BC lesions (72,73). However, similar to the results with radiolabeled 
Trastuzumab, imaging of liver metastases was difficult because of high physio-
logical uptake in the liver. Additionally, radiolabeled HER2-targeting nanobodies 
that can be labeled with different radionuclides (e.g. 18F, 68Ga and 99mTc) were 
synthesized and applied for HER2 visualization (74-76). The majority of these 
nanobodies are still under investigation in a preclinical setting, but a recent 
clinical study by Keyaerts and Xavier et al. (77) reported on the use of 68Ga-HER2- 
Nanobody in BC patients. Although not the primary goal of the study, both primary 
and metastatic BC lesions were successfully visualized. Furthermore, bio- 
distribution was favorable and no toxicity was reported. In addition, radiolabeled 
HER2 targeting RNA aptamers were synthesized for targeting HER2-positive BC 
lesions (78). These studies are still in preclinical setting and their advantage to 
HER2 targeting antibodies, affibodies and nanobodies remains to be established.
We conclude that HER2-targeted imaging can be applied to determine HER2 
expression of breast tumors and to monitor therapy responses.
Other Targets
Next to the above-mentioned targets there are some other interesting targets 
that are not extensively studied in BC (yet). Folate targeting radiotracers have 
been applied for BC imaging. Overexpression of the FR was associated with basal 
like BCs (79). In a clinical study successful SPECT imaging using a 99mTc labeled 
folate tracer was performed in 3/6 BC patients (80). Radiotracers targeting folate 
receptors are currently in clinical trials mainly focusing on targeting of ovarian 
cancer.
High expression of CXCR4 and its association with invasive disease was reported 
on primary and metastatic BC cells (81). Radiotracers targeting this receptor 
for imaging purposes were investigated in BC in a few preclinical studies and 1 
clinical study (82-84). The result of the clinical study using the CXCR4 radiotracer 
68Ga-pentixafor was disappointing and 18F-FDG seems superior to 68Ga-pentixafor 
for BC imaging. However, only few BC patients were included in this study and 
larger clinical studies are needed to accurately determine the value of CXCR4-
mediated BC imaging. Since CXCR4 mRNA expression was associated with 
ER-negative tumors (31), successful targeting would offer new imaging opportu-
nities for this patient group.
NPY1R expression has been reported on 85% of breast tumors and radiotracers for 
BC targeting have been synthesized (85-88). Highest expression of the receptors 
was reported on triple negative BCs (89). Up to date, proof of successful imaging 
using these radiotracers is very scarce, but the available data appears promising.
VEGF-A is an important protein involved in tumor angiogenesis. In BC over-
expression of VEGF-A was reported and associated with ER-negative tumors (90). 
Similar to HER2 antibodies, a VEGF-A targeting antibody used for antiangiogenic 
therapy named Bevacizumab, was radiolabeled for imaging of VEGF-A expres-
sion in tumors. To our knowledge one study was performed investigating 89Zr- 
Bevacizumab PET imaging, resulting in tumor visualization in 25/26 cases (91). 
In a preclinical setting downregulation of VEGF-A was visualized using 89Zr- 
Bevacizumab after treating BC cell lines with a heat shock protein 90 inhibitor 
(92). Although evidence is limited up to now, VEGF-A targeted nuclear imaging 
might be useful in the selection of patients suitable for VEGF-A targeted therapy 
and to monitor patients receiving treatment influencing VEGF-A expression.
Furthermore, overexpression of VIP-R on BC cell was reported in multiple studies 
and radiotracers targeting these receptors were synthesized (93,94). One pre-
clinical and one clinical study described the use of radiolabeled VIP-R radiotracers 
(18F-dVIP and 64Cu-TP3805, respectively) for imaging purposes in BC patients 
(95,96). In the clinical study by Thakur et al. (96) 20/20 BCs were successfully 
imaged. The authors hypothesize that VIP-R type 1-mediated imaging can be 
used for early and accurate detection of BC because it is overexpressed on all 
BC cells in early phases of the disease. However, the high uptake of VIP-R type 1 
targeted radiotracers in the lungs reported in studies performed in other cancer 
types should be kept in mind (97).
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The Use of Targeted Nuclear Imaging in BC
With the different targets discussed above being explored and available for target-
mediated nuclear imaging several questions remain. How can targeted nuclear 
imaging improve BC detection? What is the best target for targeted nuclear BC 
imaging? 
One target does unfortunately not suit all BCs since this tumor type is very 
heterogeneous. Figure 2 shows an overview of the targets discussed in this 
review. Of the targets currently under investigation for targeted nuclear imaging 
of BC: SSTR, GRPR, ER, PR and NPY1R are best suited for ER-positive luminal 
A and luminal B BCs, since these targets are only/highest expressed in these BC 
subtypes. Both ER and PR-targeted radiotracers, but especially ER-targeted radio- 
tracers, are currently studied in clinical trials. These radiotracers can be used 
for determining ER or PR expression of primary tumors and metastases as well 
as for evaluation of treatment response to ER-targeted therapy. However, the 
majority of ER-positive BCs acquire resistance against anti-estrogen treatment 
and in some cases this is due to loss of ER expression (99). ER status of primary 
BCs and corresponding metastases may vary (over time) and so visualization of 
metastases of ER-positive primary tumors is not feasible in all cases (100). ER- 
and PR-targeted imaging to determine receptor expression is less invasive than 
immunostaining on biopsy material as is done in current practice. Furthermore, 
ER and PR-targeted nuclear imaging comprises visualization of the complete 
tumor lesion, while biopsy material is limited and not always representative for 
the (heterogeneous) tumor. However, determining hormone receptor expres-
Figure 2. An overview of targets discussed in this review and the BC subtype with highest 
expression thereof. ER=estrogen receptor, PR=progesterone receptor, SSTR=somatostatin 
receptor, GRPR=gastrin releasing peptide receptor, NPY1R=Neuropeptide Y receptor Y1, 
HER2=human epidermal factor receptor 2, CXCR4=C-X-C chemokine receptor type 4, 
FR=folate receptor, VEGF-A=Vascular endothelial growth factor A and VIP-R1=Vasoactive 
intestinal polypeptide receptor 1. Details on histological and molecular profiles are derived 
from (98).
sion with nuclear imaging would involve scanning patients several times with 
(different) radiotracers, which causes a significant radiation burden to the patient 
that has to be kept in mind. The application of radiotracers to determine hormone 
receptor status would especially be beneficial for tumors that cannot be biopsied 
due to an inconvenient location. In cases where ER and/or PR-targeted imaging 
cannot be applied, SSTR and GRPR-mediated imaging, although not studied as 
widely as ER and PR-mediated imaging (yet), may be of benefit for imaging of 
ER-positive primary and metastatic BC lesions. GRPR targeting is preferred 
because the receptor is expressed more frequently and at higher density (42). 
Nevertheless, both SSTR and GRPR-mediated imaging can be beneficial in 
ER-positive tumors that loose ER expression in the course of the disease. For 
this to be successful the relation between SSTR2 and GRPR, and ER needs to be 
investigated to make sure that loss of ER expression does not influence GRPR 
expression. Furthermore, even though SSTR and GRPR expression is higher in 
ER-positive tumors, ER-negative tumors might also express the receptor and 
thus radiotracers targeting these receptors might also be applied in other patient 
groups. NPY1R expression was also associated with ER-positive BCs. To date 
NPY1R-targeted BC imaging has only been performed in a limited number of 
studies and more studies are needed to determine the added value of NPY1R in 
comparison to the above-mentioned targets for imaging of ER-positive BCs.
HER2-targeted BC imaging can be applied in HER2 positive BCs which account 
for approximately 15% of the BC population (98). This approach can be used to 
determine HER2 expression and to monitor response to treatment influencing 
HER2 expression. Similar to ER and PR radiotracers, determining HER2 expres-
sion with nuclear imaging can especially be beneficial in cases where biopsies 
cannot be obtained. Furthermore, as is the case for ER and PR, HER2 expression of 
primary tumors and metastases may change during the course of the disease (100).
CXCR4, FR and VEGF-A targeted nuclear imaging might be beneficial for basal 
like tumors, the BC subtype with the worse prognosis (98). CXCR4-mediated 
imaging in BC has not been successful up to date which might be caused by 
limited CXCR4 expression at the cell surface (necessary for radiotracer binding) 
or high CXCR4 expression in cancer stem cells of which only limited numbers 
are available in different BC subtypes (84). Furthermore, high FR and VEGF-A 
receptor expression was also associated with basal like tumors. Data on FR 
targeting in BC is very limited hampering discussion on the value of this radio- 
tracer. VEGF-A is involved in angiogenesis, which explains its high correlation 
with the more aggressive basal like tumors, and thus VEGF-A radiotracers are 
applied for monitoring patients after antiangiogenic treatment.
VIP-R1 is expressed on all BCs and thus radiotracers targeting VIP-R1 might be 
interesting for all BC subtypes. However, VIP-R1 is only expressed in early stage 
disease limiting the use of this tracer in advanced BC. 
A noteworthy option might be the combination of radiotracers directed against 
different targets, the so called multi-target or “cocktail” approach, with the 
purpose of enhancing BC visualization. Reubi et al. (42) studied expression of 
SSTR, GRPR, VIPR-1 and NPY1R in human BC specimens and reported that 60% 
of the tumors expressed at least 2 of the targets. In this study, GRPR, NPY1R 
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or both were expressed in almost all (93%) investigated BCs. Studies synthe-
sizing and preclinically testing a hetero-bivalent dual target probe for GRPR and 
NPY1R were performed (101). Next to these studies, other preclinical studies 
have investigated the multi-targeting approach (102-104), but to date this was not 
tested in a clinical setting. A disadvantage of this approach might be enhanced or 
more extensive uptake in healthy organs which naturally express these targets.
Targeted nuclear imaging can be used for disease visualization (e.g. preoperative 
scanning) and monitoring of receptor positive tumors, for detection of sentinel 
lymph nodes containing malignant lesions, visualization of distant metastases and 
in some cases to evaluate treatment response. It is not the preferred imaging 
technique for screening, however.
Another benefit of targeted nuclear imaging is the use of radioligands for both 
imaging and therapy, following the so-called theranostic approach. Most of these 
radioligands can be labeled with imaging radionuclides (γ- or positron-emitters) 
as well as therapeutic radionuclides (ß- or α-emitters), enabling the use of the 
same tracer for both imaging and therapy in different sessions. This is especially 
interesting for treatment of advanced disease, since distant metastases are often 
not accessible for resection and most systemic agents are accompanied by severe 
side effects (3).
Furthermore, the use of dual labeled tracers that are labeled with both radionu-
clides and optical dyes are interesting for image-guided surgery. This can benefit 
surgical resection of tumors by offering preoperative imaging (SPECT or PET), 
intraoperative guidance (by making use of γ-probes detecting the radioactive 
signal to give an approximate tumor location), and fine guidance and tumor delin-
eation (by detection of the optical signal), ultimately improving success-rate of 
tumor resection.
Overall, targeted nuclear imaging for BC imaging is promising and has the 
potential to improve BC care. There is not one appropriate target for all BCs, and 
thus a personalized approach should be applied. Depending on the BC subtype and 
the question of the physician, the appropriate target should be selected carefully 
(either by biopsy or imaging, depending on the availability of biopsy material). 
More studies are needed to directly compare the value of tracers targeting 
different receptors in specific patient groups, for example GRPR, SSTR, ER, PR 
and NPY1R targeted imaging in ER-positive BCs.
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ABSTRACT
Imaging and therapy using radioligands targeting receptors overexpressed on 
tumor cells is successfully applied in neuroendocrine tumor patients. Because 
expression of the gastrin-releasing peptide receptor (GRPR), somatostatin 
receptor 2 (SSTR2), and chemokine C-X-C motif receptor 4 (CXCR4) has been 
demonstrated in breast cancer (BC), targeting these receptors using radio-
ligands might offer new imaging and therapeutic opportunities for BC patients. 
The aim of this study was to correlate messenger RNA (mRNA) expression of 
GRPR, SSTR2, and CXCR4 with clinicopathologic and biologic factors, and with 
prognosis and prediction to therapy response, in order to identify specific BC 
patient groups suited for the application of radioligands targeting these receptors.
Methods: First, we studied GRPR and SSTR2 expression in 13 clinical BC 
specimens by in vitro autoradiography and correlated this with corresponding 
mRNA levels to investigate whether mRNA levels reliably represent cell surface 
expression. Next, GRPR, SSTR2, and CXCR4 mRNA levels were measured by 
quantitative reverse transcriptase polymerase chain reaction in 915 primary 
BC tissues and correlated with known clinicopathologic and biologic factors, 
disease-free survival, distant metastasis-free survival, and overall survival 
(DFS, MFS, and OS, respectively). In 224 adjuvant hormonal treatment-naïve 
estrogen receptor (ER, ESR1)-positive patients who received tamoxifen as first-
line therapy for recurrent or metastatic disease, the expression levels of the 
receptors were correlated with progression-free survival.
Results: Our results showed a significant positive correlation between GRPR 
and SSTR2 expression analyzed by in vitro autoradiography and by quantitative 
reverse transcriptase polymerase chain reaction (Spearman’s rank correlation 
coefficient [Rs]=0.94, P<0.001, and Rs=0.73, P=0.0042, respectively). Further-
more, high GRPR and SSTR2 mRNA levels were observed more frequently in 
ESR1-positive specimens, whereas high CXCR4 expression was associated with 
ESR1-negative specimens. Also, high mRNA expression of CXCR4 was associ-
ated with a prolonged DFS, MFS, and OS (multivariate hazard ratio MFS=0.76 
[95% confidence interval, 0.64-0.90], P=0.001), whereas high mRNA levels of 
GRPR were associated with a prolonged progression-free survival after the start 
of first-line tamoxifen treatment (multivariate hazard ratio=0.68 [95% confidence 
interval, 0.48-0.97], P=0.031). 
Conclusions: Our data indicates that imaging and therapy using GRPR or SSTR2 
radioligands might especially be beneficial for ESR1-positive BC and CXCR4 
radioligands for ESR1-negative BC.
Keywords: 
Breast Cancer, GRPR, SSTR2, CXCR4, PRS/PRRT
INTRODUCTION
Breast cancer (BC) is the most common cancer found in women worldwide. An 
estimated 1.7 million new cases were diagnosed in 2012 worldwide, and 522,000 
people died as a consequence of the disease, making it the fifth cause of death by 
cancer overall (1).
Multiple subtypes of BC exist, with different molecular characteristics such as 
the absence or presence of estrogen receptor (ER, ESR1), progesterone receptor 
(PR, PGR), and human epidermal growth factor 2 (HER2, ERBB2) (2). In the case 
of ER and HER2, these receptors also serve as therapeutic targets. ER-positive 
patients are treated with either aromatase inhibitors or ER antagonists, most 
commonly tamoxifen, whereas HER2-positive patients are often treated with the 
HER2-specific monoclonal antibody trastuzumab (2). However, in the recurrent 
or metastatic setting nearly all patients acquire resistance against tamoxifen and 
trastuzumab after an initial response (3,4).
Mammography is the standard method used for BC screening, in some cases 
supplemented with MR imaging or ultrasound (5). Unfortunately these methods 
may lead to false-positive and false-negative results (6,7). Because current 
imaging and the above-mentioned therapy options, in particular, have limitations 
and are not always successful, new imaging and therapeutic options are urgently 
needed.
Peptide receptor scintigraphy and peptide receptor radionuclide therapy are 
methods based on targeting receptors overexpressed on tumor cells using radio-
ligands for diagnostic and therapeutic purposes. Within nuclear medicine, radio-
labeled somatostatin (SST) analogs are most widely and successfully used for 
the localization, treatment, and evaluation of neuroendocrine tumors (8). These 
SST analogs bind to SST receptors (SSTR, especially SSTR2) overexpressed 
on tumor cells, enabling imaging when labeled with γ- or positron-emitters and 
therapy when labeled with β- or α-particle emitters. Currently, multiple radio-
labeled SST analogs targeting SSTR2 are available and used in the clinic (9). 
In the past decade, imaging of BC patients using SSTR2 radioligands has been 
studied with varying results (10,11). Currently, considerably improved SSTR2-
directed radiotracers and imaging equipment are available.
Other promising targeting radioligands for BC comprise of radiolabeled gastrin 
releasing peptide (GRP) analogs, earlier applied for the visualization and therapy 
of prostate cancer lesions, because significant GRP receptor (GRPR) levels are 
present in most primary prostate cancer tissues (12-14). Previous studies by 
Reubi et al. (15) showed a high expression of both SSTR2 and GRPR in BC. 
SSTR2 and high-density GRPR expression was found in 75% and 74% of BC 
cases, respectively.
Moreover, chemokine C-X-C motif receptor 4 (CXCR4) expression has 
been reported in most BCs. In a study by Salvucci et al. (16), in which 2,022 
BC specimens were analyzed for CXCR4 expression using immunohisto- 
chemistry, 67% of invasive tumors showed high nuclear staining and 41% of 
tumors showed cytoplasmic staining (12). Promising radiolabeled peptide deriva-
tives binding to CXCR4 have been synthesized to target these receptors  (17,18). 
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So 68Ga-pentixafor, a CXCR4 radioligand, has successfully been used in a clinical 
study for the imaging of multiple myeloma patients (19). Thus, these 3 promising 
categories of radiolabeled compounds could be of promise in BC patients.
Until now, little was known about the correlation between GRPR, SSTR2, and 
CXCR4 expression levels in BC lesions and important molecular and prognostic 
characteristics, such as hormone receptor expression, as well as the associa-
tion of GRPR, SSTR2, and CXCR4 expression with disease-free survival, distant 
metastasis-free survival, or overall survival (DFS, MFS, and OS, respectively) 
and with progression-free survival (PFS) after endocrine treatment.
In this study, we first analyzed the correlation between messenger RNA (mRNA) 
levels and protein expression of GRPR and SSTR2. Subsequently, we analyzed the 
mRNA expression of GRPR, SSTR2, and CXCR4 in human BC specimens. The 
aims of this study were to correlate GRPR, SSTR2, and CXCR4 mRNA expres-
sion levels with clinicopathologic and biologic factors as well as with prognosis 
and outcome on tamoxifen therapy, to assess the potential impact of radioligands 
targeting these receptors for imaging and therapeutic purposes in BC, and to 
thereby identify patient subgroups that potentially would benefit from application 
of these radiopharmaceuticals.
MATERIALS AND METHODS
Human BC Cases
The study (MEC02·953) was approved by the Erasmus MC Medical Ethical 
Committee and adhered to the Code of Conduct of the Federation of Medical 
Scientific Societies in The Netherlands. 
The primary BC tissue of 915 female patients (mean age±SD, 58±13 y) (684 
M0 [no metastasis at diagnosis] lymph-node-negative [LNN], 194 M0 lymph- 
node-positive [LNP], 24 M1 LNP, and 13 patients with unknown nodal status at 
time of primary treatment) who visited the clinic between 1979 and 2000 were 
selected from the Erasmus MC fresh-frozen tissue bank as described before (20). 
The inclusion criteria and the determination of clinicopathologic and biologic 
factors are described in the supplemental data. GRPR, SSTR2, and CXCR4 
expression was initially correlated with clinicopathologic and biologic factors 
in the LNN M0 patient group (n=194). A representative group of LNP tumors 
(n=194) was added to study the influence of positive nodal status on the corre-
lation analyses. For prognosis, we focused our analyses on the cohort of 684 
systemic treatment-naive patients with LNN disease; for prediction of therapy 
response, a cohort of 224 hormonal treatment-naive ER-positive patients who 
received tamoxifen as first-line therapy for recurrent or metastatic disease was 
analyzed. The clinicopathologic and biologic factors of the LNN M0 tumors are 
shown in Table 1, and clinicopathologic and biologic factors for the LNN and LNP 
M0 patient group and the ER-positive first-line tamoxifen-treated subcohort are 
shown in Supplemental Tables 1A+1B, respectively. Patients were censored at 
120-mo follow-up after surgical removal of the primary tumor in the regression 
analysis for DFS (283 events), MFS (241 events), and OS (223 events) and at 36 
mo after the start of tamoxifen treatment for analysis of PFS (24 events). The 
study design is depicted in Figure 1.
RNA Isolation, Complementary DNA Synthesis, and Quantitative 
Reverse Transcriptase Polymerase Chain Reaction (RT-qPCR)
Tissue processing, RNA isolation, complementary DNA synthesis, and RT-qPCR 
were performed and normalized using the δ Cq method on the average of 3 
reference genes (HMBS, HPRT1, and TBP) as described (21). All RNA samples 
that required more than 25 rounds of real-time PCR for detectable products of our 
3 reference genes at a fixed input of 10 ng of total RNA and at a threshold of 0.1 
were considered of insufficient quality and were excluded from further analysis. 
Target genes were quantified using the following intron-spanning Taqman probe-
based gene expression assays (Applied BioSystems/Life Technologies): GRPR, 
Hs01055872 m1; SSTR2, Hs0099356 m1; and CXCR4, Hs00237052 m1, according 
to the manufacturer’s instructions in a MX3000P Real-Time PCR System 
(Agilent). Genomic grade index (GGI), a gene expression pattern of histologic 
tumor grade, and ESR1, PGR, and ERBB2 levels and status of the samples were 
already known based on quantification as previously described (22-24).
Radioligands and In Vitro Autoradiography
Peptide analogs targeting the SSTR2 and GRPR, DOTA-Tyr3-octreotate 
(Mallinckrodt) and AMBA (BioSynthema), respectively, were radiolabeled with 
111In (Covidien), as previously described (25). Quenchers (10 mM methionine, 3.5 
mM ascorbic acid, and 3.5 mM gentisic acid) were used to prevent radiolysis (26). 
Specific activity of both radiotracers was 50 MBq/nmol. Radiometal incorporation 
(>99%) and radiochemical purity (>90%) were measured by instant thin-layer 
chromatography on silica gel and high-pressure liquid chromatography as previous- 
ly described (26).
The CXCR4 radioligand, pentixafor, available to us showed reduced receptor 
affinity when radiolabeled with 111In, and thus satisfying in vitro autoradiography 
studies using this compound could not be performed.
In the in vitro autoradiography assay, tissue sections of 13 fresh-frozen BC 
specimens (10 μm) were incubated with 10-9 M 111In-AMBA and 111In-DOTA-Tyr3-
octreoate for 1 h, without and with 10-6 M unlabeled tracer as control for 
nonspecific binding. H69 (SSTR2-positive, GRPR-negative) and PC3 xenografts 
(GRPR-positive, SSTR2-negative) were used as controls. Results were quanti-
fied using OptiQuant software (Perkin Elmer), and the net percentage binding of 
added dose was calculated. The in vitro autoradiography assay and quantification 
of the results are described in more detail in the supplemental data. 
Statistics
Statistical analyses are described in the supplemental data. 
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RESULTS
In Vitro Autoradiography and Correlation with mRNA Expression
Specific binding to tumor cells of the GRPR- and SSTR2-mediated radiotracers, 
111In-AMBA and 111In-DOTA-Tyr3-octreotate, respectively, was demonstrated 
using in vitro autoradiography on 13 selected human BC specimens with varying 
levels of mRNA receptor expression. Two mouse xenografts served as positive 
and negative control (Figure 2A). Autoradiography results were quantified and 
correlated with the level of mRNA expression of the respective receptors, 
resulting in a significant positive correlation for both GRPR (Spearman’s rank 
correlation coefficient [Rs]= 0.94, P<0.0001) and SSTR2 (Rs=0.73, P=0.0042) 
(Figure 2B). Furthermore, binding of the tracers was observed only on tumor 
cells and not on the surrounding stromal cells. We thus concluded that mRNA 
expression for GRPR and SSTR2 can be used as a predictor for binding of the 
radiotracers to tumor tissue.
Figure 1. Study design. mRNA expression levels of GRPR, SSTR2, and CXCR4 of 915 
primary breast cancer specimens (684 M0 LNN, 194 M0 LNP, 13 with unknown nodal status, 
and 24 M1) were analyzed using RT-qPCR. LNN and LNP M0 patient groups were used 
to study association of GRPR, SSTR2, and CXCR4 expression and clinicopathologic and 
biologic factors, with focus on M0 LNN patient group. Association of GRPR, SSTR2, and 
CXCR4 with prognostic factors was studied in M0 LNN patients. mRNA levels of ER-positive 
primary tumors of patients with recurrent breast cancer who received first-line tamoxifen 
treatment were used to study association of GRPR, SSTR2, and CXCR4 mRNA expression 
and PFS.
Figure 2. A) In vitro autoradiography of human breast cancer specimens using 111In-AMBA 
(GRP analog) and 111In-DOTA-Tyr3-octreotate (SST analog) with and without block, 
demonstrating specific binding of radiotracers to receptor-positive tumor tissue. H69 (SSTR-
positive, GRPR-negative) and PC3 xenografts (SSTR-negative, GRPR-positive) were used as 
controls. Tumor-containing areas are encircled in hematoxylin and eosin (H&E) stainings. 
As an example, arrows indicate non-tumor-containing tissue in first H&E staining. 
(B) Significant correlation between GRPR and SSTR2 mRNA levels and quantification 
of in vitro autoradiography results analyzed in 13 breast cancer specimens with variable 
receptor expression, demonstrating that mRNA levels of receptors can be used as predictor for 
radiotracer binding. %AD=percentage added dose.
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Correlation of GRPR, SSTR2, and CXCR4 mRNA Expression with 
Clinicopathologic and Biologic Factors
We focused on the 684 LNN M0 patients to study the correlation between GRPR, 
SSTR2, and CXCR4 mRNA levels and known clinicopathologic and biologic 
factors. The results of the correlation analyses are shown in Table 1. To study the 
influence of positive nodal status on the correlation analyses, a representative 
group of 194 LNP M0 tumors were added to the study. Results of the LNN and 
LNP M0 patient group are described in Supplemental Table 1A.
A significant correlation was observed between GRPR mRNA levels and a smaller 
pathologic tumor size (P=0.0014), a positive ESR1 (P<0.001) and PGR status 
(P<0.001), a negative ERBB2 (P<0.001) status, and a favorable GGI (P<0.001).
SSTR2 mRNA expression showed a significant correlation with a positive 
ESR1 (P<0.001) and PGR mRNA status (P<0.001), a negative ERBB2 status 
(P=0.0344), favorable GGI (P<0.001), and 70% or less invasive tumor cells 
(P=0.002).
CXCR4 mRNA expression showed a significant negative correlation with ESR1 
(P<0.001) and PGR mRNA status (P<0.001) and was associated with an unfa-
vorable GGI (P<0.001). Furthermore, CXCR4 mRNA levels were higher in 
tumors with 70% or less invasive tumor cells (P<0.001).
Table 1. Associations of GRPR, SSTR2, and CXCR4 mRNA levels in LNN M0 patients
Characteristic GRPR mRNA (x10-2)
SSTR2 mRNA 
(x10-2 )
CXCR4 mRNA 
(x10-2)
 No of patients*  Median
Inter-
quartile
range
Median
Inter-
quartile
range
Median
Inter-
quartile
range
All patients in 
this cohort
684 100% 0.72 7.07 0.58 1.75 11.78 13.13
Age at surgery 
(years)
 ≤40 60 9% 1.17 12.72 0.90 2.99 14.06 13.75
 41-55 252 37% 0.97 9.20 0.61 1.64 11.58 13.18
 56-70 218 32% 0.52 5.38 0.52 1.68 12.19 11.34
 >70 154 23% 0.72 4.44 0.62 1.61 9.99 12.98
P† 0.52 0.68 0.0403
Menopausal status
 Premenopausal 273 40% 1.26 10.95 0.62 1.82 11.81 13.73
 Postmenopausal 411 60% 0.60 4.87 0.55 1.57 11.76 12.12
P† 0.13 0.53 0.39
Surgery
 Lumpectomy 378 55% 0.61 7.69 0.57 1.82 11.67 13.15
 Ablation 306 45% 0.90 6.79 0.60 1.56 11.90 13.00
P† 0.69 0.59 0.65
Table 1. Continued
* Because of missing numbers, not all categories add up to 684.
† P for Mann-Whitney U or Kruskal-Wallis test when appropriate. 
‡ ESR1, PGR, and ERBB2 were determined by real-time PCR; cut points were as follows: 
ESR1=0.2, PGR=0.1, and ERBB2=18.0 (mRNA level relative to reference gene set).
§ P for Spearman rank-correlation test.
Characteristic GRPR mRNA (x10-2)
SSTR2 mRNA 
(x10-2 )
CXCR4 mRNA 
(x10-2)
 No of patients*  Median
Inter-
quartile
range
Median
Inter-
quartile
range
Median
Inter-
quartile
range
All patients in 
this cohort
684 100% 0.72 7.07 0.58 1.75 11.78 13.13
Pathological tumor size
 pT1 307 45% 1.25 8.54 0.69 1.87 12.03 13.40
 pT2+unknown 351 51% 0.41 5.25 0.51 1.65 11.53 12.84
 pT3 + pT4 26 4% 0.58 3.05 0.50 1.38 12.19 13.53
P† 0.0014 0.24 0.92
ESR1 mRNA status‡
 Negative <0.2 184 27% 0.09 0.13 0.28 0.42 14.74 13.83
 Positive ≥0.2 500 73% 2.46 10.98 0.81 2.59 10.98 12.16
 P‡ <0.001 <0.001 <0.001
PGR mRNA status‡
 Negative <0.1 285 42% 0.12 0.32 0.32 0.56 14.36 14.31
 Positive ≥0.1 399 58% 3.67 12.68 1.02 2.98 10.45 11.09
 P‡ <0.001 <0.001 <0.001
ERBB2 mRNA status‡
 Negative <18 574 84% 0.99 8.28 0.61 1.92 11.64 12.96
 Positive ≥18 107 16% 0.30 1.51 0.49 1.00 13.88 13.32
 P§ <0.001 0.0344 0.22
Grade (GGI)
 1 227 33% 2.42 10.46 0.75 2.11 10.83 11.03
 2 229 33% 0.89 6.92 0.63 2.41 11.44 14.59
 3 224 33% 0.13 1.42 0.34 0.98 13.83 13.58
 P§ <0.001 <0.001 <0.001
% Invasive tumor cells
 ≤ 70% 470 69% 0.81 6.84 0.63 1.88 12.57 13.92
 >70% 214 31% 0.64 8.28 0.43 1.28 9.13 10.70
P† 0.87 0.002 <0.001
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Association of GRPR, SSTR2, and CXCR4 mRNA Expression with 
Prognosis and Efficacy of Tamoxifen Treatment
To exclude the possible confounding effect of adjuvant therapy on prognosis, 
the association of GRPR, SSTR2, and CXCR4 expression with prognosis was 
evaluated in the LNN patient group, which did not receive adjuvant systemic 
therapy. The results of the evaluation of GRPR, SSTR2, and CXCR4 mRNA 
expression with DFS, MFS, and OS are shown in Supplemental Table 2.
No significant associations were observed between GRPR and SSTR2 mRNA 
expression and DFS, MFS, or OS. For CXCR4, however, there was a significant 
association of its expression with a favorable DFS, MFS, and OS, both when 
analyzed as a continuous variable and when dichotomized at the median level. For 
the primary endpoint MFS, the results of the multivariate analysis were hazard 
ratio (HR)=0.76 (95% confidence interval [CI], 0.64-0.90), P=0.001, when 
analyzed as a continuous variable, and HR=0.71 (95% CI, 0.55-0.91), P=0.011, 
when dichotomized at the median level.
To visualize the association of the levels of CXCR4 mRNA with MFS, Kaplan-
Meier analysis was performed as a function of the quartile levels of CXCR4 
mRNA (Figure 3). The results show a clear trend of quartiles, with lower expres-
sion having a worse MFS time.
In addition, GRPR, SSTR2, and CXCR4 mRNA expression levels were corre-
lated with the efficacy of tamoxifen treatment in ESR1-positive patients with 
recurrent disease (Supplemental Table 1B). There was a significant correlation 
between high GRPR mRNA levels and prolonged PFS after the start of first-line 
Figure 3. Distant MFS in 684 LNN patients as function of levels of CXCR4. CI=confidence 
interval; HR=hazard ratio.
tamoxifen treatment, indicating that GRPR expression has predictive value for 
the efficacy of tamoxifen therapy (Figure 4; Supplemental Table 3) (25% high vs. 
75% low, univariate HR=0.65 [95% CI, 0.47-0.91], P=0.011, and multivariate 
HR=0.68 [95% CI, 0.48-0.97], P=0.031).
DISCUSSION
We have analyzed GRPR, SSTR2, and CXCR4 mRNA expression in 915 primary 
BC tissues and correlated mRNA expression of these receptors with clinicopatho-
logic and biologic factors and with prognosis and prediction to therapy response, 
to study the relevance of the application of radioligands targeting these receptors 
for imaging and therapy in BC patients. For this, we first successfully demon-
strated in vitro binding of radiotracers for GRPR and SSTR2 to tissue sections and 
showed a significant positive correlation between radiotracer binding and mRNA 
expression, demonstrating that mRNA levels of these receptors can be used as 
a predictor for specific radiotracer binding. The CXCR4 radioligand pentixafor, 
available to us, showed reduced receptor affinity when radiolabeled with 111In for 
in vitro autoradiography purposes, hampering reliable in vitro autoradiography 
studies for CXCR4. Thus, studies correlating CXCR4 radiotracer binding and 
CXCR4 mRNA expression could not be performed. However, because Philip-
Abbrederis et al. (19) reported on detecting CXCR4 mRNA expression in cell 
lines and successful in vivo imaging of corresponding xenograft models using 
68Ga-pentixafor, we concluded that CXCR4 mRNA expression can also be used as 
a predictor for CXCR4 radioligand binding.
Figure 4. Association of GRPR expression with PFS on first-line tamoxifen treatment. 
CI=confidence interval; HR= hazard ratio.
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Concerning prognosis, we found no association between GRPR and SSTR2 expres-
sion and DFS, MFS, and OS in the M0 LNN patients. Surprisingly, we found that 
high CXCR4 levels correlated with better prognosis despite its negative correla-
tion with ER, PR, and unfavorable GGI, indicating that a component of CXCR4 
expression that is independent of these factors determines good outcome.
Other studies on CXCR4 expression in BC have associated CXCR4 expres-
sion with poor patient survival (16). The discrepancy in study outcome might 
be explained by the fact that in our study we analyzed mRNA expression of 
the receptors (independent of receptor localization), whereas in the study by 
Salvucci et al. (16) tissue microarrays were analyzed by immunohistochemistry 
and nuclear and cytoplasmatic CXCR4 staining were analyzed separately. In 
agreement with our study, Salvucci et al. (16) reported more cytoplasmic CXCR4 
staining in ER-negative (54%) than ER-positive tumors (38%).
Furthermore, we found that high GRPR expression was of modest predictive value 
for increased time to progression on tamoxifen treatment, suggesting GRPR radio-
ligands to be useful in monitoring tumor response to treatment with tamoxifen. 
Recently, preclinical 68Ga-AMBA PET imaging in a mouse model also demonstrated 
the feasibility for monitoring tumor response after treatment with tamoxifen (27).
For the association with clinicopathologic and biologic characteristics analyzed 
in the M0 LNN patients, we observed a significant positive correlation between 
GRPR and SSTR2 expression and ESR1- and PGR-positive tumors. In line with 
our findings, significant positive correlation between SSTR2 and ER expres-
sion was reported previously (28), whereas van den Bossche et al. (29) reported 
estrogen-mediated regulation of SSTR2 expression in BC cell lines. Because 
ESR1 and PGR positivity correlates with BC of the luminal subtype (2), tumors 
of this subtype could benefit most from GRPR- or SSTR2-mediated imaging or 
therapy. Moreover, ESR1-negative tumors showed low to no GRPR expression, 
and thus patients with ESR1-negative primary tumors are likely not suited for 
the application of GRPR radioligands. Because ESR1- or PGR-positive tumors 
account for 75% of the BC tumors (2), GRPR- and SSTR2-mediated imaging and 
therapy might be of benefit for the larger part of the BC patient population.
Concerning therapy, GRPR or SSTR2 radioligands can especially be of benefit 
for patients with ESR1-positive tumors who have progressed on various lines of 
endocrine treatment, because nearly all patients with recurrent disease become 
resistant against current antiestrogen treatments (4).
Previous studies we performed on GRPR and SSTR2 expression in human BC 
specimens showed GRPR expression in 48 of 50 (30) and SSTR2 expression in 26 
of 53 (SU Dalm, CHM van Deurzen, M Melis, M de Jong, unpublished data, 2014) 
of the specimens analyzed by in vitro autoradiography, emphasizing that GRPR- 
and SSTR2-mediated imaging and therapy could be applied in a large group of 
breast cancer patients.
Contrary to GRPR and SSTR2, high CXCR4 mRNA expression was correlated 
with ESR1- and PGR-negative tumors, associated with BC of the basal like subtype 
(2), indicating that these tumors, in particular, might be suitable for CXCR4-
mediated imaging or therapy. Patients with triple-negative tumors, especially, 
might benefit from CXCR4-mediated therapy, because effective therapy options 
for this aggressive subtype of BC are scarce. Differences in CXCR4 expression 
between ESR1- and PGR-negative and ESR1-and PGR-positive patients were 
less pronounced than for GRPR and SSTR2. ESR1- and PGR-positive patients 
should therefore not be ruled out for CXCR4-mediated imaging or therapy.
Except for the presence of the receptors, for the selection of patients for imaging 
or treatment with radioligands, also the density of GRPR, SSTR2, and CXCR4 
might determine the target of choice. In a study by Reubi et al. (15), among other 
receptors, GRPR and SSTR2 expression in 77 BC tissues was analyzed using in 
vitro autoradiography. Results showed that high-density GRPR expression was 
observed in 50 of 77 tumors, compared with 14 of 77 tumors with high-density 
SSTR2 expression. Similarly, in our previous work we found homogeneous GRPR 
expression in 56% of the BC specimens analyzed (30), whereas homogeneous 
SSTR2 expression was seen in 29% only (SU Dalm, CHM van Deurzen, M Melis, 
M de Jong, unpublished data, 2014).
One of the benefits of targeted imaging and therapy using GRPR, SSTR2, and 
CXCR4 radioligands is the possibility to upfront select patients who could benefit 
from these methods using one of the radioligands. For this, either frozen material 
from BC biopsies can be used to perform in vitro autoradiography with radio-
ligands or formalin-fixed paraffin-embedded material can be used for immuno-
histochemistry, or both can be used to perform RT-qPCR, to identify patients 
suited for imaging or therapy.
There are, however, also limitations to our study. First, mRNA expression was 
used as a surrogate for radiotracer binding and ER, PGR, and HER2 protein 
expression, which may, despite our current and previously published data (22,23), 
turn out not to be entirely equivalent with protein expression. Second, for the 
prognostic part only, even though our study was relatively large no independent 
validation was performed. In addition, this is a retrospective study and might not 
completely represent the current situation in patients.
CONCLUSION
We successfully identified potential BC patient groups for the application of 
radio-ligands targeting GRPR, SSTR2, or CXCR4 by analyzing associations 
between receptor expression and clinicopathologic, biologic, and prognostic 
factors. Our data shows compelling evidence that sensitive and specific nuclear 
medicine-based imaging and therapy using radioligands might be of great benefit 
for selected BC patients in a personalized setting. GRPR and SSTR2 radioligands 
in ER-positive and PR-positive tumors and CXCR4 radioligands in ER-negative 
patients might offer new, promising tools for imaging and therapy of BC.
Supplemental data
Supplemental data is available online at http://jnm.snmjournals.org.
Chapter 3 Targeting GRPR, SSTR2 and CXCR4 in Breast Cancer
6968
3
REFERENCES
1. International Agency on Research for Cancer. GLOBOCAN 2012: estimated cancer incidence, 
mortality and prevalence worldwide in 2012. International Agency on Research for Cancer 
website. http://globocan.iarc.fr/Default.aspx. Accessed August 18, 2015.
2. Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implica-
tions. World J Clin Oncol. 2014;5:412-424.
3. Brufsky AM. Current approaches and emerging directions in HER2-resistant breast cancer. 
Breast Cancer (Auckl). 2014;8:109-118.
4. Milani A, Geuna E, Mittica G, Valabrega G. Overcoming endocrine resistance in metastatic 
breast cancer: current evidence and future directions. World J Clin Oncol. 2014;5:990-1001.
5. Garcia EM, Storm ES, Atkinson L, Kenny E, Mitchell LS. Current breast imaging modalities, 
advances, and impact on breast care. Obstet Gynecol Clin North Am. 2013;40:429-457.
6. Mahoney MC, Newell MS. Screening MR imaging versus screening ultrasound: pros and cons. 
Magn Reson Imaging Clin N Am. 2013;21:495-508.
7. Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Cumula-
tive probability of false-positive recall or biopsy recommendation after 10 years of screening 
mammography: a cohort study. Ann Intern Med. 2011;155:481-492.
8. Bison SM, Konijnenberg MW, Melis M, et al. Peptide receptor radionuclide therapy using radio-
labeled somatostatin analogs: focus on future developments. Clin Transl Imaging. 2014;2:55-
66.
9. Laznicek M, Laznickova A, Maecke HR. Receptor affinity and preclinical biodistribution of 
radiolabeled somatostatin analogs. Anticancer Res. 2012;32: 761-766.
10. Skånberg J, Ahlman H, Benjegard SA, et al. Indium-111-octreotide scintigraphy, intraoperative 
gamma-detector localisation and somatostatin receptor expression in primary human breast 
cancer. Breast Cancer Res Treat. 2002;74: 101-111. 
11. Van Den Bossche B, Van Belle S, De Winter F, Signore A, Van de Wiele C. Early prediction of 
endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scinti-
graphy. J Nucl Med. 2006;47:6-13.
12. Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J Nucl Med. 2008;49:1735-
1738.
13. Wieser G, Mansi R, Grosu AL, et al. Positron emission tomography (PET) imaging of prostate 
cancer with a gastrin releasing peptide receptor antagonist- from mice to men. Theranostics. 
2014;4:412-419.
14. Bodei L, Ferrari M, Nunn AD, et al. 177Lu-AMBA bombesin analogue in hormone refractory 
prostate cancer patients: a phase I escalation study with singlecycle administrations [abstract]. 
Eur J Nucl Med Mol Imaging. 2007;34:S221.
15. Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular 
basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2002;29:855-
862.
16. Salvucci O, Bouchard A, Baccarelli A, et al. The role of CXCR4 receptor expression in breast 
cancer: a large tissue microarray study. Breast Cancer Res Treat. 2006;97:275-283.
17. Hanaoka H, Mukai T, Tamamura H, et al. Development of a 111In-labeled peptide derivative 
targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol. 2006;33:489-494.
18. Demmer O, Dijkgraaf I, Schumacher U, et al. Design, synthesis, and functionalization of 
dimeric peptides targeting chemokine receptor CXCR4. J Med Chem. 2011;54:7648-7662.
19. Philipp-Abbrederis K, Herrmann K, Knop S, et al. In vivo molecular imaging of chemokine 
receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 
2015;7:477-487.
20. Jansen MP, Sieuwerts AM, Look MP, et al. HOXB13-to-IL17BR expression ratio is related with 
tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective 
study. J Clin Oncol. 2007;25:662-668.
21. Sieuwerts AM, Lyng MB, Meijer-van Gelder ME, et al. Evaluation of the ability of adjuvant 
tamoxifen-benefit gene signatures to predict outcome of hormonenaive estrogen receptor-
positive breast cancer patients treated with tamoxifen in the advanced setting. Mol Oncol. 
2014;8:1679-1689.
22. Toussaint J, Sieuwerts AM, Haibe-Kains B, et al. Improvement of the clinical applicability of 
the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed 
paraffin-embedded tissues. BMC Genomics. 2009; 10:424.
23. van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, et al. Relevance of breast cancer 
antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. 
J Clin Oncol. 2009;27:542-549.
24. Sieuwerts AM, Usher PA, Meijer-van Gelder ME, et al. Concentrations of TIMP1 mRNA 
splice variants and TIMP-1 protein are differentially associated with prognosis in primary 
breast cancer. Clin Chem. 2007;53:1280- 1288.
25. de Blois E, Schroeder RJ, De Ridder CA, Van Weerden WM, Breeman WP, De Jong M. 
Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin 
receptor-mediated imaging of prostate cancer. Q J Nucl Med Mol Imaging. June 19, 2013 [Epub 
ahead of print]. 
26. de Blois E, Chan HS, Konijnenberg M, de Zanger R, Breeman WA. Effectiveness of quenchers 
to reduce radiolysis of 111In- or 177Lu-labelled methionine-containing regulatory peptides: 
maintaining radiochemical purity as measured by HPLC. Curr Top Med Chem. 2012;12:2677-
2685.
27. Prignon A, Nataf V, Provost C, et al. 68Ga-AMBA and 18F-FDG for preclinical PET imaging 
of breast cancer: effect of tamoxifen treatment on tracer uptake by tumor. Nucl Med Biol. 
2015;42:92-98.
28. Kumar U, Grigorakis SI, Watt HL, et al. Somatostatin receptors in primary human breast 
cancer: quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein 
expression and tumor pathology. Breast Cancer Res Treat. 2005;92:175-186.
29. Van Den Bossche B, D’Haeninck E, De Vos F, et al. Oestrogen-mediated regulation of somato-
statin receptor expression in human breast cancer cell lines assessed with 99mTc-depreotide. 
Eur J Nucl Med Mol Imaging. 2004; 31:1022-1030.
30. Dalm SU, Martens JW, Sieuwerts AM, et al. In-vitro and in-vivo application of radiolabeled 
gastrin releasing peptide receptor ligands in breast cancer. J Nucl Med. 2015;56:752-757.
Prospects of Targeting the 
Gastrin Releasing Peptide 
Receptor, Chemokine 
C-X-C Motif Receptor 4 and 
Somatostatin Receptor 2 for 
Nuclear Imaging and Therapy  
in Metastatic Breast Cancer
Chapter 4
S.U. Dalm1, W.A.M.E. Schrijver2, A.M. Sieuwerts3, M.P. Look3, 
A.C.J. Ziel - van der Made4, V. de Weerd3, J.W. Martens2, 
P.J. van Diest2, M. de Jong1 and C.H.M. van Deurzen3
Submitted to PLOS ONE, September 2016
Revised version accepted January 2017
1Dept. of Radiology & Nuclear Medicine, Erasmus MC, 
Rotterdam, The Netherlands;
2Dept. of Pathology, University Medical Center Utrecht, 
Utrecht, The Netherlands; 
3Dept. of Medical Oncology and Cancer Genomics 
Netherlands, Erasmus MC Cancer Institute, Erasmus 
MC, Rotterdam, The Netherlands; and 
4Dept. of Pathology, Erasmus MC, Rotterdam, 
The Netherlands
Chapter 4 GRPR, CXCR4 and SSTR2 in Metastatic Breast Cancer
7372
4
ABSTRACT
The gastrin releasing peptide receptor (GRPR), chemokine C-X-C motif receptor 
type 4 (CXCR4) and somatostatin receptor 2 (SSTR2) are overexpressed on 
primary breast cancer (BC), making them ideal candidates for receptor-mediated 
nuclear imaging and therapy. The aim of this study was to determine whether 
these receptors are also suitable targets for metastatic BC. 
Methods: mRNA expression of human BC samples were studied by in vitro auto-
radiography and associated with radioligand binding. Next, GRPR, CXCR4 and 
SSTR2 mRNA levels of 60 paired primary BCs and metastases from different 
sites were measured by quantitative reverse transcriptase polymerase chain 
reaction. Receptor mRNA expression levels were associated with clinico- 
pathologic factors and expression levels of primary tumors and corresponding 
metastases were compared.
Results: Binding of GRPR and SSTR radioligands to tumor tissue correlated 
significantly with receptor mRNA expression. High GRPR and SSTR2 mRNA 
levels were associated with estrogen receptor (ESR1)-positive tumors (P<0.001 
for both receptors). High GRPR and SSTR2 mRNA levels were associated with 
estrogen receptor (ESR1)-positive tumors (P<0.001 for both receptors). There 
was no significant difference in GRPR and CXCR4 mRNA expression of primary 
tumors versus paired metastases. Regarding SSTR2 mRNA expression, there 
was also no significant difference in the majority of cases, apart from liver and 
ovarian metastases which showed a significantly lower expression compared to 
the corresponding primary tumors (P=0.02 and P=0.03, respectively). 
Conclusions: Targeting the GRPR, CXCR4 and SSTR2 for nuclear imaging and/
or treatment has the potential to improve BC care in primary as well as meta-
static disease.
Keywords:
GRPR, CXCR4, SSTR2, Metastatic Breast Cancer, Targeted Nuclear Imaging and 
Therapy
INTRODUCTION
Breast cancer (BC) is the second most common cancer found in women and 
the fifth cause of cancer related death (1). The disease is very heterogeneous. 
Different subtypes with distinctive morphological and molecular characteristics 
exist. The four major intrinsic BC subtypes are luminal A, luminal B, human 
epidermal growth factor 2 (HER2)-driven and basal-like BC (2,3). Treatment 
and prognosis of the disease are highly dependent on these subtypes; luminal A 
and luminal B tumors have a better prognosis than basal-like BC (2,3). Although 
multiple therapy options for BC exist, 20-30% of BC patients experience relapse 
with metastatic disease (4). 
Peptide receptor scintigraphy and peptide receptor radionuclide therapy are 
methods successfully used in the clinic for imaging and treatment of neuro-
endocrine tumors (5). These methods are based on targeting receptors that are 
overexpressed on cancer cells using radiolabeled peptide analogues. Regarding 
BC, multiple studies have demonstrated overexpression of the gastrin releasing 
peptide receptor (GRPR), chemokine C-X-C motif receptor type 4 (CXCR4) and 
somatostatin receptor 2 (SSTR2). In line with this, several preclinical as well as 
clinical studies demonstrated feasibility of imaging and/or treatment of BC with 
GRPR and SSTR2 radioligands with promising results, and indicated specific BC 
patient groups that can benefit from the application of these radioligands (6-11). 
However, previous studies were solely based on primary BC while BC-related 
death is largely caused by metastatic disease. Targeting the GRPR, CXCR4 and 
SSTR2 could thus especially be advantageous for treatment of metastatic BC.
In this study, we examined the GRPR, CXCR4 and SSTR2 mRNA expression 
levels of primary tumors and paired metastases, in order to evaluate whether 
nuclear imaging and therapy might also be beneficial for metastatic BC.
MATERIALS AND METHODS
Human BC Cases
Retrospectively, we selected 74 formalin-fixed paraffin-embedded (FFPE) 
primary BCs and 77 corresponding metastases from an existing database of 
the University Medical Center Utrecht and from the pathology archive of the 
Erasmus Medical Center (12,13). Fresh frozen (FF) tissue of 6 paired primary 
tumors and regional lymph node metastases were also included. Each specimen 
was reviewed by a pathologist (CvD) to confirm the presence of malignancy 
and to determine the percentage of tumor cells (cut-off point of >50% tumor 
cells). Inclusion criteria were: availability of clinicopathologic data, the presence 
of enough tumor tissue and good RNA quality to reliably determine Quantita-
tive Reverse Transcriptase Polymerase Chain Reaction (RT-qPCR) levels. 
After applying these inclusion criteria, 68 primary tumors and 60 metastases 
remained, resulting in 60 paired primary BCs and metastases from different 
sites, including brain (n=12), regional lymph nodes (n=20), liver (n=10), ovary 
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(n=5), lung (n=5) and other sites (n=8, consisting of bone (n=2), uterus (n=1), 
gastrointestinal tract (n=2) and distant lymph node metastases (n=3)). Clinico-
pathologic characteristics included age, primary tumor size, histological subtype, 
histological grade according to Bloom & Richardson (14), estrogen receptor (ER) 
status, HER2 status, and regional lymph node status.
The use of anonymous or coded left over material for scientific purposes is part of 
the standard treatment agreement with patients and therefore informed consent 
was not required according to Dutch law (15,16). 
RNA Isolation and RT-qPCR
Ten 10 μm slides were cut from the FFPE and 10×20 μm from the FF primary 
BCs and paired metastases. The first and last sections (5 μm) were stained with 
hematoxylin and eosin to guide macro-dissection of the tumor cells for RNA 
extraction. Total RNA was isolated from the macro-dissected FFPE sections 
with the AllPrep DNA/RNA FFPE Kit (Qiagen) and from the FF sections with 
RNA-B (Campro Scientific) according the manufacturer’s instructions. Nucleic 
acid concentrations were measured with a Nanodrop 1000 system. cDNA was 
generated for 30 min at 48°C with RevertAid H minus (ThermoFisher Scien-
tific) and gene-specific pre-amplified with Taqman PreAmp Master mix 
(ThermoFisher Scientific) for 15 cycles, followed by Taqman probe-based real time 
PCRs according the manufacturer’s instructions in a MX3000P Real-Time PCR 
System (Agilent). The following gene expression assays were evaluated (all from 
ThermoFisher Scientific): GRPR, Hs01055872_m1; CXCR4, Hs00237052_m1; 
SSTR2, Hs0099356_m1; ESR1, Hs00174860_m1; ERBB2, Hs01001580_m1, 
and quantified relative to the average expression of GUSB, Hs9999908_m1; 
HMBS, Hs00609297_m1 and TBP, Hs00427620_m1 using the δ Cq method 
(δ Cq=2ˆ(average Cq reference genes-Cq target gene)). Samples that resulted 
in amplifiable products within 25 cycles for this reference gene set at an input 
of 50 ng total RNA (91.2% of the samples) were considered to be of good quality 
to reliably determine RT-qPCR levels. Additional quality and quantity control 
measurements that were taken to ensure reliable RT-qPCR data analysis are 
described in the Supplementary text.
In this study, we used ESR1 and ERBB2 mRNA expression levels to determine 
ESR1 and ERBB2 status (using a cut-off δ Cq for ESR1>1 and ERBB2>3.5 
by optimal binning for n=92 and n=87 overlapping samples, respectively. See 
Supplemental Figure S1.
Radioligands and In Vitro Autoradiography
The radiolabeled GRPR antagonist, JMV4168 (17), and the radiolabeled SSTR2 
agonist, DOTA-Tyr3-octreotate (Mallinckrodt) were radiolabeled with 111In (Covidien) 
using quenchers to prevent radiolysis as previously described (18,19). Specific 
activity was 80 MBq/nmol for both radiotracers. Radiochemical purity and radiometal 
incorporation, measured by instant thin-layer chromatography on silica gel and high-
pressure liquid chromatography as previously described, were >90% (19).
Slides (10 μM) of FF primary BC and paired metastases (n=6 each) were used 
for autoradiography experiments. Tissue sections were incubated with 100 μL 
incubation buffer containing 10-9 M of the radiolabeled peptide for 1 h, with and 
without 10-6 M unlabeled tracer to determine specificity of binding. Results of the 
autoradiography experiments were quantified using Optiquant (Perkin Elmer) 
and the percentage added dose (%AD) of the radioligand bound to the tumor 
tissue was used as an indirect measurement for the level of protein expression. 
Radioligand binding to primary tumors and paired metastasis was compared 
and correlated with the measured GRPR and SSTR2 mRNA expression levels 
in corresponding FF tumor material. Furthermore, mRNA receptor expression 
measured in FF tumor material was correlated with mRNA receptor expres-
sion measured from FFPE tumor material of the same tumor. These correla-
tion analyses were performed to demonstrate that mRNA expression of FFPE 
material could be used as a surrogate for radiotracer binding. The autoradio- 
graphy experiments and quantification of the results were performed as described 
in the Supplementary text.
In vitro autoradiography experiments were not performed for CXCR4, since the 
CXCR4 radioligand available to us, pentixafor, showed reduced receptor affinity 
when radiolabeled with 111In.
Statistics
For the analysis, the STATA statistical package v14.1 and SPSS version 23 were 
used. Variables were checked for normality prior to analysis. To compare mean 
values between two or more groups, the Student t-test or analysis of variance 
ANOVA were used. To compare values for primary and metastatic disease the 
paired t-test was applied. Pearson and Spearman correlations were calculated 
when appropriate. P≤0.05 were considered statistically significant.
RESULTS 
In Vitro Autoradiography
Six pairs of primary BCs and regional lymph node metastases (n=12 samples) 
with varying mRNA receptor expression were analyzed for their ability to bind the 
GRPR radioligand, 111In-JMV4168, and the SSTR2 radioligand, 111In-DOTA-Tyr3-
octreotate, using in vitro autoradiography. Figure 1A shows the in vitro auto-
radiography results for four of the paired samples. From the six paired samples 
analyzed, two cases showed specific binding of the GRPR and SSTR2 radioligands 
in both the primary tumor and the lymph node metastases. In three cases there 
was no binding of GRPR and SSTR2 radioligands in both the primary tumors 
and the lymph node metastases. In one case binding of the GRPR radioligand 
was observed in the primary tumor but not in the lymph node metastasis, while 
binding of the SSTR2 radioligand was observed in the lymph node metastasis, but 
not in the primary tumor. 
When the %AD of the radiotracer bound to the FF tumor tissue was correlated 
with the mRNA receptor expression of the FF tumor material, a significant 
positive correlation was found for both GRPR (Spearman Rs=0.83, P=0.0008) 
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and SSTR2 (Spearman Rs=0.87, P=0.0003) (Figure 1B+D). Furthermore, 
correlation analysis of mRNA receptor expression levels quantified in FF and 
FFPE material of the same tumor, resulted in a significant positive correlation 
for both GRPR (Spearman Rs=0.77, P=0.0034) and SSTR2 (Spearman Rs=0.72, 
P=0.0082) (Figure 1C+E).
Association of GRPR, CXCR4 and SSTR2 mRNA Expression with 
Clinicopathologic Factors
Table 1 and Supplemental Table S1 show the patient characteristics, including 
the association of GRPR, CXCR4 and SSTR2 mRNA expression of primary 
BCs with clinicopathologic factors. High GRPR mRNA expression levels were 
significantly associated with low histologic grade, lobular subtype, ESR1-positive 
and ERBB2-negative tumors. High SSTR2 mRNA expression levels were also 
significantly associated with lobular subtype and ESR1-positive tumors. CXCR4 
mRNA expression of the primary BC showed no association with the studied 
clinicopathologic factors.
GRPR, CXCR4 and SSTR2 mRNA expression levels of the metastases were 
correlated with ESR1 and ERBB2 expression of the metastasis itself (Table 2). 
Similar to the primary tumors, high GRPR and SSTR2 mRNA levels were signifi-
cantly associated with ESR1-positive metastases. Furthermore, high GRPR 
mRNA status was significantly associated with ERBB2-negative metastases. 
Unlike the primary tumors, high SSTR mRNA levels were significantly asso-
ciated with ERBB2-negative metastatic lesions. In line with the primary BCs 
studied, CXCR4 mRNA expression levels of the metastases showed no signifi-
cant association with ESR1 and ERBB2 status.
GRPR, CXCR4 and SSTR2 mRNA Expression of Primary BC vs. 
Corresponding Metastases
Figure 2 shows the box plots of GRPR, CXCR4 and SSTR2 mRNA expression in 
primary tumors and corresponding metastases.
Comparison of receptor mRNA expression levels of primary tumors and corre-
sponding metastases showed no significant difference in GRPR and CXCR4 
mRNA levels between primary tumors and corresponding regional lymph node 
and distant metastases in the brain, lung, liver and ovaries. However, in the group 
of metastases from other sites, GRPR mRNA expression levels were significantly 
lower in the metastases compared to the corresponding primary BC (P=0.02).
Regarding SSTR2 mRNA levels, there were no significant differences in SSTR2 
mRNA expression of the primary tumor and the paired metastasis in regional 
lymph nodes, brain, lung and other locations. However, SSTR2 mRNA levels of 
liver and ovarian metastases were significantly lower compared to the expression 
in the corresponding primary BC (P=0.02 and P=0.03, respectively).
Next, we compared the receptor mRNA expression levels between distant metas-
tases from various metastatic sites amongst each other. GRPR mRNA levels 
were significantly higher in the ovarian metastases (P=0.03) and CXCR4 mRNA 
expression levels were significantly higher in liver metastases (P=0.05). 
Figure 1. In vitro auto-radiography of primary BC and corresponding regional lymph node 
metastases. A) Hematoxylin and eosin (H&E) staining and autoradiography results after 
incubating cells with the GRPR radioligand, 111In-JMV4168, and the SSTR2 radioligand, 
111In-DOTA-Tyr3-Octreotate. B+D) Correlation of quantified auto-radiography results (%AD) 
with mRNA expression of fresh frozen (FF) tissue. C+E) Correlation of mRNA expression of 
FF and formalin fixed paraffin embedded (FFPE) tissue of the same tumor.
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Table 1. Association of GRPR, CXCR4 and SSTR2 mRNA expression with clinicopathologic 
factors of primary BC *
Characteristic GRPR mRNA log2
CXCR4 
mRNA log2
SSTR2 
mRNA log2
No of 
patients
Percentage 
of patients Mean SD Mean SD Mean SD
All patients in this 
cohort
68 100 -2.90 3.8 0.48 0.88 -2.51 2.15
Age at surgery 
(years)
≤ 40 11 16 -1.63 4.02 0.34 1.10 -2.23 2.13
41-55 27 39 -1.96 3.75 0.53 0.89 -2.08 2.38
56-70 22 32 -4.96 2.85 0.29 0.80 -3.07 1.94
> 70 7 10 -2.72 4.32 1.09 0.67 -2.90 2.04
P† 0.08 0.32 0.22
Tumor size
≤ 2 cm 25 36 -2.62 3.97 0.34 0.88 -2.61 2.24
2 ≤ 5 cm 29 42 -3.47 3.44 0.53 0.91 -2.32 2.16
> 5 cm 10 14 -2.00 4.22 0.53 0.89 -2.95 2.09
P‡ 0.51 0.70 0.72
Histopathologic 
subtypes
Ductal 55 80 -3.34 3.76 0.50 0.90 -2.82 2.15
Lobular 11 16 -0..80 3.44 0.49 0.84 -1.04 1.74
Other 2 3 -2.38 3.72 -0.32 0.14 -2.04 1.26
P§ 0.04 0.96 0.01
Bloom &  
Richardson grade
I + II 15 22 -1.23 3.57 0.18 0.86 -1.80 2.20
III 44 64 -3.66 3.91 0.62 0.89 -2.88 2.18
P¶ 0.04 0.10 0.12
ESR1 status
Negative 25 36 -6.52 1.68 0.54 0.90 -3.83 2.09
Positive 42 61 -0.79 3.04 0.41 0.87 -1.79 1.80
P¶ <0.001 0.58 <0.001
ERBB2 status
Negative 46 67 -2.12 3.60 0.50 0.89 -2.44 2.26
Positive 11 16 -5.04 2.62 0.81 0.89 -2.7 2.23
P¶ 0.006 0.32 0.73
There were no significant differences in SSTR2 mRNA expression levels in 
distant metastases from different sites.
In some cases studied (n=11), there was a discordance regarding ESR1 status of 
primary BCs and corresponding metastases. When studying the effect of change 
in ESR1 status on receptor mRNA expression in primary tumors and paired 
metastasis, GRPR and SSTR2 mRNA expression changed accordingly (higher 
GRPR/SSTR2 mRNA expression in ESR1-positive lesions compared to ESR1-
negative lesions) in the majority of the tumors. However, this difference was only 
significant (P<0.05) for ESR1-positive primary BCs with corresponding ESR1-
negative metastases (n=6). Discordance regarding ERBB2 status was seen in 
6 paired samples. In these samples a change in ERBB2 status of primary BCs 
and corresponding metastases did not have a consistent effect on GRPR mRNA 
expression levels.
DISCUSSION
Targeting of GRPR, CXCR4 and SSTR2 overexpressed on BC cells with radio-
ligands can offer novel imaging and therapy options for BC. Previous clinical 
and preclinical studies reported promising results. However, these studies were 
restricted to primary BC, while metastases are the main cause of BC-related 
death. In this study, we compared GRPR, CXCR4 and SSTR2 mRNA expres-
sion levels in a unique dataset of primary BC and corresponding metastases to 
determine whether receptor-based imaging and/or therapy could also be useful 
for metastatic BC. For this purpose, we selected FFPE material of primary 
BCs and corresponding metastases from different sites, and compared mRNA 
Table 1. Continued
Characteristic GRPR mRNA log2
CXCR4 
mRNA log2
SSTR2 
mRNA log2
No of 
patients
Percentage 
of patients Mean SD Mean SD Mean SD
All patients in this 
cohort 
68 100 -2.90 3.8 0.48 0.88 -2.51 2.15
Regional lymph 
node status
Negative 15 22 -4.40 3.06 0.66 1.01 -2.96 2.33
Positive 44 64 -2.67 4.02 0.40 0.82 -2.48 2.01
P¶ 0.13 0.33 0.44
* Due to missing values numbers don’t always add up to 68.
† Receptor expression of ductal BC and lobular BC was compared using the student t-test.
‡ P for Pearson correlation.
§ P for variance of ANOVA.
¶ P for student t-test.
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receptor expression levels of the paired samples. Prior to this, we confirmed 
that mRNA expression levels of tumor tissue properly represent radioligand 
binding, by correlating in vitro autoradiography results with mRNA expression 
levels of selected primary tumors and corresponding metastases with varying 
mRNA receptor expression. This was only done for GRPR and SSTR2 because 
our CXCR4 radioligand could not be labelled with a radionuclide suited for in vitro 
autoradiography. However, based on a previous study by Philipp-Abbrederis et. 
al. (20), who reported on CXCR4 mRNA expression in BC cell lines and CXCR4 
targeted imaging of corresponding xenograft models, we assumed that CXCR4 
mRNA expression can be used as a surrogate for CXCR4 radioligand binding. 
Next, we determined the GRPR, CXCR4 and SSTR2 mRNA expression of 
the paired primary BCs and metastases. When we associated receptor mRNA 
expression levels of primary BCs and metastases with clinicopathologic factors, 
we observed a significantly higher GRPR and SSTR2 expression in both ESR1-
Table 2. Associations of receptor mRNA expression with ESR1 and ERBB2 status in BC 
metastases
ER status ERBB2 status
Negative Positive P* Negative Positive P*
 Mean SD Mean SD Mean SD Mean SD  
All metastases           
No of patients 24 35 48 11
GRPR -6.26 2.76 -1.87 3.90 <0.001 -2.67 3.77 -7.98 2.15 <0.001
CXCR4 0.27 1.28 0.29 1.07 0.95 0.17 1.14 0.74 1.13 0.15
SSTR2 -3.95 1.64 -2.89 2.23 0.04 -2.91 1.96 -5.11 1.49 <0.001
Regional lymph 
node metastases
No of patients 4 16 16 4
GRPR -7.0 1.96 -1.70 3.53 0.003 -1.70 3.54 -7.02 1.84 0.002
CXCR4 0.04 0.91 0.14 0.90 0.85 0.10 0.88 0.21 1.00 0.86
SSTR2 -4.03 0.97 -2.92 2.67 0.20 -2.77 2.47 -4.62 1.92 0.16
All distant 
metastases†
No of patients 20 19 32 7
GRPR -6.12 2.92 -2.01 4.27 0.001 -3.15 3.84 -8.52 2.26 <0.001
CXCR4 0.31 1.36 0.41 1.20 0.82 0.21 1.26 1.05 1.14 0.12
SSTR2 -3.94 1.76 -2.86 1.85 0.07 -2.98 1.69 -5.40 1.26 0.001
* P for student t-test.
† Numbers do not add up to 60 because for 1 patient ESR1 and ERBB2 were unknown.
positive primary BC and metastases. These findings are in agreement with our 
previous findings (11) and findings by Kumar et. al. (21) and Stoykow et al. (7). 
The latter publication describes a clinical study in which the GRPR radioligand, 
68Ga-RM2 was successfully used for imaging of BC lesions and imaging success-
rate associated positively with ER and PR status. Furthermore, Prignon et al. 
(22) demonstrated that 68Ga-AMBA, a GRPR agonist, was better suited for moni-
toring response to hormonal treatment than 18F-FDG PET in an ER-positive BC 
model. In another study, van den Bossche et al. (23) published data indicating 
an estrogen-dependent regulation of SSTR expression in BC cell lines. Since 
ER-positive BC accounts for approximately 75% of the BC population, applying 
Figure 2. GRPR, CXCR4 and SSTR2 mRNA levels in primary BC (PBC) and corresponding 
metastases (BCM). Significant differences are indicated by *.
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receptor targeted nuclear imaging and/or therapy using GRPR or SSTR2 radio-
ligands could be beneficial for the majority of the BC population (2).
In contrast to our previous study we did not find a significant association of high 
CXCR4 mRNA expression with ESR1-negative tumors. A potential explanation 
for this is the smaller sample size analyzed in this study. Nevertheless, CXCR4 
might be a good candidate for targeting of ER-negative BCs, that usually have a 
poor prognosis (2).
In paired primary tumors and metastases a change in ESR1 expression from 
positive to negative resulted in a significant decrease in GRPR and SSTR2 mRNA 
levels. This may indicate an ESR1 dependent expression of GRPR and SSTR2, 
which is consistent with literature (23,24). Difference in ERBB2 status in primary 
tumors and paired metastasis did not show a clear effect on GRPR mRNA expres-
sion, although these numbers were too small for reliable conclusions.
Comparison of GRPR, CXCR4 and SSTR2 mRNA levels of primary tumors and 
corresponding metastasis resulted in similar GRPR and CXCR4 mRNA expres-
sion in primary tumors and paired regional lymph nodes and distant metastases 
of the brain, lung, liver and ovaries. However, GRPR mRNA expression was 
significantly higher in primary tumors compared to corresponding metastases 
from other sites. Since this group is very diverse, containing metastases from 
distant lymph nodes, bone, uterus and metastases from the gastrointestinal tract, 
it is not possible to draw solid conclusions. Regarding SSTR2, mRNA expression 
levels were significantly lower in liver and ovarian metastases compared to the 
paired primary BC.
Combining our findings, both GRPR and SSTR2 are promising targets for nuclear 
imaging and/or therapy in primary and metastatic ER-positive BC, but GRPR 
seems more suitable due to its retained expression in the metastases. This 
finding is also supported by a previous study by our group, in which we demon-
strated GRPR expression in 48/50 BCs (6), while SSTR2 was only expressed in 
26/53 BCs (SU Dalm, CHM van Deurzen, M Melis, JW Martens and M de Jong, 
unpublished data, 2014).
Since a substantial portion of BC patients experience relapse with metastatic 
disease, it is important to develop new treatment options for this late stage 
of disease. We showed that receptor mRNA expression levels were similar in 
primary tumors and corresponding metastases in the majority of the cases, 
implying that targeting these receptors for disease monitoring or therapy might 
improve BC patient care. 
Biopsy material or excised tumors can be used to determine receptor expression 
by immunohistochemistry, RNA in situ, in vitro autoradiography or RT-qPCR 
(25). Disease monitoring of receptor-positive tumors can then be performed by 
single photon emission computed tomography/computer tomography (SPECT/
CT), positron emission tomography (PET)/CT or PET/magnetic resonance 
imaging using radioligands targeting these receptors. Also, dedicated breast PET 
cameras can be used. These dedicated cameras have improved sensitivity and 
specificity compared to whole body PET, because of a restricted field of view, 
resulting in higher cancer detection (26). Furthermore, tumors can be treated 
with therapeutic radioligands. Another option is to use GRPR, CXCR4 or SSTR2 
radioligands for visualization of sentinel node metastases or as a guide for BC 
surgery (e.g. preoperative imaging, radioguided surgery) in patients with receptor 
positive primary tumors (27,28).
The next step would be to perform clinical studies to investigate the feasibility 
of imaging primary tumors and metastases with radioligands targeting these 
receptors. One important aspect is to study physiological uptake of the radio-
ligands in other organs, since this is of great importance for successful nuclear 
imaging and treatment. However, previous studies using radioligands targeting 
these receptors on other tumor types did not report on any alarming physiolo-
gical uptake (5,7,29).
CONCLUSION
The presented data indicates that nuclear based imaging and therapy has the 
potential to improve BC patient care in primary as well as in metastatic disease, 
by targeting GRPR, CXCR4 and SSTR2. Both GRPR and SSTR2 radioligands, 
but especially GRPR radioligands, are promising for imaging and treatment of 
ER-positive primary and metastatic BC. Furthermore, imaging and treatment of 
metastases derived from CXCR4-positive primary tumors using CXCR4 radio-
ligands seems to be feasible.
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SUPPLEMENTAL DATA
Supplemental Methods
Quality and Quantity Control Measurements for Reliable Quantitative 
Reverse Transcriptase Polymerase Chain Reaction (RT-qPCR).
For reliable RT-qPCR measurements, only samples that resulted in amplifiable 
products within 25 cycles for the used reference gene set at an input of 50 ng total 
RNA (91.2% of the samples) were considered to be of good quality for reliable 
determination of RT-qPCR levels. Furthermore, a serially diluted fresh frozen 
(FF) and formalin fixed paraffin embedded (FFPE) breast tumor sample was 
included in each experiment to evaluate the linear amplification and efficiencies 
for all genes included in the panel, and absence of amplification in the absence of 
reverse transcriptase. All gene transcripts were 100% efficient amplified (range 
89-113%) and were negative in the absence of reverse transcriptase. To ensure 
unbiased results from FF and FFPE samples, these 2 data sets were normalized 
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based on the expression levels measured in a set of n=13 matched FF-FFPE 
samples.
Estrogen Receptor (ER/ESR1) and Receptor Tyrosine-protein Kinase 
erbB-2 Status/Human Epidermal Growth Factor 2 (ERBB2/HER2) 
Status of the Investigated Samples
Because data regarding ER and HER2 protein expression of our data set was 
incomplete, ESR1 and ERBB2 mRNA expression was used to determine ESR1 
and ERBB2 mRNA status (using a δ Cq cut-off for ESR1>1 and ERBB2>3.5 
by optimal binning for n=92 and n=87 overlapping samples, respectively 
(Figure S1)). Because ER and HER2 are determined on protein level in daily 
clinical practice (using a scoring system according to national and international 
guidelines (30,31)), we investigated whether the ESR1 and ERBB2 mRNA status 
accurately reflected the ER and HER2 protein status as reported in the pathology 
reports in samples with known receptor protein status. These cut-offs resulted 
for ESR1 in a sensitivity of 0.88 and specificity of 0.85 and for ERBB2 in a sensi-
tivity of 0.89 and specificity of 0.97.
In Vitro Autoradiography
Fresh frozen tumor sections (10 μm) were incubated with 100 μL 10-9 M of the radio- 
ligands for 1 h, without and with 10-6 M unlabeled tracer. Octreotide (Covidien) 
and Tyr4-bombesin (Sigma-Aldrich) were used to block the somatostatin receptor 
and the gastrin releasing peptide receptor, respectively. Subsequently unbound 
radioligand was removed and slides were exposed to super-resolution phosphor 
screens (Perkin Elmer) for at least 24 h. Next, screens were read using the 
cyclone (Perkin Elmer) and the results were quantified using OptiQuant Software 
(Perkin Elmer). For this tumor containing regions, identified with the help of 
hematoxylin and eosin staining of adjacent tumor sections, were encircled and the 
digital light units/mm2 (DLU/mm2) were measured. Specific binding was deter-
mined by subtracting DLU/mm2 of blocked tissue sections from the DLU/mm2 
of the unblocked sections (DLU/mm2unblocked - DLU/mm2blocked = DLU/mm2specific). 
Standards containing 1 μL drops of the radiotracer solution were also quantified 
and used to determine the percentage of added dose that was bound to the tumors 
(%AD = (DLU/mm2specific / (DLU/mm2standard × 100)) × 100%).
Figure S1. Correlation of ER and HER2 protein status with ESR1 and ERBB2 mRNA levels. 
Arrows indicate used cut-off value.
RLN 
n=20
Brain 
n=12
Lung 
n=5
Liver 
n=10
Ovarian 
n=5
Other 
n=8
Characteristic 
of primary 
tumor № % № % № % № % № % № % № %
Age at surgery 
(years)
≤ 55 34 57 10 50 6 50 3 60 7 70 4 80 4 50
≥ 56 25 42 10 50 6 50 2 40 2 20 1 20 4 50
Tumor size
< 2 - 5 cm 48 80 18 90 9 75 3 60 8 80 2 40 8 100
> 5 cm 9 15 2 10 1 8 1 20 2 20 3 60
Histopathologic 
subtypes
Ductal 50 83 16 80 11 92 5 100 10 100 2 40 6 75
Lobular 9 15 3 15 1 8 3 60 2 25
Other 1 2 1 5
Bloom &  
Richardson 
grade
I + II 12 20 3 15 2 17 4 40 2 40 1 13
III 40 67 16 80 10 83 4 80 5 50 2 40 3 38
ESR1 mRNA 
status
Negative 21 35 9 45 8 67 2 40 1 10 1 13
Positive 38 63 11 55 4 33 3 60 8 80 5 100 7 88
ERBB2 mRNA 
status
Negative 46 77 14 70 10 83 4 80 6 60 5 100 7 88
Positive 13 22 6 30 2 17 1 20 3 30 1 13
Table S1. Overview of clinicopathologic characteristics of the primary BC associated with the 
site of the paired metastases*
* Due to missing values and rounding off numbers do not add up to 100%.
RLN = Regional lymphnode metastases.
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ABSTRACT
Imaging and therapy using radiolabeled somatostatin analogues are methods 
successfully used in patients with somatostatin receptor (SSTR)-expressing 
neuroendocrine tumors. Since these techniques were first introduced, many 
improvements have been made. SSTR expression has also been reported on 
breast cancer (BC). Currently mammography, magnetic resonance imaging and 
ultrasound are the most frequent methods used for BC imaging. Since SSTR 
expression on BC was demonstrated, clinical studies examining the feasibility of 
visualizing primary BC using SSTR radioligands have been performed. However, 
to date SSTR-mediated nuclear imaging is not used clinically in BC patients. The 
aim of this review is to assess whether recent improvements made within nuclear 
medicine may enable SSTR-mediated imaging to play a role in BC management. 
For this we critically analysed results of past studies and discussed the potential 
of the improvements made within nuclear medicine on SSTR-mediated nuclear 
imaging of BC.
Methods: Seven databases were searched for publications on BC imaging with 
SSTR radioligands. The papers found were analysed by 3 individual observers to 
identify whether the studies met the pre-set inclusion criteria defined as studies 
in which nuclear imaging using radiolabeled SST analogues was performed in 
patients with breast lesions. Twenty-four papers were selected for this review 
including studies on SSTR-mediated nuclear imaging in BC, neuroendocrine BC 
and other breast lesions. 
Results: The analysed studies were heterogeneous with respect to the imaging 
method, imaging protocol, patient groups and the radiolabeled SST analogues 
used. Despite the fact that the analysed studies were heterogeneous, sensitivity 
for primary BC ranged from 36-100%. In a subset of the studies LN lesions were 
visualized, but sensitivity was lower compared to that for primary tumors. A 
part of the studies included benign lesions and specificity ranged from 22-100%. 
Furthermore, false negatives and false positives were reported. In the majority of 
the studies scan outcome was not associated with BC subtype.
Conclusions: The introduction of better imaging techniques, e.g. hybrid SPECT/
CT, PET/CT using 68Ga labelled SSTR radioligands and the development of 
dedicated breast cameras, have led to major improvements in the field of radio-
nuclide imaging with regard to sensitivity and spatial resolution. Combining the 
improved imaging techniques with higher receptor affinity somatostatin analogues 
and careful selection of BC subtypes suited for SSTR-mediated imaging, might 
greatly improve nuclear imaging of BC using SSTR radioligands and could poten-
tially provide a role for SSTR-mediated imaging in BC management.
Keywords: 
Breast cancer, Nuclear Imaging, Somatostatin receptor, Somatostatin Receptor-
mediated Imaging
INTRODUCTION 
Breast cancer (BC) has the highest incidence and mortality rate of malignancies 
in women worldwide (1). The disease is highly heterogeneous; subtypes are char-
acterized by molecular properties, such as estrogen receptor (ER) expression, 
that highly influence treatment and prognosis of the disease (2). BC diagnosis 
and classification is based on cytology (3). For detection, staging and monitoring 
of BC lesions several imaging techniques are applied. Mammography is used for 
nationwide BC screenings. The accuracy of this method is influenced by age and 
breast density, which may lead to false positive (6-10% per screening round) or 
false negative (0.1-0.15% per screening round) results (4,5). Other radiology-
based methods applied include magnetic resonance imaging (MRI) and ultra-
sound (US). Both methods have limitations as well, as MRI is labor-intensive and 
US outcome is operator-dependent. Within nuclear medicine multiple methods 
have been described for BC imaging e.g. 18F-FDG PET, and 99mTc-MIBI or 201Th- 
scintigraphy. These methods vary in sensitivity and are not tumor-specific as 
they are based on accumulation of radioactive compounds in highly proliferative 
tissue (4,6). 
Receptor-mediated nuclear imaging and therapy using radiolabeled somatostatin 
(SST) analogues is successfully applied in patients with neuroendocrine tumors 
(NETs) (7,8). In the late 1980s high somatostatin receptor (SSTR) expression 
was described on various NETs, after which radiolabeled SST analogues were 
synthesized to perform imaging and later on radionuclide therapy studies (9). 
In previous studies, SSTR expression was also demonstrated on BC. In 1990 
Reubi et al. (10) demonstrated SSTR expression in 21% of small lesions and 46% 
of large tumors when BC specimens were analysed by in vitro autoradiography. 
Furthermore, Orlando et al. (11) reported lower expression of SSTR subtype 
2 in normal breast tissue compared to malignant breast lesions. Also, studies 
have been performed demonstrating that high SSTR expression in BC tissue is 
positively correlated with ER and progesterone receptor (PR) expression, lymph 
node (LN) involvement, postmenopausal status and tumor grade (11,12).
From the 1990s several studies have been performed to examine the feasibility 
of visualization of primary (and metastatic) BC lesions using radiolabeled SST 
analogues; primarily 111In- or 99mTc-labelled octreotide. Planar scintigraphy was 
the standard method of imaging, in some cases compared with single-photon 
emission computed tomography (SPECT) techniques. These studies showed 
variable results regarding specificity and sensitivity; and currently SSTR- 
mediated imaging is not a standard procedure to localize or stage BC. However, 
major improvements have been made in the field of nuclear imaging; the 
resolution of γ-imaging equipment has increased, sensitive and multimodal 
SPECT/computed tomography (CT) and positron emission tomography (PET)/
CT platforms have been introduced, including dedicated breast cameras, SST 
analogues with higher affinity have been developed and new radionuclides for 
imaging are now available (13-16). Since the expression of SSTR is a prerequisite 
for successful SSTR-mediated imaging, the above mentioned improvements might 
especially be beneficial for breast tumors with low density SSTR expression. 
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Furthermore, our knowledge about BC and its different subtypes and their 
molecular profiles in association with SSTR expression has expanded, enabling 
us to better identify patient groups in which SSTR imaging can be of benefit.
The aim of this review is to assess whether the improvements made within 
the field of nuclear medicine, with respect to imaging modalities, radiolabeled 
peptide analogues and our knowledge about BC itself, may improve SSTR- 
mediated imaging of BC. For this, we critically analysed the past studies and their 
limitations, and discuss the potential influence of recent developments on SSTR-
mediated nuclear imaging in BC and the possible role of this imaging method in 
BC patient care.
LITERATURE SEARCH STRATEGY 
Seven databases (Embase, Medline OvidSP, Scopus, Web-of-Science, Cochrane, 
PubMed publisher and Google Scholar) were searched for publications using the 
following keywords: “somatostatin OR somatostatin receptor OR somatostatin 
derivative OR somatostatin analogue OR depreotide OR pentetreotide OR octre-
otide OR tetraxetan OR 99mTc OR 111In OR 68Ga OR 125I OR 131I OR isotope 
OR radiolabeled OR breast tumor OR breast cancer OR mamma tumor OR mamma 
carcinoma OR metastasis OR neoplasm OR carcinoma OR imaging OR radiodiag-
nosis OR diagnostic imaging equipment OR scintigraphy OR PET OR SPECT OR 
tomography OR tumor detection”. We found a total of 1170 papers (405 papers 
via Embase, 149 papers via Medline OvidSP, 4 papers via Cochrane, 283 papers 
via Web-of-Sience, 326 papers via Scopus and 3 papers via PubMed publisher). 
After removing duplicates 599 papers remained. These papers were analysed by 
3 individual researchers based on pre-set inclusion criteria defined by studies 
in which nuclear imaging using radiolabeled SST analogues was performed in 
patients with breast lesions.
Figure 1 shows a flowchart of the identified and included studies. From the 599 
studies found, 24 studies (17-40), published between 1994 and 2014, fulfilled the 
criteria and were included in this review. The selected papers included studies in 
which SSTR-mediated nuclear imaging was performed in patients with suspected 
or proven breast tumors, patients with neuroendocrine BC and other non-BC 
related lesions in the breast.
ANALYSIS OF SELECTED LITERATURE 
In eleven (17-27) of the selected studies BC patients were included. These 
studies were published between 1994 and 2010 and included a total of 285 
patients (Table 1). BC was either detected by physical examination, cytology, 
mammography, conventional diagnostic methods, clinical findings or histopatho-
logic findings. In 6 of the studies (17-19,22-24) 111In-DTPA-octreotide was the 
only radiopharmaceutical used. In 1 study (20) both 111In-DTPA-octreotide and 
99mTc-Sestamibi were used, while in another study (21) 201Tl-DTPA-octreotide and 
111In-DTPA-octreotide were compared. In the remaining 3 studies 99mTc labelled 
SST analogues were used: 99mTc-depreotide in 1 study (25) and 99mTc-octreotide 
in 2 studies (26,27). Reported sensitivity for SSTR-mediated nuclear imaging 
ranged from 26-100%. Only 6 studies (19,21-23,26,27) included benign lesions, 
resulting in a specificity ranging from 22-100%. In 5 studies SSTR expression 
of the tumor lesions was analysed by in vitro autoradiography, immunohisto 
chemistry (IHC), mRNA analyses or northern blot. Three of these studies 
reported on SSTR specificity of imaging of 93% (17), 85% (22) and 96% (23). 
False positive results were reported in 3 studies: one mastopathy (23), multiple 
fibroadenomas (21,26) and one abscess (21). Non-specific tracer uptake which 
Figure. 1. Flowchart of the studies identified and included in this review
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was not related to the presence of benign nor malignant breast lesions was 
observed in 1 study (18). Multiple explanations were given for uptake in non-
cancerous breast tissue such as the presence of activated peripheral mononuclear 
leucocytes or increased blood flow in case of the abscess, biological 111In-DTPA-
octreotide distribution, non-specific accumulation due to changed breast tissue 
permeability, and binding to premalignant cells (18,21). Four studies (18,20,22,27) 
reported on false negative results in small lesions staged as T1 (<20 mm). 
Furthermore, van Eijck et al. (17) reported on higher sensitivity for T2 than 
T1 tumors. Next to tumor size, 3 studies (17,18,22) reported on false negative 
results in lesions with heterogeneous and/or low density SSTR expression. 
Thus lesions size and SSTR density were indicated as limiting factors for SSTR- 
mediated nuclear imaging. Concerning BC subtypes, a significant correlation of BC 
histological subtype and positive SSTR-mediated nuclear imaging was described 
in 1 study (van Eijck et al. (17): sensitivity of 85% for invasive ductal carcinomas 
(IDCs) vs. 56% for invasive lobular carcinomas (ILCs)). This finding was not 
confirmed in the 4 other studies (18,22,23) that included both IDCs and ILCs. 
Furthermore, 4 studies (18,20,22,24) determined ER and PR expression of the 
visualized lesions, but no correlation was found. Detection of axillary lymph nodes 
(LNs) containing malignant lesions was included in some of the selected studies 
(17,18,20-22,24,26). LN lesions were successfully visualized in all studies but 
this was dependent on the size and the number of lesions present. However, in all 
cases sensitivity was less than in primary tumors. Regarding technical aspects, 
planar scintigraphy was the main imaging method, in 3 cases (18,20,23) supple-
mented with SPECT. The studies by Bajc et al. (18) and Chiti et al. (20) reported 
that SPECT had added value, while this was not discussed in the study by Schulz 
et al. (23). In the majority of the studies imaging was performed at 4 and/or 24 
h post injection (p.i.), but imaging was also performed at other time points e.g. 
0.5 h, 1 h, 5 h and 48 h p.i. There seemed to be a preference for later time points 
(24 h p.i.) e.g. Vural et al. (21) reported on a better tumor to background ratio 
in late images (24 h p.i.) compared to early images (4 h p.i.). In 1 study (22) 
subcutaneous local administration and intravenous administration of 111In-DTPA-
octreotide was compared, resulting in no significant difference between the 
two administration routes. In addition we found 10 papers or abstracts (28-37), 
published between 1995 and 2014, presenting 11 cases of histologically proven 
primary neuroendocrine BC where SSTR-mediated nuclear imaging successfully 
identified the primary tumor, metastases or both. In 8 of these studies planar 
scintigraphy was used (28-35). This was accompanied by SPECT acquisitions 
in 5 studies (29,32-35), while 1 study (31) also acquired images using scinti- 
mammography, presumably with a dedicated camera. 111In-DTPA-octreotide 
was used as radiopharmacon in 7 papers (28-31,33-35) and 99mTc-depreotide in 1 
paper (32). In a study by Huetteman et al. (36) from 2010, PET was performed, 
no details on camera or radiopharmacon were provided though. In the most 
recent study by Mukherjee et al. (37) PET/CT was successfully performed 
using 68Ga-DOTA-NOC. Main reasons for performing SSTR-mediated nuclear 
imaging was to identify the primary tumor after presentation with axillary lymph- 
adenopathy (3 patients, 2 of whom afterwards had radio-guided surgery (28,33) 
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and 1 patient who had a biopsy identifying a neuroendocrine BC (30)), work-up for 
possible peptide receptor radionuclide therapy (3 patients) (34-36) or to exclude 
local remnant disease and/or distant metastases after surgery (1 patient) (31). In 
4 patients described in 3 studies SSTR-mediated nuclear imaging was added to 
preoperative staging without a stated reason (29,32,37).
Furthermore we found 3 papers (38-40) with 5 case reports of positive SSTR-
mediated nuclear scans of the breast for other reasons. Two of these cases visual-
ized NET metastases in the breast, originating from midgut or bronchus carcinoid 
(40). One case of juvenile fibroadenoma (38) and two cases scanned at 1 and 
1.5 month postpartum (39) all showed diffuse high uptake in glandular tissue. 
It was hypothesized by the authors that post-partum uptake of 111In-DTPA- 
octreotide could be the result of upregulation of SSTR2 caused by high blood 
levels of estrogen during pregnancy.
LIMITATIONS OF THE ANALYSED STUDIES
In order to assess whether improvements made within the field of nuclear 
medicine and our knowledge about BC can improve SSTR-mediated imaging in 
BC patients, we critically analysed clinical studies on SSTR-mediated nuclear 
imaging in patients with breast lesions that have been performed over the past 
decades. The analysed studies demonstrated feasibility of BC imaging with SSTR 
radioligands and indicated that lesion size and SSTR density are determining 
factors for successful SSTR-mediated nuclear imaging in BC patients. However, 
combining the data of the presented studies to come to an overall conclusion 
was difficult since the studies were performed in heterogeneous BC popula-
tions, small patients groups were studied, and various SSTR radioligands and 
different imaging protocols were used. Furthermore, details on tumor size, SSTR 
status, BC subset and molecular BC subtype were not reported in many of the 
investigations. Especially the latter is a major flaw of the performed studies. BC 
is a very heterogeneous disease that is characterized by molecular properties 
that influence prognosis as well as treatment of the disease. Examples of the 
most important molecular properties in BC are ER, PR and human epidermal 
growth factor receptor 2 (HER2) expression (2). The heterogeneity within the 
disease is an important factor that cannot be ignored when new imaging and/or 
therapy options are studied, e.g. SSTR expression between BC subtypes may 
vary, making SSTR-mediated imaging unsuitable for some BC subtypes. From 
the 11 studies that included BC patients, only 4 studies (18,20,22,24) correlated 
SSTR expression with ER and PR expression and no correlation was found. Yet, in 
another included study treatment with tamoxifen in hormone-sensitive patients 
resulted in a reduced uptake of 99mTc-depreotide, whereas non-responders showed 
increased uptake in the follow-up scan (25), indicating an association between ER 
expression and SSTR-mediated nuclear imaging. Furthermore, recent preclinical 
studies by Dalm et al. (12) showed a positive correlation between SSTR2 mRNA 
expression and ER and PR mRNA expression in a cohort of 684 LN-negative 
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patients, resulting in the identification of ER- and PR-positive BC patients as 
potential targets for SSTR-mediated nuclear imaging and potentially also therapy. 
This discrepancy can most likely be explained by the relatively small group size 
used in the imaging studies and underlines the need for studies with well-chosen 
homogenous patient groups of sufficient size. Ten of the analysed studies visual- 
ized neuroendocrine breast tumors. This type of tumor is characterized by 
neuroendocrine markers and therefore cannot be compared to other BC subtypes 
(41).
IMPROVEMENTS WITHIN NUCLEAR MEDICINE 
AND SSTR-MEDIATED IMAGING IN BC 
Over the past decades major improvements have been made in the field of 
nuclear medicine with respect to nuclear imaging techniques as well as radio- 
labeled peptide analogues with improved receptor affinity. One such a develop-
ment is the introduction of multimodal SPECT/CT and PET/CT which led to 
major improvement of radionuclide imaging regarding resolution and sensitivity. 
Combining SPECT and PET with anatomical localization by CT increased diag-
nostic accuracy. The superiority of hybrid SPECT/CT over planar imaging or 
SPECT has been demonstrated using 111In-DTPA-octreotide for NET detection, 
as well as for other clinical problems such as head and neck tumors (13). Further-
more SPECT/CT offers quantification of tracer uptake to perform dosimetry and 
evaluation of therapy response (42). PET/CT is even better suited for reliable 
quantification and shows higher sensitivity and spatial resolution than SPECT/CT. 
Several 68Ga-labelled SST analogues are available for PET imaging, which have 
been studied only sporadically in BC cases (37,43). Figure 2 illustrates the differ-
ence between planar scintigraphy (A) and PET/CT (B) in BC patients. In NET 
patients multiple studies demonstrated that 68Ga-DOTA-TOC and 68Ga-DOTA-
TATE PET/ CT were superior to 111In-based SPECT (14,44,45).
Another noteworthy improvement for nuclear BC imaging is the development 
of dedicated PET cameras. The advantage of dedicated breast PET cameras is 
a restricted field of view resulting in an improved spatial resolution to achieve 
higher cancer detection performance, ultimately leading to better sensitivity and 
specificity (15). Currently multiple dedicated breast PET devices are available 
(46). Many studies have been performed comparing full body PET and dedicated 
PET in BC patients, showing preference for a dedicated PET camera. Kalinyak 
et al. (47) observed that imaging using a dedicated PET camera visualized more 
index tumors compared to full body PET and PET/CT. One other welcome 
advantage of dedicated breast PET cameras is enhanced visualization of axillary 
lesions, which are of great importance in BC.
Further improvement could be gained by application of radiolabelled SSTR anta-
gonists. Superior images were obtained when SSTR antagonists were compared 
with SSTR-agonists (such as the currently used octreotide and octreotate), as 
was shown by Ginj et al. (16) and by Wild et al. (48,49). Preclinical studies by 
Cescato et al. (50) examining in vitro binding of an SSTR-agonist and antagonist 
in BC tissues showed an 11±4 times higher binding of the antagonist compared 
to the agonist, indicating that the application of radiolabelled SSTR-antagonists 
might improve detection of BC lesions.
Besides SSTR other targets expressed on BC have been identified for imaging 
(and therapeutic) purposes. Overexpression of the gastrin releasing peptide 
receptor (GRPR) was reported on the majority of BC cases (51). Radiolabelled 
GRPR agonists and antagonists have been described for imaging and therapeutic 
purposes, primarily aiming at prostate cancer patients (52). However, similar 
studies using radiolabelled GRPR-analogues have not yet have been performed in 
BC patients. Furthermore, radiolabelled hormone receptor analogues are studied 
for PET/CT application in BC. Examples of such are 18F-Fes and 89Zr-bevacizumab 
targeting ER and HER2, respectively (53). Currently imaging using these radio-
labeled hormone receptor analogues are not part of the standard clinical routine, 
but investigations proving their benefits are ongoing. With a number of other 
targets being explored for BC imaging, it is important to study the potential 
of SSTR-mediated imaging of BC patients with the current peptide analogues 
and imaging techniques available, in order to accurately compare the available 
compounds.
SSTR-MEDIATED NUCLEAR IMAGING AND  
BC PATIENT CARE 
Taking into account the above described limitations of the past studies and recent 
developments within nuclear medicine, future well designed studies using the 
currently available imaging techniques and the best available radiolabelled SST 
analogues, will better investigate the potential role of SSTR-mediated imaging in 
BC. The question remains whether and how this will contribute to BC patient care. 
One option is to use SSTR-mediated imaging as a tool to monitor therapy response 
after anti-estrogen treatment, since a correlation between ER-positive tumors 
and SSTR expression was demonstrated (12). Furthermore, SSTR-mediated 
imaging might be used for the visualization of sentinel node lesions as a guidance 
for sentinel node biopsy or to exclude the presence of tumor containing lesions, 
in both cases sparing axial lymph node dissection, and the associated costs and 
side effects (54). SSTR expression can be determined prior to scanning using IHC 
of paraffin embedded tissue of biopsy material to determine whether a patient is 
eligible for SSTR-mediated imaging (in the case of sentinel nodes SSTR expres-
sion of primary tumor material can be determined). This prevents unnecessary 
interventions and can easily be added to routine clinical practice since ER, PR 
and HER2 expression is currently also determined by IHC. For patients with a 
positive scan, treatment with ß- or α-labelled SST analogues might be an option. 
Since about 70% of the total BC population is ER-positive, we consider that a 
large part of the BC patients might benefit from SSTR-mediated imaging and 
therapy (2). Focusing on therapeutic possibilities, therapy using radiolabelled 
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SST analogues can potentially be an option for BC patients that show resis- 
tance against anti-estrogen treatment, which is about 40% of the patients that are 
eligible for this type of treatment (55).
CONCLUSION 
From 1990 onward studies were performed 
showing the feasibility of SSTR-mediated 
nuclear imaging in BC patients, despite varia- 
tions in study parameters, imaging agents 
and imaging techniques used. Since high 
sensitivity and specificity rates have been 
found in the reviewed studies, we expect that 
the recent major improvements in the field 
of nuclear medicine, including application 
of radiolabelled SST analogues with higher 
receptor affinity and/or antagonistic proper-
ties, will be of great benefit for this purpose. 
In future studies, the different subtypes of 
BC should be taken into account, since BC is 
a very heterogeneous disease and this might 
lead to the identification of specific subtypes 
of BC that can benefit most from the use 
of radiolabelled SST analogues for targeted 
imaging and potentially also for therapeutic 
applications, which might have a significant 
impact on BC patient care.
Figure 2. Comparison of a planar whole body scintigram (A) and a PET/CT scan (B). The 
improvements within nuclear medicine enable SSTR-mediated tumor visualization with a 
higher sensitivity and resolution, leading to improved diagnostic accuracy. A) Whole-body 
scintigram of a patient with confirmed bilateral ductal carcinoma (Bajc et al. (18)). Images 
were obtained 0.5, 5 and 24 h after i.v. injection of 110 MBq 111In-DTPA-octreotide (18). 
B) 68Ga-DOTA-NOC PET/CT scan of a patient with a NET of the breast (Mukherjee et al. 
(37)). SSTR-expressing metastatic lesions were found in multiple bilateral axillary and right 
cervical lymph nodes, bilateral lungs and multiple skeletal sites (I-VII) (37).
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ABSTRACT
Recent studies showed enhanced tumor targeting by novel somatostatin receptor 
(SSTR) antagonists compared to clinically widely used agonists. However, these 
results have been obtained in neuroendocrine tumors; as yet no data are available 
for cancer types with lower SSTR expression, including breast cancer (BC). In 
this preclinical study, we investigated whether application of a SSTR antagonist 
could improve SSTR-mediated BC imaging.
Methods: 111In-DOTA-Tyr3-octreotate (SSTR agonist) and 111In-DOTA-JR11 
(SSTR antagonist) binding to 40 human BC specimens was compared using in vitro 
autoradiography. Furthermore, in vivo SPECT/MR imaging was performed in a 
BC mouse model after injection of 177Lu-DOTA-Tyr3-octreotate or 177Lu-DOTA-
JR11. Also, radioactivity uptake of excised tumors was measured.
Results: 111In-DOTA-JR11 binding to human BC tissue was 6±11 times higher 
than 111In-DOTA-Tyr3-octreotate binding. SPECT/MRI resulted in better tumor 
visualization with the antagonist, corresponding with the measured tumor uptake.
Conclusions: SSTR antagonists are promising candidates for BC imaging.
Keywords: 
Breast Cancer, Imaging, Somatostatin Receptor, Somatostatin Receptor 
Antagonist
INTRODUCTION
Somatostatin receptor (SSTR)-mediated imaging of neuroendocrine tumors 
using SSTR agonists is successfully applied in the clinic. In 1990, Reubi et al. (1) 
reported SSTR expression in 21-46% of BC specimens. Since then, multiple 
studies targeting these receptors were performed. However, due to conflicting 
results SSTR-mediated imaging is currently not routinely used in BC patients. 
Low and heterogeneous SSTR expression seems to be the main reason for 
unsuccessful tumor targeting (2). Therefore, novel developments are needed to 
improve SSTR-mediated breast cancer (BC) imaging.
A promising development is the application of SSTR antagonists. Enhanced tumor 
targeting of receptor antagonists vs. agonists is counterintuitive, since agonists 
can be internalized leading to intracellular accumulation of radioactivity. However, 
Ginj et al. (3) reported that SSTR antagonists bind to more binding sites. Based 
on the results of recent studies demonstrating enhanced tumor targeting with 
SSTR antagonists (3-6), the ability of the antagonist to bind to more binding sites 
could be more important than internalization. The previous studies are mainly 
based on neuroendocrine tumors. However, the enhanced binding of antagonists 
might especially be interesting for targeting of low SSTR-expressing cancers, 
such as BC.
The aim of this study was to investigate whether the use of SSTR antagonists 
could improve SSTR-mediated BC imaging. For this purpose, we compared 
the use of the SSTR agonist (DOTA-Tyr3-octreotate) and the SSTR antagonist 
(DOTA-JR11) in 40 human BC specimens and in a BC mouse model.
MATERIALS AND METHODS
Radioligands
The SSTR agonist, DOTA-Tyr3-octreotate (BioSynthema) and the SSTR anta-
gonist, DOTA-JR11 (kindly provided by Dr. Helmut Maecke) were used. The 
radiotracers were radiolabeled with 111In (Covidien) or 177Lu (IDB) as previ-
ously described (7). Specific activity was 80 and 100 MBq/nmol for the 111In and 
177Lu labeled peptide analogs, respectively. Radiometal incorporation and radio- 
chemical purity were >90%. 
Human BC Specimens
Fresh frozen tissue specimens from 40 human BCs (31 ductal carcinomas, 4 
lobular carcinomas and 5 other subtypes) were selected from the Erasmus MC 
tissue bank for autoradiography studies comparing SSTR agonist and anta-
gonist binding. The majority of the cases were positive for estrogen receptor 
(ER: 75%), progesterone receptor (PR: 55%) and human epidermal growth factor 
2 (HER2: 18%).
The study adhered to the Code of Conduct of the Federation of Medical Scientific 
Societies in The Netherlands. 
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In Vitro Autoradiography
Fresh frozen tissue sections (10 µm) were incubated for 1.5 h with 100 μL 
10-9 M 111In-DOTA-Tyr3-octreotate or 111In-DOTA-JR11, with or without 10-6 M 
octreotide as a control for receptor specificity. Following incubation, the excess 
radiotracer was removed and tissue sections were exposed to super resolution 
phosphor screens (Perkin Elmer) for 3 d, after which screens were read using the 
Cyclone (Perkin Elmer). Binding of the radiotracers to tumor containing regions, 
identified by hematoxylin and eosin (H&E) stainings of adjacent tissue sections, 
was quantified using OptiQuant software (Perkin Elmer) and expressed as digital 
lights units per mm2 (DLU/mm2). Quantified uptake was corrected for non-specific 
binding by subtracting DLU/mm2 of the blocked sections from DLU/mm2 of the 
unblocked sections. Drops containing 1 μL 10-9 M of the radiotracers were used 
as standards to determine the added dose (DLU/mm2standards×100). Tumor-bound 
radiotracer was expressed relative to the added dose (%AD). 
Mouse Model, SPECT/MRI and Biodistribution
All animal experiments were approved by the Animal Welfare Committee and 
conducted in accordance to accepted guidelines.
In order to select an appropriate in vivo mouse model, excised tumor material 
from 6 BC patient derived tumor xenografts (pdx) were tested for agonist and 
antagonist binding using autoradiography. Subsequently, one xenograft was used 
to create an in vivo model for imaging and biodistribution studies.
For the in vivo studies, tumor pieces (~6 mm3) from a donor animal were trans-
planted in the 4th mammary fat pad of Balb c nu/nu female mice supplemented 
with 4 mg/L ß-estradiol. When tumors were ~1300 mm3, animals received an 
intravenous injection of ~20 MBq/200 pmol 177Lu-DOTA-Tyr3-octreotate or 
177Lu-DOTA-JR11 (n=2 per radiotracer). SPECT/MRI was performed 4 h after 
radiotracer injection, while animals were anesthetized using isoflurane/O2 and 
body temperature was maintained. Focused SPECT images were acquired using 
a 4-head multipinhole system (NanoScan SPECT/MRI, Mediso Medical Imaging) 
in 30 min (28 projections, 60 s/projection). Images were reconstructed using 
the OSEM method with 6 iterations. Concerning MRI, T1 and T2 images were 
acquired using a gradient echo sequence (TR/TE=12/2 ms) and a spin echo 
sequence (TR/TE=4500/52 ms). Other scan parameters were: field of view: 70 
mm, matrix: 128×128 and slice thickness: 1 mm. The MR images were used to 
assess tumor composition.
After imaging, animals were euthanized, organs and tumors were excised, 
weighed and counted in an automatic γ-counter (1480 WIZARD, PerkinElmer) 
to determine the percentage of injected dose per gram tumor (%ID/g tissue). 
A radionuclide specific energy window, a counting time of 60 s and a counting 
error <5% were used for γ-counter measurements.
Fresh frozen tissue from excised tumors was used to perform H&E and SSTR2-im-
munostaining (SS-8000-RM SSTR2A antibody (BIO-TREND), dilution: 1:50, 
Ventana Medical System).
Statistics
Grahpad Prism 5 was used for statistical analyses. The Wilcoxon signed rank 
test was used to compare the %AD of the radiotracers in human BC samples. To 
compare radioligand binding of ER, PR and HER2 positive vs. negative samples, 
the Mann Whitney test was used. P<0.05 were considered statistically signifcant. 
Figure 1. A) Representative autoradiography results performed with 111In-DOTA-JR11 and 
111In-DOTA-Tyr3-octreotate, and H&E stainings indicating tumor cells. B) Quantified uptake 
(%AD) of the radiotracers. C) Ratio of radiotracer binding (antagonist/agonist).
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Figure 2. A) Autoradiography results (without and with octreotide to determine specificity of 
binding) of tumor material from 6 pdx’s. B) Quantified uptake (%AD) of 111In-DOTA-JR11 
and 111In-DOTA-Tyr3-octreotate of the autoradiography displayed in A.
RESULTS
In Vitro Autoradiography
The results of the in vitro autoradiography experiment were quantified. The %AD 
of the antagonist bound to the BC specimens was significantly higher (P<0.001) 
than that of the agonist (Figure 1). Amongst the receptor positive tumors (38/40), 
the ratio %AD antagonist to %AD agonist ranged from 1 (only 1 case) to 57 
(average ratio±sd=6±11). 
There was no significant association between the %AD of 111In-DOTA-JR11 or 
111In-DOTA-Tyr3-octreotate with ER (P=0.2 and 0.8, respectively), PR (P=0.3 
and 0.1, respectively) and HER2 status (P=0.2 and 0.09, respectively).
Six excised tumors from BC pdx’s were tested for agonist and antagonist binding 
(Figure 2). Antagonist binding was clearly higher for 3/6 xenografts (T126, 
T283 and T250), while low binding was observed in the remaining xenografts. 
Two xenografts showed relatively high 111In-DOTA-JR11 and 111In-DOTA-Tyr3-
octreotate binding (T126 and T283) and were suited for in vivo experiments. 
Finally, T126 was chosen to create an in vivo mouse model, since this model 
is ER-positive which seems to be the most promising BC subtype for SSTR-
mediated imaging (8). 
SPECT/MRI and Biodistribution
The images acquired with 177Lu-DOTA-Tyr3-octreotate and 177Lu-DOTA-JR11 
are displayed in Figure 3A+B. The T1 and T2 MR images showed homogenous 
signal intensity throughout the tumor, indicating viability. SPECT images demon-
strated higher uptake of 177Lu-DOTA-JR11 vs. 177Lu-DOTA-Tyr3-octreotate. H&E 
and SSTR2-immunostaining demonstrated SSTR2 expression on the tumor 
(Figure 3C+D). 
In line with SPECT/MRI results, biodistribution studies resulted in a 1.9 
times higher tumor uptake of the antagonist vs. the agonist (Figure 3E). High 
177Lu-DOTA-JR11 and 177Lu-DOTA-Tyr3-octreotate uptake was also observed in 
the pancreas (5.51±0.01 and 0.91±0.06 %ID/g tissue, respectively) and kidneys 
(12.07±2.42 and 6.30±1.25 %ID/g tissue, respectively). This resulted in a better 
tumor to pancreas ratio with 177Lu-DOTA-Tyr3-octreotate vs. 177Lu-DOTA-JR11 
(1.02 vs. 0.33), while tumor to kidney ratio was similar.
DISCUSSION
SSTR-mediated nuclear imaging is currently not applied for BC, due to variable 
results of clinical studies. However, most of these studies were performed over 
a decade ago, while recently major improvements have been made including 
the development of SSTR antagonists. Previous research demonstrated that 
SSTR antagonists bind to more binding sites than agonists (3). Furthermore, 
antagonists are described to be more chemically stable and hydrophobic, which 
could result in a longer time of action (3). Therefore, the application of SSTR 
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Figure 3. SPECT/MR images acquired post injection of 177Lu-DOTA-JR11 (A) and 
177Lu-DOTA-Tyr3-octreotate (B). Scales are equal for both images. The dotted lines indicate 
the area scanned with SPECT. Arrows indicate tumor xenografts. C+D) H&E and SSTR2-
immunostaining of excised tumors showing SSTR2 expression. Arrows indicate normal 
tissue without SSTR2 expression. E) Radioactivity uptake (%ID/g tissue) measured in 
excised tumors and organs.
antagonists might offer novel possibilities for successful BC imaging. In this 
study, we compared the SSTR agonist 111In-DOTA-Tyr3-octreotate and the anta-
gonist 111In-DOTA-JR11 in 40 human BC specimens and in a BC mouse model. 
Since both DOTA-Tyr3-octreotate and DOTA-JR11 have high affinity for SSTR 
subtype 2 and low affinity for other SSTR subtypes, the observed difference in 
binding/uptake is mainly based on interaction with SSTR subtype 2 (9,10).
We found significant higher binding of 111In-DOTA-JR11 vs. 111In-DOTA-Tyr3-
octreotate to the BC specimens. Our findings are in line with results of Cescato 
et al. (4), who demonstrated higher binding of 177Lu-DOTA-BASS, another SSTR 
antagonist, compared to 177Lu-DOTA-Tyr3-octreotate in 7 BCs. The authors also 
compared 177Lu-DOTA-BASS and 177Lu-DOTA-Tyr3-octreotate in other tumor 
types, including pheochromocytoma’s. Binding of the antagonist to BCs was as 
high as binding of the agonist to pheochromocytoma’s. Since pheochromocytoma’s 
are successfully targeted with the agonist (4), this indicates the potential of 
targeting BC with SSTR antagonists.
In our in vivo-model, tumors were visualized better with 177Lu-DOTA-JR11 
vs. 177Lu-DOTA-Tyr3-octreotate, corresponding to the measured ex vivo tumor 
uptake. High radiotracer uptake was also observed in the kidneys and pancreas. 
Kidney uptake can be reduced by co-injecting with kidney protectors (6,11). The 
higher tumor to pancreas ratio with the antagonist has to be taken into account, 
especially when the radiotracer will be used for therapy. However, radiosensi-
tivity of the pancreas is relatively low (12) and the washout seems to relatively 
fast (5). 
Dude et al. (13) compared the uptake of 2 SSTR agonists (68Ga-DOTATOC and 
68Ga-DOTA-Tyr3-octreotate) and 1 SSTR antagonist (68Ga-NODAGA-JR11) in 
another BC model. The authors reported a higher uptake of 68Ga-DOTATOC vs. 
68Ga-NODAGA-JR11, while similar to our findings 68Ga-NODAGA-JR11 tumor 
uptake was higher than that of 68Ga-DOTA-Tyr3-octreotate. These findings could 
be explained by the different affinity of 68Ga-DOTATOC for SSTR subtypes 
compared to 68Ga-NODAGA-JR11 and 68Ga-DOTA-Tyr3-octreotate and indicate 
that SSTR antagonist might not always be superior for tumor targeting.
Considering that 177Lu is a therapeutic radionuclide, the next step would be to 
determine whether 177Lu-DOTA-JR11 could also be used for safe and effective BC 
treatment. In line with our previous study in a human lung cancer model (5), we 
expect that the enhanced in vivo tumor uptake of the antagonist in BC will also 
result in a better therapeutic efficacy. Thus, SSTR-mediated BC targeting can 
offer both imaging and therapy options.
In conclusion, we demonstrated the advantage of radiolabeled SSTR antagonists 
vs. agonists for BC targeting in a preclinical setting, shedding new light on SSTR-
mediated BC imaging. The application of an SSTR antagonist, combined with 
other recent developments, including dedicated breast cameras (14) and PET 
radionuclides (15), is very promising and might result in a (more) important role 
for SSTR-mediated imaging (and treatment) of BC patients.
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ABSTRACT
Peptide receptor scintigraphy and peptide receptor radionuclide therapy using 
radiolabeled somatostatin receptor (SSTR) agonists are successfully used in 
the clinic for imaging and treatment of neuroendocrine tumors. Contrary to the 
paradigm that internalization and the resulting accumulation of radiotracers 
in cells is necessary for efficient tumor targeting, recent studies have demon-
strated the superiority of radiolabeled SSTR antagonists for imaging purposes, 
despite little to no internalization in cells. However, studies comparing the thera-
peutic antitumor effects of radiolabeled SSTR agonists versus antagonists are 
lacking. The aim of this study was to directly compare the therapeutic effect of 
177Lu-DOTA-octreotate, an SSTR agonist, and 177Lu-DOTA-JR11, an SSTR anta-
gonist.
Methods: We analyzed radiotracer uptake (both membrane-bound and inter-
nalized fractions) and the produced DNA double-strand breaks, by determining 
the number of p53 binding protein 1 foci, after incubating SSTR2-positive 
cells with 177Lu-diethylene triamine pentaacetic acid, 177Lu-DOTA-octreotate, 
or 177Lu-DOTA-JR11. Also, biodistribution studies were performed in tumor- 
xenografted mice to determine the optimal dose for therapy experiments. 
Afterward, in vivo therapy experiments comparing the effect of 177Lu-DOTA-
octreotate and 177Lu-DOTA-JR11 were performed in this same animal model.
Results: We found a 5 times higher uptake of 177Lu-DOTA-JR11 than of 177Lu-DOTA-
octreotate. The major part (88%±1%) of the antagonist uptake was membrane-
bound, whereas 74%±3% of the total receptor agonist uptake was internalized. 
Cells treated with 177Lu-DOTA-JR11 showed 2 times more p53-binding protein 1 
foci than cells treated with 177Lu-DOTA-octreotate. Biodistribution studies with 
177Lu-DOTA-JR11 (0.5 μg/30 MBq) resulted in the highest tumor radiation dose 
of 1.8±0.7 Gy/MBq, 4.4 times higher than the highest tumor radiation dose found 
for 177Lu-DOTA-octreotate. In vivo therapy studies with 177Lu-DOTA-octreotate 
and 177Lu-DOTA-JR11 resulted in a tumor growth delay time of 18±5 and 26±7 d, 
respectively. Median survival rates were 43.5, 61, and 71 d for the control group, 
177Lu-DOTA-octreotate group, and the 177Lu-DOTA-JR11-treated group, respec-
tively.
Conclusions: On the basis of these results, we concluded that the use of radio-
labeled SSTR antagonists such as JR11 might enhance peptide receptor scinti-
graphy and peptide receptor radionuclide therapy of neuroendocrine tumors and 
provide successful imaging and therapeutic strategies for cancer types with rela-
tively low SSTR expression.
Keywords:
PRRT, Somatostatin Receptor, Agonist, Antagonist, Therapy
INTRODUCTION
Radiolabeled somatostatin (SST) analogs targeting SST receptors (SSTRs), espe-
cially SSTR2, overexpressed on tumor cells are successfully used for imaging 
and treatment of neuroendocrine tumors. These applications are referred to as 
peptide receptor scintigraphy (PRS) and peptide receptor radionuclide therapy 
(PRRT), respectively. PRS using radiolabeled SST analogs was first described in 
the late 1980s by Krenning et al. (1), and soon after the first studies using radio-
labeled SST analogs for PRRT followed. 111In-diethylene triamine pentaacetic acid 
(DTPA)-octreotide was the first SSTR radioligand used for therapy and although 
results were positive, partial remissions were uncommon. Over time multiple 
SST analogs with improved receptor affinity, mostly receptor agonists, have been 
developed and described. These SST analogs have been coupled to different 
chelators, enabling labeling of the SST analogs with positron-emitters, such as 68Ga 
for PET scanning, and β-emitters, such as 90Y and 177Lu for therapeutic purposes, 
leading to better imaging and therapy results. Concerning therapy, response 
rates between 10% and 35% have been reported after treatment of gastroen-
tero-pancreatic neuroendocrine tumors using 90Y-DOTATOC or 177Lu-DOTA- 
octreotate (2,3). Although results are positive, there is room for improvement 
of PRRT using SSTR radioligands. Recent developments to improve therapeutic 
outcome with SSTR radioligands include the use of a combination of 90Y- and 
177Lu-labeled peptide analogs, PRRT using α-emitters, and the combination of 
PRRT with other anticancer agents (4). Another recent development is the intro-
duction of SST analogs with receptor antagonistic properties. For decades it was 
believed that radiolabeled receptor agonists would be superior to antagonists, 
because they are internalized upon receptor binding, resulting in accumulation of 
radioactivity in tumor cells. However, recent in vitro and human studies surpri- 
singly showed higher tumor uptake of SSTR antagonists than SSTR agonists 
(5-8). Wild et al. (8) reported a 1.7- to 10.6-fold-higher tumor dose when patients 
were scanned with 177Lu-DOTA-JR11, an SSTR antagonist, than with 177Lu-DOTA-
octreotate, an SSTR agonist. Furthermore, in this same study it was demon-
strated that therapy with 177Lu-DOTA-JR11 is feasible (8).
To date, to our knowledge no study, neither preclinical nor clinical, has been 
performed comparing therapeutic responses between radiolabeled SSTR agonists 
and SSTR antagonists. The aim of this study was to compare the therapeutic 
effect of 177Lu-DOTA-octreotate and 177Lu-DOTA-JR11 in vivo in the H69 SSTR-
positive mouse xenograft model. We first determined the optimal peptide amount 
for therapy using these radiotracers by performing biodistribution studies. Also, 
in vitro experiments were performed studying the uptake and the DNA damage 
response after treatment with the radiotracers.
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MATERIALS AND METHODS
Radioligands
The SSTR agonist DOTA-octreotate (molecular weight: 1,436 g/mol) (BioSynthema) 
and the SSTR antagonist JR11 (molecular weight: 1,690 g/mol) (9) (kindly provided 
by Dr. Helmut Maecke) were radiolabeled with 177Lu (IDB), using quenchers to 
prevent radiolysis, as previously described (8,10,11). Specific activity was 53 MBq/
nmol for in vitro studies and 0.5 μg/30 MBq, 1.0 μg/30 MBq, and 2.0 μg/30 MBq for 
in vivo studies. Instant thin-layer chromatography on silica gel and high-pressure 
liquid chromatography were used to measure radiometal incorporation (>95%) and 
radiochemical purity (>90%) as previously described (11).
Cell Lines and Cell Culture
The SSTR2 complementary DNA sequence from image clone 3875163 (Life 
Technologies) was cloned into the pcDNA3.1 vector (Life Technologies). Human 
osteosarcoma cells (U2OS) were transfected with the pcDNA3.1-SSTR2 vector 
using X-treme GENE HP Transfection Reagent (Roche Life Sciences) and selected 
for 2 wk with Geneticin (Life Technologies). Single cell colonies were grown to 
obtain a pure SSTR2-positive cell line (U2OS+SSTR2). Cells were cultured in 
Dulbecco modified Eagle medium (Lonza), supplemented with 10% fetal bovine 
serum (Biowest) and 5 mL of penicillin (5,000 units/mL) and streptomycin (5,000 
μg/mL) (Sigma Aldrich), at 37°C and 5% CO2.
Uptake Assay
The membrane-bound and internalized fractions of the radiotracers were deter-
mined after incubation of the cells with 4 different concentrations of 177Lu-DOTA-
octreotate or 177Lu-DOTA-JR11. To demonstrate SSTR specificity of the uptake, 
cells were also incubated with equal amounts of 177Lu-DTPA.
Cells were seeded in 12-well plates 1 d before the experiment. The next day, 
adhered cells (8×104 cells/well) were incubated with 5×10-8 M/2.5 MBq, 2×10-8 
M/1 MBq, 5×10-9 M/0.25 MBq, or 2×10-9 M/0.1 MBq of 177Lu-DOTA-octreotate, 
177Lu-DOTA-JR11, or equal amounts of 177Lu-DTPA in 1 mL of culture medium for 
4 h at 37°C. After incubation, supernatant was removed and cells were washed 
twice with phosphate-buffered saline (PBS) (Lonza). Membrane-bound radi-
otracer fraction was separated from the internalized fraction by incubating cells 
for 10 min with an acid solution (50 mM glycine and 100 mM NaCl, pH 2.8). 
Subsequently, cells were lysed using 0.1 M NaOH to collect the internalized radio-
tracer fraction. Membrane-bound and internalized radiotracer fractions were 
counted in a γ-counter (1480 WIZARD automatic γ-counter; PerkinElmer) using 
a radionuclide-specific energy window, a counting time of 60 s, and a counting 
error of 5% or less. Data are expressed as percentage added dose.
DNA Damage Immunofluorescent Staining
DNA double-strand break (DSB) formation was determined by quantifying the 
number of p53-binding protein 1 (53BP1) foci per nucleus over time in cells 
treated with the radiotracers. 53BP1 is a key protein that is recruited to DSB 
during early repair and is therefore a good marker for DSBs (12). Its accumula-
tion on the DSB is visualized as nuclear foci.
To measure DNA DSBs, cells were seeded on glass coverslips in 6-well plates 
1 d before the experiment. The next day, adhered cells were incubated with 5 
MBq of 177Lu-DTPA, 7.9×10-8 M/5 MBq of 177Lu-DOTA-octreotate, or 7.9×10-8 
M/5 MBq of 177Lu-DOTA-JR11 in 2 mL culture medium for 4 h at 37°C. Subse-
quently, cells were washed twice with PBS and incubated for different time points 
(0, 1, 2, and 3 d) in culture medium without radiotracers. Cells were fixed with 
1 mL of 2% paraformaldehyde (Sigma Aldrich) for 15 min at room temperature 
(RT), permeabilized in PBS containing 0.1% Triton X-100 (Sigma Aldrich) by 
incubating twice for 10 min at RT, and incubated in blocking buffer (PBS, 0.1% 
Triton X-100, 2% bovine serum albumin [Sigma Aldrich]) for 30 min at RT. Next, 
cells were incubated for 90 min at RT with the primary antibody, anti-53BP1 
(NB100-304 [Novus Biologicals]; 1/1,000) diluted in blocking buffer. After incuba-
tion, cells were washed 3 times for 5 min at RT with PBS and 0.1% Triton X-100 
and incubated with the secondary antibody (goat antirabbit Alexa Fluor 594 [Life 
Technologies]; 1/1,000) in blocking buffer for 60 min at RT. Cells were mounted 
with Vectashield (Vector Laboratories) containing DAPI (4’,6-diamidino-2- 
phenylindole). Z-stack imaging was performed using a TCS SP5 confocal micro-
scope (Leica), and foci were counted from 30 to 40 cells per condition using Image 
J software (National Institutes of Health). Foci were considered legitimate when 
their size was between 20 and 100 squared pixels; foci smaller or bigger were 
considered background staining.
In Vivo Biodistribution Studies
All animal experiments were approved by the Animal Welfare Committee of the 
Erasmus MC, and all experiments were conducted in accordance to accepted 
guidelines.
Balb c nu/nu male animals, subcutaneously (right shoulder) inoculated with 
4×106-4×107 cells of the SSTR2-positive human small cell lung cancer cell line 
H69, were used in this study. Tumors were allowed to grow for 3-4 wk after 
cell inoculation. Tumor size was 241±151 mm3 for biodistribution studies and 
701±387 mm3 for in vivo therapy studies.
To determine the optimal radiotracer peptide amount for therapy, biodistribution 
studies were performed. Because studies determining the optimal dose 
for 177Lu-DOTA-octreotate were previously performed at our department, 
biodistribution studies were performed only for 177Lu-DOTA-JR11. For this, 
animals were injected with 0.5 μg/30 MBq, 1 μg/30 MBq, or 2 μg/30 MBq of 
177Lu-DOTA-JR11. At 4 time points (4 h, 2 d, 4 d, and 7 d) after injection, animals 
(n=4 per peptide amount for each time point) were euthanized, and tumors 
and organs were collected, weighed, and counted in a γ-counter as previously 
mentioned. The radioactivity uptake in tumor and organs was determined and 
expressed as percentage injected dose per gram of tissue (%ID/g).
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In Vivo Therapy Studies
In the therapy experiment, 24 Balb c nu/nu male mice with subcutaneous H69 
xenografts were intravenously injected with 0.5 μg/30 MBq of 177Lu-DOTA-JR11, 
0.5 μg/30 MBq of 177Lu-DOTA-octreotate, or 200 μL of injection fluid (sham) 
(n=8 each group). Animals injected with either one of the radiotracers were pre-
injected with 4 mg of modified fluid gelatin (Gelofusin; Braun) to reduce renal 
uptake (13). Tumor size, weight, and physical well-being of the animals were 
monitored 3 times per week. Mice were euthanized when tumor size reached 
2,000 mm3 or animal weight decreased by 10% or more.
Dosimetry
Absorbed doses were calculated for both compounds in organs with physiologic 
uptake and in the tumor xenografts. Organ dosimetry was performed according 
to the MIRD principle following the equation for absorbed dose in organ j as a 
summation from all source organs i: .
Time-activity curves were determined by least-squares fitting of single- 
exponential curves through the data, using Prism software (GraphPad). The 
time-integrated activity coefficients ãi in each source organ i were determined 
by integration of the exponential curves folded with the 177Lu decay (half-life, 
6.647 d). The S value 177Lu dose factors were taken from the 25-g RADAR stylized 
mouse phantom (14). The absorbed doses in the tumor xenografts were deter-
mined using the spheric node option within the Olinda/EXM software (15).
Statistics
Tumor growth curves were individually determined by least-squares fitting of 
single-exponential growth curves to the tumor size measurements against 
time. The growth curves of animals were extrapolated to later times beyond 
the censoring endpoint due to the maximum tumor volume of 2,000 mm3. The 
extrapolated data were combined with the data of the longest surviving animals to 
obtain a collective growth curve within each group. Group-averaged mean values 
of tumor size as a function of time were considered only for normally distri-
buted tumor volumes at each time point using the Shapiro-Wilk normality test. 
A Pearson correlation coefficient R2>0.8 was used for acceptance of the fits. The 
growth delay time was defined as the difference in time to reach the maximum 
tumor volume of 2,000 mm3 between the treatment group and the control. Signifi-
cant differences were evaluated using the 1-way ANOVA test, after checking 
for normality by the Shapiro-Wilk normality test. All statistical evaluations were 
performed with Prism software.
RESULTS
In Vitro Uptake of 177Lu-DOTA-octreotate and 177Lu-DOTA-JR11
In the in vitro assay, tumor cell uptake of both 177Lu-DOTA-octreotate and 
177Lu-DOTA-JR11 was observed. Little to no uptake was seen, on the other 
hand, when cells were incubated with 177Lu-DTPA, demonstrating receptor 
specificity of the radiotracers. The total uptake of 177Lu-DOTA-JR11 was up to 
5 times higher than the 177Lu-DOTA-octreotate uptake (Figure 1). Furthermore, 
the lowest peptide amount added resulted in the highest percentage added dose 
uptake of both radiotracers. Most radioactivity uptake of 177Lu-DOTA-octreotate, 
74±3 %, was internalized, whereas most, 88±1%, of 177Lu-DOTA-JR11 uptake was 
membrane-bound, in line with the receptor agonistic versus receptor antagonistic 
properties of the 2 radiotracers.
DNA Damage Response
The timing and level of DNA DSB induction and repair were quantified by 
counting the number of 53BP1 foci per nucleus over time (Figure 2). Initially, 
DSBs were induced by 177Lu-DTPA, 177Lu-DOTA-octreotate, and 177Lu-DOTA-
JR11. However, after unbound radioactivity/radiotracers were removed, the 
177Lu-DTPA-induced DSBs were repaired within a day, whereas DSBs caused by 
177Lu-DOTA-octreotate and 177Lu-DOTA-JR11 remained present for at least 3 d. 
In line with the difference in uptake, 177Lu-DOTA-JR11 treatment produced more 
DSBs than 177Lu-DOTA-octreotate treatment, and this increased level of DSBs 
remained over time.
Figure 1. Uptake of SSTR agonist 177Lu-DOTA-octreotate and SSTR antagonist 
177Lu-DOTA-JR11 in the SSTR2-transfected U2OS cell line. %AD=percentage added dose.
Chapter 7 Therapy with A Radiolabeled SSTR Agonist vs. Antagonist
127126
7
Figure 2. DNA damage response studied by analyzing 53BP1 foci in U2OS+SSTR2 cells after 
treatment with 177Lu-DOTA-octreotate and 177Lu-DOTA-JR11. Nontreated and 177Lu-DTPA-
treated cells were taken along as controls. A) Pictures of 53BP1 and DAPI (nuclear) staining 
of treated and untreated samples at different time points after treatment. 53BP1 is in red, 
DAPI is in blue. B) Quantification of 53BP1 foci in 30-40 cells per condition after treatment. 
Error bars represent SEM.
In Vivo Biodistribution and Dosimetry of 177Lu-DOTA-JR11
Biodistribution studies were performed at 4 different time points after injection 
of 0.5 μg/30 MBq, 1.0 μg/30 MBq, or 2.0 μg/30 MBq of 177Lu-DOTA-JR11. 
Injection of 0.5 μg/30 MBq of the radiotracer resulted in the highest tumor 
uptake, with the lowest variation (20.8±3.4 %ID/g of tissue 4 h after injection). 
Next to the tumor uptake, high uptake was seen in the kidneys (31.1±5.5 %ID/g 
of tissue 4 h after injection), as a consequence of urinary excretion and partial re- 
absorption of the radiotracer, and in the SSTR2-expressing pancreas (9.28±1.22 
%ID/g of tissue 4 h after injection) and stomach (7.74±1.00 %ID/g of tissue 4 h 
after injection). Kidney, stomach, and pancreas radioactivity decreased rela-
tively quickly, with clearance half-lives ranging between 14 and 19 h, whereas 
tumor uptake remained longer, with a clearance half-life of 30 h. Seven days after 
injection of 0.5 μg/30 MBq of 177Lu-DOTA-JR11, tumor radioactivity was 6.8±2.5 
%ID/g of tissue, whereas kidney, stomach, and pancreas uptake was 1.20±0.26, 
0.64±0.20, and 0.32±0.07 %ID/g of tissue, respectively. The results of the 
biodistribution study are displayed in Table 1. Dosimetry calculations resulted in 
a tumor radiation dose of 1.8±0.7 Gy/MBq using 0.5 μg of the radiotracer. The 
tumor and highest organ doses for the different peptide amounts are indicated in 
Table 2. The tumor, pancreas, and stomach doses were reduced considerably by 
higher peptide amount, whereas the dose to the kidney remained constant.
In Vivo Therapy Studies
Balb c nu/nu animals with H69 xenografts received either a sham injection, a 
therapeutic injection of 0.5 μg/30 MBq of 177Lu-DOTA-octreotate, or 0.5 μg/30 
MBq of 177Lu-DOTA-JR11, the optimal peptide amount previously reported for 
177Lu-DOTA-octreotate and the optimal peptide amount measured in biodistribu-
tion studies for 177Lu-DOTA-JR11. Animals treated with 177Lu-DOTA-JR11 showed 
a decrease in tumor size up to 45±7 d after injection after which tumor regrowth 
occurred (Figure 3). For 177Lu-DOTA-octreotate, tumor regrowth was already 
observed 41±2 d after injection of the radiotracer. Furthermore, median survival 
rates were 43.5, 61, and 71 d for the control group, the 177Lu-DOTA-octreotate 
group, and the 177Lu-DOTA-JR11-treated group, respectively (Figure 4).
The mean time to reach 2,000 mm3 was 45±10 d for control animals, 64±14 d 
for 177Lu-DOTA-octreotate, and 71±10 d for 177Lu-DOTA-JR11-treated animals. 
Hence, the growth delay times were 18±5 and 26±7 d for 177Lu-DOTA- 
octreotate and 177Lu-DOTA-JR11-treated groups, respectively. This was signifi-
cantly different from the control group but did not show a significant difference 
between the 2 compounds.
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Organs 0.5 µg 1.0 µg Organs 1.0 µg 2.0 µg
4 h 2 d 4 d 7 d 4 h  2 d 4 d 7 d 4 h 2 d 4 d 7 d
Blood 0.23±0.04 0.03±0.01 0.02±0.01 0.01±0.00 0.11±0.02 0.01±0.00 Blood 0.01±0.01 0.01±0.00 0.10±0.08 0.04±0.04 0.01±0.00 0.00±0.00
Spleen 0.56±0.15 0.35±0.08 0.29±0.05 0.30±0.07 0.55±0.07 0.29±0.09 Spleen 0.24±0.05 0.25±0.04 0.43±0.21 0.23±0.03 0.18±0.05 0.17±0.04
Pancreas 9.28±1.22 1.32±0.13 0.56±0.08 0.32±0.07 8.22±1.20 0.99±0.11 Pancreas 0.47±0.12 0.28±0.02 3.07±1.06 0.39±0.05 0.20±0.05 0.10±0.01
Adrenals 1.58±0.92 0.49±0.26 0.30±0.04 0.19±0.06 2.04±2.25 0.33±0.13 Adrenals 0.22±0.07 0.19±0.05 0.47±0.09 0.24±0.06 0.15±0.05 0.14±0.07
Kidney 31.13±5.50 7.40±1.04 2.74±0.51 1.20±0.26 30.06±3.80 7.23±1.79 Kidney 2.58±0.18 1.07±0.51 32.56±13.20 6.27±0.54 2.26±0.53 0.84±0.22
Liver 1.93±0.03 0.68±0.08 0.47±0.01 0.35±0.07 2.36±0.24 0.59±0.11 Liver 0.43±0.03 0.25±0.03 1.39±0.59 0.42±0.03 0.33±0.03 0.19±0.03
Stomach 7.71±1.00 2.03±0.52 1.10±0.10 0.64±0.20 5.38±1.17 1.22±0.17 Stomach 1.01±0.12 0.52±0.04 2.30±0.93 0.58±0.09 0.32±0.05 0.21±0.04
Duodenum 0.98±0.31 0.34±0.20 0.11±0.03 0.08±0.01 0.96±0.26 0.14±0.04 Duodenum 0.11±0.03 0.07±0.02 0.48±0.19 0.08±0.01 0.06±0.02 0.03±0.01
Muscle 0.22±0.20 0.05±0.02 0.04±0.01 0.03±0.01 0.20±0.10 0.04±0.01 Muscle 0.06±0.02 0.03±0.01 0.18±0.15 0.03±0.00 0.02±0.01 0.03±0.01
Tumor 20.78±3.37 11.21±2.68 10.21±6.49 6.75±2.46 21.44±9.84 13.57±3.25 Tumor 8.61±2.51 6.25±1.55 13.64±6.15 7.05±1.62 4.32±1.10 3.38±1.05
Tail 1.22±0.28 0.33±0.08 0.38±0.20 0.30±0.22 1.27±0.15 0.38±0.21 Tail 0.19±0.04 0.17±0.11 1.07±0.28 0.28±0.12 0.10±0.02 0.09±0.06
Table 1. Biodistribution of 177Lu-DOTA-JR11 in H69 xenografted mice
Figure 3. Tumor growth extrapolation of control, 177Lu-DOTA-octreotate, and 177Lu-DOTA-
JR11-treated animals. 177Lu-DOTA-octreotate and 177Lu-DOTA-JR11-treated animals were 
pre-injected with modified fluid gelatin to reduce renal uptake of radiotracers.
Table 2. Absorbed dose per administered activity (Gy/MBq) in 220 mg H69 tumor xenograft 
and organs for 177Lu-DOTA JR11
Organs 0.5 µg 1.0 µg 2.0 µg
Tumor 1800 1645 936
Kidneys 969 925 886
Stomach 249 189 78
Pancreas 238 202 82
Figure 4. Kaplan-Meier survival curve of control animals, 177Lu-DOTA-octreotate, and 
177Lu-DOTA-JR11-treated animals.
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DISCUSSION
Previous studies demonstrated SSTR antagonists to be superior to SSTR agonist 
for tumor targeting, contradicting the paradigm that internalization and accumu-
lation of the radiotracer is necessary for efficient tumor targeting. However, up 
to now no study has been performed directly comparing the therapeutic effect of 
radiolabeled SSTR agonists and antagonists. In this study, we compared the thera-
peutic response of the radiolabeled SSTR agonist 177Lu-DOTA-octreotate and the 
radiolabeled SSTR antagonist 177Lu-DOTA-JR11 in vitro, in U2OS+SSTR2 cells, 
and in vivo in H69-xenografted mice.
First, we studied the in vitro uptake of the 2 radiotracers and found uptake to be 
up to 5 times higher with 177Lu-DOTA-JR11 than with 177Lu-DOTA-octreotate. 
We saw that the major part of 177Lu-DOTA-octreotate was internalized, whereas 
the major part of the total uptake of 177Lu-DOTA-JR11 remained membrane-
bound, consistent with the receptor agonistic and antagonistic properties of the 
2 peptides. These data are in line with previous findings by Fani et al. (9) who 
demonstrated SSTR2-specific antagonism of Ga-NODAGA-JR11 by immuno-
fluorescence imaging in the presence and absence of the SSTR2 agonist Tyr3- 
octreotide.
To compare efficacy of the 2 radiolabeled peptides at the molecular level, we 
also analyzed the DNA damage response after treating cells with 177Lu-DOTA- 
octreotate or 177Lu-DOTA-JR11. 177Lu emits β-particles that can induce several 
types of DNA damage, among which DSBs are the most genotoxic. Unrepaired 
DSBs can trigger cell cycle arrest, cell death, and chromosomal aberrations. DSB 
induction initiates a cascade of events, including accumulation of the necessary 
repair proteins (e.g. 53BP1) (12). Quantification of 53BP1 foci per nucleus is 
therefore a powerful tool to examine DSB induction and repair (16,17). 177Lu-
DTPA produced only transient DSBs comparable to DSBs induced by an external 
radiation source (16). 177Lu-DOTA-JR11 produced 2 times more DSBs than 
177Lu-DOTA-octreotate, even though we observed up to 5 times higher uptake of 
the radiolabeled antagonist in the uptake assay. This difference might be explained 
by the different peptide concentrations used in the assays, because radiotracer 
uptake is dependent on the peptide amount used (2×10-9 M of the radiotracers 
resulted in a 5 times higher uptake of 177Lu-DOTA-JR11 vs. 177Lu-DOTA- 
octreotate, whereas the uptake was only 3 times higher with 5×10-8 M of the 
radio-tracers). Furthermore, being a receptor antagonist, 177Lu-DOTA-JR11 
remained bound to the cell membrane, whereas the receptor agonist 177Lu-DOTA- 
octreotate is internalized. The 177Lu coupled to JR11, therefore, resides on 
average at a larger distance from the nucleus and its DNA content. This might 
reduce the number of β-particles effectively reaching the DNA to induce damage, 
especially when cells are grown in 2-dimensional cell culture.
177Lu-DOTA-JR11 biodistribution studies in mice with H69 xenografts resulted in 
the highest tumor uptake with the lowest variation using 0.5 μg/30 MBq of the 
radiotracer. This was similar to the 22.4±7.6 ID/g of tissue 2 h after injection of 
100 pmol 68Ga-DOTA-JR11 reported by Fani et al. (9). Previous biodistribu-
tion studies with 177Lu-DOTA-octreotate in the same animal model resulted in 
the highest tumor uptake of 4.03±0.83 %ID/g of tissue using 0.5 μg/30 MBq 
of 177Lu-DOTA-octreotate 2 d after injection of the radiotracer (S Bison, M 
Konijnenberg, and M de Jong, unpublished data, December 2013). At this time point, 
0.5 μg/30 MBq of 177Lu-DOTA-JR11 resulted in an almost 3-times-higher tumor 
uptake of 11.21±2.68 %ID/g of tissue in our biodistribution studies. This was higher 
than the 1.2 times higher uptake of 68Ga-DOTA-JR11 compared with 68Ga-DOTA-
octreotate 2 h after injection of the radiotracers reported by Fani et al. (9).
The higher tumor uptake after 177Lu-DOTA-JR11 resulted in a tumor radiation 
dose of 1.8±0.7 Gy/MBq, 4.4-fold higher than the maximum tumor radiation 
dose for 177Lu-DOTA-octreotate (0.36±0.07 Gy/MBq). Wild et al. (8) reported a 
1.7 to 10.6 fold higher tumor dose of 177Lu-DOTA-JR11 in patients, due to higher 
tumor uptake and longer residence time of the receptor antagonist, indicating the 
applicability and translational value of our mouse model.
Next to the tumor, high kidney uptake of 177Lu-DOTA-JR11 was found. To reduce 
the renal uptake in the in vivo therapy studies, animals were pre-injected with 
modified fluid gelatin. Previous studies showed a decrease in renal uptake of 
60% when animals received a pre-injection of modified fluid gelatin (13). Despite 
the high renal uptake, the treated animals showed no signs of kidney insuffi-
ciency. However, in our study animals received only 1 therapeutic injection of 
177Lu-DOTA-JR11, and follow-up time was limited. To accurately determine the 
effect of the radiotracer on the kidneys, additional experiments are needed. In the 
pilot study by Wild et al. (8), patients were pre-injected with a solution of arginine 
and lysine to reduce renal uptake, resulting in a 6.2 fold higher tumor-to-kidney 
ratio for 177Lu-DOTA-JR11 than 177Lu-DOTA-octreotate. Although the patients in 
this study already had grade 2 or 3 chronic renal failure, no additional decrease in 
tubular kidney function was reported. Additional studies in larger patient groups 
without renal problems and studies with longer follow up times are necessary to 
further investigate potential adverse effects.
Comparing the in vivo therapeutic effect of 177Lu-DOTA-octreotate and 
177Lu-DOTA-JR11, we found a longer tumor growth delay time and a longer 
median survival after 177Lu-DOTA-JR11 treatment. This finding is in line with 
the higher uptake we found in the in vitro internalization assay and the in vivo 
biodistribution study. However, the difference in growth delay time between the 
177Lu-DOTA-JR11 and 177Lu-DOTA-octreotate-treated animals was not signifi-
cant. This can be explained by variation in initial tumor size and the fact that 
animals received only 1 therapeutic injection of the radiotracers. Furthermore, 
the absorbed dose factor for 177Lu in the cytoplasm (as a consequence of agonist 
internalization) is 1.5-2 times higher than the absorbed dose factor for 177Lu 
uptake that is limited to the cell membrane (most of the antagonist uptake) (18).
The superiority of receptor antagonists to receptor agonist has also been reported 
for other radioligands. So, studies evaluating the use of radiolabeled gastrin 
releasing peptide receptor agonists and antagonists for targeting of gastrin 
releasing peptide receptors overexpressed on prostate cancer cells also showed 
superiority for antagonists (19).
Studies with unlabeled SSTR antagonists BIM-23454 and BIM-23627 in rats 
showed an increase in growth hormone secretion after administration (20), which 
Chapter 7 Therapy with A Radiolabeled SSTR Agonist vs. Antagonist
133132
7
may have a negative effect on tumor therapy. However, the minimal effective 
concentration, 1 mg/kg for BIM-23454 and 0.02 mg/kg for BIM-23627, necessary 
to promote growth hormone release was much higher than the dose used for 
imaging and therapy with radiolabeled SSTR antagonists, for example, 150±20 μg 
for imaging and 2-3 cycles of 105±35 μg for therapy in the study by Wild et al. (8).
The higher uptake of radiolabeled SSTR antagonists might offer possibilities for 
SSTR-mediated PRS and PRRT to be applied in cancer types with lower SSTR 
expression, for example, breast cancer. Previous studies by Reubi et al. (21) 
reported high-density SSTR expression in 21% of the breast tumors analyzed, 
whereas in total 75% of the tumors expressed the SSTR. Cescato et al. (6) 
compared binding of the SSTR antagonist 177Lu-DOTA-BASS with the SSTR 
agonist 177Lu-DOTA-octreotate and reported 11±4-fold-higher binding of the 
antagonist in 7 breast carcinomas analyzed by in vitro autoradiography. Further-
more, imaging studies in breast cancer patients using SSTR agonists have been 
performed with varying results (22,23). The use of JR11 may improve these 
results and provide imaging and therapy options for different tumors.
CONCLUSION
The use of radiolabeled SSTR antagonist such as JR11 may contribute to the 
improvement of PRS and PRRT in neuroendocrine tumors as well as provide 
opportunities for SSTR-mediated PRS and PRRT in tumor types with relatively 
low SSTR expression.
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ABSTRACT
Breast cancer (BC) consists of multiple subtypes defined by various molecular 
characteristics, for instance, estrogen receptor (ER) expression. Methods for 
visualizing BC include mammography, MR imaging, ultrasound, and nuclear 
medicine-based methods such as 99mTc-sestamibi and 18F-FDG PET, unfortu-
nately all lacking specificity. Peptide receptor scintigraphy and peptide receptor 
radionuclide therapy are successfully applied for imaging and therapy of somato-
statin receptor-expressing neuroendocrine tumors using somatostatin receptor 
radioligands. On the basis of a similar rationale, radioligands targeting the gastrin 
releasing peptide receptor (GRPR) might offer a specific method for imaging and 
therapy of BC. The aim of this study was to explore the application of GRPR 
radioligands for imaging and therapy of BC by introducing valid preclinical in vitro 
and in vivo models.
Methods: GRPR expression of 50 clinical BC specimens and the correlation with 
ER expression was studied by in vitro autoradiography with the GRPR agonist 
111In-AMBA. GRPR expression was also analyzed in 9 BC cell lines applying 
111In-AMBA internalization assays and quantitative reverse transcriptase poly-
merase chain reaction. In vitro cytotoxicity of 177Lu-AMBA was determined on 
the GRPR-expressing BC cell line T47D. SPECT/CT imaging and biodistribution 
were studied in mice with subcutaneous and orthotopic ER-positive T47D and 
MCF7 xenografts after injection of the GRPR antagonist 111In-JMV4168.
Results: Most of the human BC specimens (96%) and BC cell lines (6/9) were 
found to express GRPR. GRPR tumor expression was positively (P=0.026, 
χ2(4)=12,911) correlated with ER expression in the human BC specimens. 
Treatment of T47D cells with 10-7 M/50 MBq of 177Lu-AMBA resulted in 80% 
reduction of cells in vitro. Furthermore, subcutaneous and orthotopic tumors 
from both BC cell lines were successfully visualized in vivo by SPECT/CT using 
111In-JMV4168; T47D tumors exhibited a higher uptake than MCF7 xenografts.
Conclusions: Targeting GRPR-expressing BC tumors using GRPR radioligands is 
promising for nuclear imaging and therapy, especially in ER-positive BC patients.
Keywords: 
Breast Cancer, PRS/PRRT, GRPR, AMBA, JMV4168
INTRODUCTION
Breast cancer (BC) is a highly heterogeneous disease characterized by multiple 
molecular features, such as expression of the estrogen receptor (ER), proges-
terone receptor, and human epidermal growth factor receptor 2 (1). On the basis 
of molecular characteristics, BC can be divided in 4 subgroups: luminal A and B, 
human epidermal growth factor receptor 2-like, and triple-negative tumors (2). The 
treatment and prognosis of BC are highly dependent on this classification. Mammo-
graphy is the standard imaging technique used during nationwide screening of BC. 
Additional MR imaging or ultrasound can be performed (3). However, all 3 methods 
have drawbacks. Mammography lacks sensitivity and specificity, leading to false- 
positive and false-negative results. Especially in women with dense breast tissue, 
mammograms are hard to interpret (4). MR imaging and ultrasound also lack 
specificity. In addition, MR imaging is labor-intensive and expensive, whereas 
ultrasound is operator-dependent (5).
In nuclear medicine, methods to detect BC lesions and monitor response to 
treatment include 201Tl-scintigraphy, 99mTc-sestamibi or 99mTc-tetrofosmin scinti-
graphy, and 18F-FDG PET (6). Unfortunately, these methods also lack specificity.
Peptide receptor scintigraphy applies specific in vivo targeting of tumor lesions 
overexpressing a receptor of interest. This method was first described by 
Krenning et al. (7), using a radioactive somatostatin receptor (SSTR) ligand 
to image neuroendocrine tumors (NETs) overexpressing the SSTR subtype 2. 
To date, imaging with SSTR radioligands is routinely applied to characterize 
and evaluate (tumor localization, staging, monitoring) NETs (8). Furthermore, 
SSTR radioligands labeled with therapeutic radionuclides are successfully used 
for treatment of NET patients, using so-called peptide receptor radionuclide 
therapy (PRRT) (9).
Following the same principle, the gastrin-releasing peptide receptor (GRPR) can 
be targeted. GRPRs are expressed on most BC cases; autoradiography studies by 
Reubi et al. (10) showed that 65% of the breast tumors analyzed expressed the 
GRPR. Moreover, also lymph node metastases from primary tumors expressing 
GRPR were positive (10-12). GRPR binds a family of peptides, including the 
gastrin-releasing peptide; its C-terminal fragment neuromedin C, both endo-
genous in humans; and the amphibian tetradecapeptide bombesin.
The application of GRPR radioligands, analogs of the above native peptides, might 
offer a sensitive and specific method for imaging of GRPR overexpressing BC. 
In addition, PRRT with radiolabeled GRPR ligands might be feasible. Recently, 
multiple GRPR radioligands, receptor agonists and antagonists, have been 
described that can be labeled with positron and γ-emitters, for example, 68Ga and 
111In, for imaging and with β- and α-emitters, for example, 177Lu and 213Bi, for ther-
apeutic purposes, as yet primarily aiming at application in prostate cancer (13). 
Preclinical studies evaluating the potential of targeting the GRPR in BC using 
GRPR radioligands are limited. The aim of this study was to further characterize 
the GRPR as a potential target for the visualization of BC lesions and for PRRT. 
For this purpose, we analyzed GRPR expression in human clinical BC specimens 
and correlated this with ER expression. In addition, we used selected GRPR- 
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/ER-expressing human-derived BC cells to perform in vitro cytotoxicity assays and 
to develop suitable xenograft-bearing animal models for preclinical imaging studies.
MATERIALS AND METHODS
Radiolabeled GRPR Ligands
For in vitro studies, the GRPR agonist AMBA (BioSynthema) was used (14). 
Because radiolabeled AMBA exhibits high uptake in the gastrointestinal tract 
that potentially interferes with orthotopic tumor visualization, the GRPR anta-
gonist JMV4168 (University of Montpellier) was used for in vivo studies (14,15). 
The GRPR ligands were radiolabeled with 111In (Covidien) or 177Lu (IDB), using 
quenchers (10 mM methionine, 3.5 mM ascorbic acid, and 3.5 mM gentisic acid) 
to prevent radiolysis (16). Radiolabeling was performed for 20 min at 80°C as 
previously described (17), with a specific activity of 100 MBq/nmol (for in vitro 
studies, both 111In and 177Lu) or 150 MBq/nmol (in vivo studies). Radiometal 
incorporation and radiochemical purity, measured by instant thin-layer chromato- 
graphy on silica gel and high-pressure liquid chromatography as previously 
described (16), were greater than 95% and greater than 90%, respectively.
In Vitro Autoradiography on Human BC Specimens
In vitro autoradiography was performed on 50 human BC specimens with known 
ER protein status. Specimens were selected from the Erasmus MC fresh frozen 
tissue bank. The study (MEC02·953) was approved by the Erasmus MC Medical 
Ethical Committee and adhered to the Code of Conduct of the Federation of 
Medical Scientific Societies in The Netherlands.
Frozen sections (10 μm) of the BC specimens were incubated with 10-9 M/0.1 
MBq of 111In-AMBA, without or with 10-6 M unlabeled Tyr4-bombesin (Sigma-
Aldrich), to determine nonspecific binding, for 1 h and exposed to super resolu-
tion phosphor screens (PerkinElmer) for at least 24 h and read using the Cyclone 
(PerkinElmer). Adjacent tissue sections were stained with hematoxylin and eosin 
to determine tumor content. Autoradiography results were scored visually by 3 
independent observers. Among the positive tumors, a division was made between 
tumors that were 1-25%, 26-50%, 51-75%, and 76-100% positive.
Cell Culture, Internalization Assay, and Quantitative Reverse 
Transcriptase Polymerase Chain Reaction
Nine human-derived BC cell lines, obtained from the Department of Medical 
Oncology, Erasmus MC, with different molecular properties (Supplemental Table 1) 
were screened for GRPR expression using internalization assays and Quantita-
tive Reverse Transcriptase Polymerase Chain Reaction (RT-qPCR). Cell lines, 
authenticated by short tandem repeat profiling using the Powerplex STR kit 
(Promega), were cultured as described by Riaz et al. (18).
In the internalization assay, cells were incubated for 1 h at 37°C with 10-9 M/0.1 MBq 
of 111In-AMBA (without or with 10-6 M unlabeled Tyr4-bombesin). In addition, 
assays were performed using 10-7 M/10 MBq, 10-8 M/1 MBq, and 10-9 M/0.1 MBq 
of 111In-AMBA with incubation times of 1, 2, and 4 h to select the optimal condi-
tions for the in vitro cytotoxicity studies. The internalization assay protocol is 
described in the supplemental materials.
To measure GRPR mRNA levels of the BC cell lines, RNA was isolated using 
RNA-Bee (Campro Scientific) according to the manufacturer’s instructions. 
Subsequently, complementary DNA synthesis and RT-qPCR were performed and 
normalized using the δ Cq method on the average of 2 reference genes (HMBS 
and HPRT1) as previously described (19). The quantification of target genes 
was performed using the Taqman probe-based gene expression assay, GRPR: 
Hs01055872_m (Applied BioSystems/Life Technologies), according to the manu-
facturer’s instructions.
In Vitro Cytotoxicity Studies
Cells (12.5×106/5 mL in a T25 culture flask, seeded 1 d before the experi-
ment) were treated with 10-7 M/50 MBq, 5×10-8 M/25 MBq, or 10-8 M/5 MBq of 
177Lu-AMBA in 5 mL of internalization medium for 4 h. Untreated cells, 
177Lu-diethylenetriaminepentaacetic acid (DTPA)-treated, and unlabeled AMBA-
treated cells served as controls. After incubation, cells were washed twice with 
phosphate-buffered saline (GIBCO/Life Technologies) and detached using 0.1 mM 
ethylenediaminetetraacetic acid. Cells were resuspended in medium, counted, 
and seeded in 3 wells of 12-well plates (12,500 cells/well/1 mL). Seven days 
after treatment, cells were fixed using 1 mL of 10% trichloroacetic acid (Sigma-
Aldrich), and a sulforhodamine B colometric assay was performed to determine 
cell density. Results are expressed as percentages relative to untreated controls. 
The sulforhodamine B colometric assay protocol is described in the supplemental 
materials.
In Vivo Imaging, Biodistribution, and In Vitro Autoradiography of BC 
Xenografts
All animal studies were in agreement with the Animal Welfare Committee require-
ments of Eramus MC and conducted in accordance with accepted guidelines. Balb c 
nu/nu female mice (6-8 wk) (Janvier), supplemented with β-estradiol (4 mg/L; 
Sigma-Aldrich) in drinking water, were subcutaneously (between the shoulders) 
and orthotopically (left fourth mammary fat pad) inoculated with 8×106 T47D 
cells or 7×106 MCF7 cells (n=6 for each cell line).
A 40-min SPECT/CT scan was acquired at 2 time points after inoculation (time 
point 1 [t1], 40±3 d, and time point 2 [t2], 103±3 d), using the NanoSPECT/CT 
scanner (Bioscan) 4 h after intravenous injection of approximately 35 MBq/200 
pmol of 111In-JMV4168, co-injected with 300 μg of phosphoramidon (Peptides 
International Inc.) to inhibit in vivo enzymatic degradation of the peptide. During 
the scan acquisition, the animals were anesthetized with isoflurane/O2 and body 
temperature was maintained. Bladder uptake was masked after reconstruction 
of the images. After the second scan, animals were euthanized, and tumors and 
organs were collected, weighed, and counted in a γ-counter. Data obtained were 
expressed as percentage injected dose per gram of tissue (%ID/g). In addition, in 
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vitro autoradiography was performed on the excised tumors, using 111In-JMV4168 
without or with 10-6 M unlabeled Tyr4-bombesin, to demonstrate receptor speci-
ficity of the tracer. Scanning, reconstruction, and counting details are described 
in the supplemental materials. Supplemental Figure 1 depicts the time line of the 
in vivo experiments.
Statistics
Statistical analyses are described in the supplemental materials.
RESULTS
GRPR Expression in Clinical BC Specimens
The autoradiography results of 50 human BC tissue specimens with known ER 
protein status were scored for GRPR expression. Hematoxylin and eosin staining 
of adjacent tissue sections was used to discriminate between malignant and 
healthy tissue (Figure 1A). Most (48/50 [96%]) of the BC specimens analyzed 
were positive for GRPR. The majority (56%) of the samples showed greater than 
75% positivity, indicating a homogeneous GRPR expression. Of the remaining 
samples, 29% was 1-25% positive, 8% was 26-50% positive, and 6% was 51-75% 
positive (Figure 1B). In addition, a significant, positive (P=0.026, χ2(4)=12,911) 
correlation was found between ER status and extent of GRPR expression.
GRPR Expression in Human-Derived BC Cell Lines and In Vitro 
Cytotoxicity Studies
Most of the BC cell lines examined (6/9) selectively bound and internalized 
111In-AMBA, although to a variable extent (Figure 2A). This process was GRPR 
specific, because binding and internalization were significantly decreased when 
an excess of unlabeled GRPR ligand was added. The extent of 111In-AMBA 
binding and internalization seemed higher in ER-positive BC cell lines than in 
the ER-negative BC cell lines. However, the observed difference was not statisti-
cally significant (P=0.757), probably because of the lower power of the cell line 
study than the clinical BC specimen study. Also, no clear correlation with proges-
terone receptor (P=0.209) and human epidermal growth factor receptor 2 status 
(P=0.192) of the BC cell lines was found.
To confirm that internalization levels correlated with GRPR expression and were 
not attributed to, for example, receptor recycling efficiency, GRPR expression 
was independently quantified by RT-qPCR (Supplemental Table 1). A significant 
positive correlation (P=0.0108, Rs=0.8167) was found between mRNA levels of 
GRPR and 111In-AMBA uptake (Figure 2B).
The ER-positive cell lines T47D and MCF7 showed the highest uptake of 111In-
AMBA. T47D was therefore selected for in vitro cytotoxicity experiments, and 
both T47D and MCF7 were used for inoculation in mice to create relevant in vivo 
models.
To determine the optimal incubation time and radioligand concentration for in vitro 
cytotoxicity studies, taking into account potential GRPR saturation, T47D cells 
were incubated with 3 different concentrations of 111In-AMBA (10-7 M/10 MBq, 
10-8 M/1 MBq, and 10-9 M/0.1 MBq) for 3 different incubation times (1, 2, and 4 h). 
The highest absolute amount of 111In-AMBA (counts per minute) was observed 
after 4 h of incubation with 10-7 M 111In-AMBA, both in the membrane-bound and 
in the internalized fraction (Figure 3A).
When T47D cells were treated for 4 h with 177Lu-AMBA, a significant reduction 
in cell number of 20%, 50%, and 80% was observed after incubation with 
10-8 M/5  MBq, 5×10-8 M/25 MBq, or 10-7 M/50 MBq of 177Lu-AMBA, respectively 
(Figure 3B). Treatment with the same amount of 177Lu-DTPA for 4 h, which is not 
actively internalized, did not inhibit cell proliferation, similarly to incubation with 
unlabeled AMBA. Therefore, the therapeutic effect of 177Lu-AMBA can be associ-
ated to the combination of specific GRPR-mediated uptake and retention of 177Lu 
within the cells over time.
Figure 1. A) Hematoxylin and eosin staining of sections indicating tumor-containing regions, 
corresponding to autoradiography results in B. B) Representative examples of 111In-AMBA 
binding to human BC specimens, without (-block) and with (+block) 10-6 M Tyr4-bombesin. 
Binding was GRPR-specific because no binding was observed when the GRPR was blocked by 
Tyr4-bombesin. Among GRPR-positive tumors, a subdivision was made between tumors that 
were 1-25%, 26-50%, 51-75%, and 76-100% GRPR-positive.
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111In-AMBA by GRPR-expressing human-derived BC cell line T47D, 
at 1, 2, and 4 h after incubation with 10-7 M/10 MBq, 10-8 M/1 MBq, or 10-9 M/0.1 MBq of 
111In-AMBA. Results shown are average of 2 independent experiments, each performed in 
triplicate (mean±SD). B) Treatment of T47D cells with 3 different concentrations of AMBA, 
177Lu-DTPA, and 177Lu-AMBA for 4 h. Significant reduction of 80% in cell viability was 
reached when cells were treated with 10-7 M/50 MBq of 177Lu-AMBA, whereas no significant 
effects were observed when cells were similarly treated with AMBA or 177Lu-DTPA. Results 
shown are average of 3 independent experiments, each performed in triplicate (mean±SD).
In Vivo Visualization of GRPR Expression in BC Xenografts
We successfully obtained T47D and MCF7 xenografts in immune-deficient female 
mice orally supplemented with estrogen.
At 2 time points after tumor cell inoculation, T47D and MCF7 xenografts were 
visualized using in vivo SPECT/CT imaging after an injection of approximately 
35 MBq/200 pmol of 111In-JMV4168 + 300 μg of phosphoramidon. T47D xeno-
grafts had a significantly (P<0.0001) higher uptake than MCF7 xenografts (748-
1,706 vs. 169-658 kBq/g for subcutaneous tumors and 1,151-2,127 vs. 189-672 
kBq/g for orthotopic tumors). Therefore, T47D xenografts were visualized with 
higher contrast than MCF7 xenografts (Figure 4). No significant difference in 
Figure 4. SPECT/CT scans indicating orthotopic (orange arrows) and subcutaneous 
(white arrows) tumors of T47D and MCF7 xenograft-bearing mice at 4 h after injection of 
approximately 35 MBq (200 pmol) of 111In-JMV4168 + 300 μg of phosphoramidon. T47D 
xenografts were scanned at t1=43 d (A) and t2=100 d (B). MCF7 xenografts were scanned 
at t1=37 d (C) and t2=106 d (D). Bladder uptake is masked. Mice were provided with a chip 
for identification purposes. T47D xenografts were visualized with higher contrast than MCF7 
xenografts.
Figure 2. A) Selective binding and internalization after 1 h of incubation with 10-9 M/0.1 
MBq of 111In-AMBA, a GRPR agonist. Nine human-derived BC cell lines with different 
molecular properties (18) were screened. Both membrane- and internalized/cell fraction 
are displayed. Results shown are average of 3 independent experiments, each performed in 
triplicate (mean±SD). B) Significant correlation (P=0.0108, Rs=0.8167) between GRPR 
mRNA expression and level of 111In-AMBA uptake (membrane plus cell fraction).
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uptake between orthotopic and subcutaneous tumors of both T47D (P=0.92) and 
MCF7 xenografts (P=0.95) was determined. Biodistribution results obtained 
at t2 confirmed higher radiotracer uptake and a better tumor-to-kidney ratio 
(2.1 vs. 0.4) in T47D than MCF7 xenografts (Figure 5). In vitro autoradiography 
of the excised tumors demonstrated specific binding of 111In-JMV4168 (Supple-
mental Figure 2). However, the proliferation of MCF7 xenografts was faster than 
that of T47D xenografts; orthotopic tumors ranged from 178 to 390 mm3 for T47D 
xenografts and from 755 to 1,830 mm3 for MCF7 xenografts at t1. At that time 
point, subcutaneous T47D xenografts ranged from 11 to 630 mm3, compared 
with 532-2,095 mm3 for MCF7 xenografts. As yet, we cannot exclude the effect 
of tumor size on radiotracer uptake. Two of 6 T47D subcutaneous tumors were 
small (12.3 and 4.0 mm3) and were therefore excluded from the biodistribution 
study.
DISCUSSION
To gain more insight into the feasibility of diagnostic imaging and therapeutic appli-
cations of GRPR radioligands in BC patients, we aimed to develop reliable pre- 
clinical models expressing the GRPR based on well-characterized human-derived 
BC cell lines. We first confirmed GRPR expression on clinical BC specimens and 
found that most (96%) indeed expressed the GRPR, which was higher than the 
Figure 5. Quantification of 111In-JMV4168 uptake in tumors and organs collected after last 
scan (t2); n=6 for each mouse model (2 small subcutaneous T47D xenografts were excluded). 
Significantly (P<0.0001) higher uptake of 111In-JMV4168 was determined in T47D than in 
MCF7 xenografts.
65% of GRPR-expressing BC specimens reported by Reubi et al. (10). In the latter 
study, GRPR, analyzed by in vitro autoradiography, was more frequently and more 
densely expressed than any other of the investigated targets, including neuropeptide 
Y receptor subtype 1, SSTR, and vasoactive intestinal peptide receptor. We observed 
a homogeneous GRPR expression in more than half (56%) of the tumors, supporting 
the conclusion that GRPR is a suitable target for radioligands in BC patients.
Furthermore, a significant correlation was found between GRPR and ER expres-
sion in the clinical BC specimens analyzed. ER-positive tumors were associated 
with higher GRPR expression, indicating BC patients with ER-positive tumors 
as a potential target group for imaging or therapy with GRPR radioligands. Our 
findings were in accordance with studies by Halmos et al. (12), showing a signifi-
cant positive correlation between ER expression and GRPR binding affinity 
examined on isolated cell membranes from BC samples. Because ER-positive 
tumors account for 75% of all breast tumors, GRPR-based imaging could offer 
new imaging and therapeutic possibilities for most BC patients (2,20). In addition, 
because current treatments with antihormonal agents, such as tamoxifen and 
aromatase inhibitors, are ineffective in about 40% of the ER-positive metastatic 
BC patients (20,21), GRPR ligands radiolabeled with particle emitters might offer 
new therapeutic options for these patients.
Furthermore, we found that most of the examined BC cell lines expressed 
the GRPR. T47D was selected for in vitro therapy and, together with MCF7, for 
in vivo imaging studies.
Treatment of T47D cells with 177Lu-AMBA resulted in a significant decrease in 
cell viability, proving this cell line to be suitable as a model for future in vivo 
therapy studies in xenograft-bearing mice. An 80% decrease in cell viability was 
established using 10-7 M/50 MBq of 177Lu-AMBA. The uptake of 177Lu by the tumor 
cells appeared to be a prerequisite, because the same amounts of 177Lu-DTPA, 
which does not bind or internalize, showed no significant effect on cell viability 
after 4 h exposure. Müller et al. (22) also studied the effect of 177Lu-DTPA on cell 
viability, next to 177LuCl3. In line with our results, treatment with 177LuCl3, which 
is also internalized by cells, resulted in a larger decrease in cell viability than 
treatment with 177Lu-DTPA. In the study by Müller et al. (22), a decrease in cell 
viability was measured after treatment with 177Lu-DTPA as well, but cells were 
treated for 4 d with 177Lu-DTPA in contrast to the 4 h treatment in our study, 
which can explain the discrepancy.
On the basis of our in vitro cytotoxicity studies with 177Lu-AMBA, we expect a 
similar effect of GRPR antagonists on cell viability, because binding of the radio-
ligand to the receptor results in cell membrane-bound accumulation of 177Lu, 
enabling radiation-induced DNA damage and thus cytotoxicity, despite the lack 
of internalization. A recent study by Wild et al. (23) comparing the application 
of 177Lu-labeled SSTR agonist and antagonist for PRRT in NET patients showed 
a higher tumor dose for the SSTR antagonist than for the agonist and therefore 
successful therapeutic effects, providing evidence that treatment with receptor 
antagonists is feasible.
According to previous studies, adverse effects have been reported during the 
clinical evaluation of 177Lu-AMBA in prostate cancer patients (24). Such undesirable 
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effects can be evaded with GRPR antagonists instead of agonists (25). For this 
reason and to prevent interference with orthotopic tumor visualization, the GRPR 
antagonist JMV4168 was used for in vivo imaging studies.
With the aim of inhibiting the in vivo enzymatic degradation of 111In-JMV4168, 
which may potentially interfere with GRPR targeting and tumor uptake, 111In-
JMV4168 was co-injected with the neutral endopeptidase inhibitor phosphor-
amidon (26). Recent studies by Nock et al. (27) have shown significantly prolonged 
survival of several radioligands in the circulation when phosphoramidon was 
administered simultaneously. In the current study, 111In-JMV4168 + phosphor-
amidon was successfully applied to visualize both orthotopic and subcutaneous 
BC tumors in mice, approximately 100 mm3 in size, indicating that GRPR expres-
sion was sufficiently high to discriminate tumor lesions. Already approximately 1 
%ID/g uptake of MCF7 xenografts resulting in approximately 200 kBq of 111In/g 
enabled visualization of tumor lesions, which was even higher for T47D xeno-
grafts, showing about 5 %ID/g uptake. Parry et al. (28) reported a similar tumor 
uptake in subcutaneous T47D xenografts using different GRPR radioligands. 
Thus, these mouse models will now be used for future studies to examine the 
therapeutic potential of 177Lu-labeled GRPR radioligands.
Recently several imaging studies using 99mTc-labeled bombesin analogs in BC 
patients were performed with promising results (29-32), identifying tumor lesions 
in patients suspected for BC based on mammography. In the most recent study 
by Shariati et al. (32), a sensitivity of 61% and specificity of 100% were reported, 
indicating that imaging with bombesin analogs is promising and deserves further 
investigation. Interestingly, 2 of these imaging studies described the identi-
fication of lymph node metastases, demonstrating the presence of the GRPR 
on lymph node metastases next to primary tumor tissue (31,32). However, the 
capacity to visualize distant metastases still needs to be established. In a study by 
Bergsma et al. (33), 50% of the disseminated BC lesions studied were success-
fully visualized using the 68Ga-labeled GRPR antagonist Sarabesin 3 without 
adverse effects, once more showing the successful application of radiolabeled 
GRPR antagonists in BC patients. None of these studies reported on correlation 
of positive scintigraphy with BC subtype and molecular markers.
Up to now, GRPR-based PRRT has been performed targeting prostate cancer, 
either in xenograft-bearing animals, with GRPR agonists or antagonists (14,34), 
or in patients during a pilot study using 177Lu-AMBA (24). However, GRPR-based 
PRRT is not yet being applied in BC animal models or patients. When GRPR 
radioligands will be used for therapeutic purposes, the physiologic uptake in the 
pancreas should be considered regarding safety. Yet, the radiosensitivity of the 
pancreas is relatively low, and the fast pancreatic washout of radiolabeled GRPR 
antagonists is favorable in this respect (35).
The results obtained in the current study together with the positive first experi-
ence with 99mTc and 68Ga labeled GRPR radioligands to localize BC are encour-
aging for future application of the so-called theranostic approach in BC, using, 
for example DOTA-coupled receptor ligands radiolabeled with 111In and 68Ga for 
imaging or with 177Lu, 90Y, or 213Bi for therapeutic purposes.
CONCLUSION
We confirmed GRPR expression in clinical BC specimens, correlating with ER 
expression. Hence, ER-positive BC patients are potential candidates for imaging 
and PRRT using GRPR radioligands. In addition, we successfully developed BC 
xenograft mouse models by inoculation of the selected ER- and GRPR-positive 
BC cell lines T47D and MCF7 and visualized the generated tumors using 111In-
JMV4168, co-injected with phosphoramidon. These mouse models will be used 
to study the therapeutic effects of 177Lu-labeled GRPR radioligands, such as 177Lu-
JMV4168.
Supplemental data
Supplemental data is available online at http://jnm.snmjournals.org.
Chapter 8 GRPR Radioligands in Breast Cancer
153152
8
REFERENCES
1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 
2000;406:747-752. 
2. Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implica-
tions. World J Clin Oncol. 2014;5:412-424. 
3. Garcia EM, Storm ES, Atkinson L, Kenny E, Mitchell LS. Current breast imaging modalities, 
advances, and impact on breast care. Obstet Gynecol Clin North Am. 2013;40:429-457. 
4. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the 
evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:347-360. 
5. Mahoney MC, Newell MS. Screening MR imaging versus screening ultrasound: pros and cons. 
Magn Reson Imaging Clin N Am. 2013;21:495-508. 
6. Schillaci O, Buscombe JR. Breast scintigraphy today: indications and limitations. Eur J Nucl 
Med Mol Imaging. 2004;31(suppl 1):S35-S45. 
7. Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumours with 
radioiodinated analogue of somatostatin. Lancet. 1989;1: 242-244. 
8. Kim KW, Krajewski KM, Nishino M, et al. Update on the management of gastroenteropancre-
atic neuroendocrine tumors with emphasis on the role of imaging. AJR. 2013;201:811-824. 
9. Bodei L, Pepe G, Paganelli G. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine 
tumors with somatostatin analogues. Eur Rev Med Pharmacol Sci. 2010;14:347-351. 
10. Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular 
basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2002;29:855-
862.
11. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic 
human breast. Am J Pathol. 1999;155:2067-2076. 
12. Halmos G, Wittliff JL, Schally AV. Characterization of bombesin/gastrin-releasing peptide 
receptors in human breast cancer and their relationship to steroid receptor expression. Cancer 
Res. 1995;55:280-287. 
13. Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J Nucl Med. 2008;49:1735-
1738. 
14. Lantry LE, Cappelletti E, Maddalena ME, et al. 177Lu-AMBA: synthesis and characterization 
of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl 
Med. 2006;47:1144-1152. 
15. Marsouvanidis PJ, Nock BA, Hajjaj B, et al. Gastrin releasing peptide receptordirected radio- 
ligands based on a bombesin antagonist: synthesis, 111In-labeling, and preclinical profile. 
J Med Chem. 2013;56:2374-2384. 
16. de Blois E, Chan HS, Konijnenberg M, de Zanger R, Breeman WA. Effectiveness of quenchers 
to reduce radiolysis of 111In- or 177Lu-labelled methionine-containing regulatory peptides: 
maintaining radiochemical purity as measured by HPLC. Curr Top Med Chem. 2012;12:2677-
2685.
17. De Blois E, Schroeder RJ, De Ridder CA, Van Weerden WM, Breeman WP, De Jong M. 
Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin 
receptor-mediated imaging of prostate cancer. Q J Nucl Med Mol Imaging. June 19, 2013 [Epub]
18. Riaz M, van Jaarsveld MT, Hollestelle A, et al. miRNA expression profiling of 51 human breast 
cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res. 
2013;15:R33. 
19. Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, et al. How ADAM-9 and ADAM-11 
differentially from estrogen receptor predict response to tamoxifen treatment in patients with 
recurrent breast cancer: a retrospective study. Clin Cancer Res. 2005;11:7311-7321. 
20. Droog M, Beelen K, Linn S, Zwart W. Tamoxifen resistance: from bench to bedside. Eur 
J Pharmacol. 2013;717:47-57. 
21. Williams C, Lin CY. Oestrogen receptors in breast cancer: basic mechanisms and clinical impli-
cations. Ecancermedicalscience. 2013;7:370. 
22. Müller C, Reber J, Haller S, et al. Direct in vitro and in vivo comparison of 161Tb and 177Lu 
using a tumour-targeting folate conjugate. Eur J Nucl Med Mol Imaging. 2014;41:476-485. 
23. Wild D, Fani M, Fischer R, et al. Comparison of somatostatin receptor agonist and antagonist 
for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55:1248-1252. 
24. Bodei L, Ferrari M, Nunn AD, et al. 177Lu-AMBA bombesin analogue in hormone refrac-
tory prostate cancer patients: a phase I escalation study with single-cycle administrations 
[abstract]. Eur J Nucl Med Mol Imaging. 2007;34(suppl 2):S221. 
25. Cescato R, Maina T, Nock B, et al. Bombesin receptor antagonists may be preferable to agonists 
for tumor targeting. J Nucl Med. 2008;49:318-326. 
26. Suda H, Aoyagi T, Takeuchi T, Umezawa H. Letter: a thermolysin inhibitor produced by 
actinomycetes-phospholamidon. J Antibiot (Tokyo). 1973;26:621-623. 
27. Nock BA, Maina T, Krenning EP, de Jong M. “To serve and protect”: enzyme inhibitors as 
radiopeptide escorts promote tumor targeting. J Nucl Med. 2014;55:121-127. 
28. Parry JJ, Andrews R, Rogers BE. MicroPET imaging of breast cancer using radiolabeled 
bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat. 
2007;101:175-183. 
29. Scopinaro F, Di Santo GP, Tofani A, et al. Fast cancer uptake of 99mTc-labelled bombesin 
(99mTc BN1). In Vivo. 2005;19:1071-1076. 
30. Soluri A, Scopinaro F, De Vincentis G, et al. 99MTC [13LEU] bombesin and a new gamma 
camera, the imaging probe, are able to guide mammotome breast biopsy. Anticancer Res. 
2003;23:2139-2142. 
31. Van de Wiele C, Phonteyne P, Pauwels P, et al. Gastrin-releasing peptide receptor imaging in 
human breast carcinoma versus immunohistochemistry. J Nucl Med. 2008;49:260-264. 
32. Shariati F, Aryana K, Fattahi A, et al. Diagnostic value of 99mTc-bombesin scintigraphy for 
differentiation of malignant from benign breast lesions. Nucl Med Commun. 2014;35:620-625.
33. Bergsma HKH, Meuller D, Maina T, et al. PET/CT imaging with a novel 68Ga-labelled GRP- 
receptor antagonist, “Sarabesin 3”: first clinical data in patients with prostate and breast 
cancer [abstract]. J Nucl Med. 2013;54(suppl 2):280.
34. Dumont RA, Tamma M, Braun F, et al. Targeted radiotherapy of prostate cancer with a 
gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination 
with rapamycin. J Nucl Med. 2013;54:762-769.
35. Stewart FA, Akleyev AV, Hauer-Jensen M, et al. ICRP publication 118: ICRP statement on 
tissue reactions and early and late effects of radiation in normal tissues and organs-threshold 
doses for tissue reactions in a radiation protection context. Ann ICRP. 2012;41:1-322
68Ga/177Lu-NeoBOMB1, a Novel 
Radiolabeled GRPR Antagonist 
for Theranostic Use in Oncology
Chapter 9
Adapted from J Nucl Med 2016 Sep. 8 
[epub ahead of print]
*Authors equally contributed to the work
1Dept. of Radiology & Nuclear Medicine, Erasmus MC, 
Rotterdam, The Netherlands; 2Advanced Accelerator 
Applications, Colleretto Giacosa, Italy; 
and 3Molecular Radiopharmacy, INRASTES, NCSR 
“Demokritos”, Athens, Greece
S.U. Dalm1*, I.L. Bakker1*, E. de Blois1, 
G.N. Doeswijk1, M.W. Konijnenberg1, F. Orlandi2, 
D. Barbato2, M. Tedesco2,  T. Maina3, 
B.A. Nock3 and M. de Jong1
Chapter 9 GRPR Radioligand for Theranostic Use
157156
9
ABSTRACT
Since overexpression of the gastrin releasing peptide receptor (GRPR) has been 
reported on various cancer types, e.g. prostate cancer and breast cancer, targeting 
this receptor with radioligands might have significant impact on staging and 
treatment of GRPR-expressing tumors. NeoBOMB1 is a novel DOTA-coupled 
GRPR antagonist with high affinity for GRPR and excellent in vivo stability. The 
purpose of this preclinical study was to further explore the use of NeoBOMB1 
for theranostic application by determining the biodistribution of 68Ga-NeoBOMB1 
and 177Lu-NeoBOMB1.
Methods: PC-3 tumor-xenografted Balb c nu/nu mice were injected with either ~13 MBq/250 pmol 68Ga-NeoBOMB1, or a low (~1 MBq/200 pmol) vs. high (~1 
MBq/10 pmol) peptide amount of 177Lu-NeoBOMB1 after which biodistribution 
and imaging studies were performed. At 6 time points (15, 30, 60, 2 h, 4 h and 
6 h for 68Ga-NeoBOMB1 and 1, 4, 24, 48, 96 and 168 h for 177Lu-NeoBOMB1) 
post injection (p.i.) tumor and organ uptake was determined. To assess receptor- 
specificity additional groups of animals were co-injected with an excess of unlabeled 
NeoBOMB1. Results of the biodistribution studies were used to determine 
pharmacokinetics and dosimetry. Furthermore, positron emission tomography/
computed tomography (PET/CT) and single photon emission computed tomo-
graphy/magnetic resonance imaging (SPECT/MRI) was performed.
Results: Injection of ~250 pmol 68Ga-NeoBOMB1 resulted in a tumor and 
pancreas uptake of 12.4±2.3 and 22.7±3.3 %ID/g tissue 120 min p.i., respectively. 
177Lu-NeoBOMB1 biodistribution studies revealed a higher tumor uptake (17.9±3.3 
vs. 11.6±1.3 %ID/g tissue 4 h p.i.) and a lower pancreatic uptake (19.8±6.9 vs. 
105±13 %ID/g tissue 4 h p.i.) with the higher peptide amount injected, leading 
to a significant increase in the absorbed dose to the tumor vs. the pancreas 
(200 pmol: 570 vs. 265 mGy/MBq, 10 pmol: 435 vs. 1393 mGy/MBq). Using this 
data to predict patient dosimetry we found a kidney, pancreas and liver exposure 
of 0.10, 0.65 and 0.06 mGy/MBq, respectively. Imaging studies resulted in good 
visualization of the tumor with both 68Ga-NeoBOMB1 and 177Lu-NeoBOMB1. 
Conclusions: Our findings indicate that 68Ga/177Lu-NeoBOMB1 is a very 
promising radiotracer with excellent tumor uptake and favorable pharmacoki-
netics for imaging and therapy of GRPR-expressing tumors.
Keywords:
Cancer Theranostics, Gastrin Releasing Peptide Receptor, GRPR Antagonist, 
Biodistribution, Dosimetry
INTRODUCTION
The gastrin releasing peptide receptor (GRPR), also known as bombesin receptor 
subtype 2, is a G-protein coupled receptor expressed in various organs, including 
those of the gastrointestinal tract (GI-tract) and the pancreas (1,2). Upon 
binding of a suitable ligand, the GRPR is activated, eliciting multiple physio- 
logical processes, such as regulation of exocrine and endocrine secretion (1,2). In 
the past decades, GRPR expression has been reported in various cancer types, 
including prostate cancer and breast cancer (3,4). Therefore, the GRPR became 
an interesting target for receptor mediated tumor imaging and treatment, such 
as peptide receptor scintigraphy and peptide receptor radionuclide therapy (2). 
Following the successful use of radiolabeled somatostatin peptide analogs in neuro- 
endocrine tumors for nuclear imaging and therapy (5,6), multiple radiolabeled 
GRPR radioligands have been synthesized and studied in preclinical as well as 
in clinical studies, mostly in prostate cancer patients. Examples of such peptide 
analogs include AMBA, the Demobesin-series and MP2653 (7-11). Recent studies 
have shown a preference for GRPR antagonists compared to GRPR agonists 
(12,13). Receptor antagonists often show higher binding and favorable pharma-
cokinetics compared to agonists (14). Also, clinical studies with radiolabeled 
GRPR agonists reported unwanted side effects in patients caused by activation of 
the GRPR after binding of the peptide to the receptor (15).
Although, imaging and treatment with radiolabeled GRPR peptide analogs is not 
yet approved for routine clinical practice, progress made over the years led to new 
diagnostic radiotracers which are most promising. On the route to developing a 
new successful imaging and treatment strategy for GRPR-expressing tumors, the 
development of radiotracers with favorable pharmacokinetics that can be labeled 
with different radionuclides is an essential step. Further studies are now needed 
to optimize the use of GRPR radioligands for imaging and treatment of GRPR-
expressing tumors to determine the clinical value of GRPR-targeting radio- 
tracers. 
In this study, we explored the use of a novel DOTA-coupled GRPR antagonist, 
NeoBOMB1, derived from a previously reported GRPR antagonist, SB3 (16). The 
peptidic part of NeoBOMB1 however is based on a different GRPR-antagonist 
first described by Heimbrook et al. (17) and generated by modification of the 
C-terminal Leu13-Met14-NH2 and the replacement of Asn6 by DPhe6 of native 
bombesin(6-14). NeoBOMB1 was chosen for further studies because of its 
improved affinity for the GRPR (18,19). Coupling of the antagonist to a DOTA 
chelator enables labeling with different radionuclides such as 68Ga (for positron 
emission tomography (PET)), 111In (for single photon emission computed tomo-
graphy (SPECT)) and 177Lu (for radionuclide therapy), which makes theranostic 
use of NeoBOMB1 possible. In a preliminary communication on NeoBOMB1, a 
GRPR-affinity in the low nanomolar range for natGa-NeoBOMB1 and excellent in 
vivo stability of 67Ga-NeoBOMB1 was reported (18).
The aim of our study was to further explore the perspectives of 68Ga-NeoBOMB1 
and 177Lu-NeoBOMB1 for clinical translation by performing biodistribution 
studies in PC-3-xenografted mice. Two peptide amounts of 177Lu-NeoBOMB1 
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were studied in order to define the optimal peptide amount for increasing 
tumor targeting while minimizing background radioactivity levels. Data of the 
177Lu-NeoBOMB1 biodistribution studies were used to determine dosimetry in 
mice and to predict dosimetry in humans.
MATERIALS AND METHODS
Radiotracer and Radiolabeling Procedure
NeoBOMB1 (Advanced Accelerator Applications) (Figure 1) (20) was diluted in 
ultra-pure water and concentration and chemical purity were monitored with an 
in-house developed titration method (21). Labeling of NeoBOMB1 was based on 
a previously published kit approach by Castaldi et. al. (22). Radioactivity was 
added (60 MBq/nmol 68Ga or 100 MBq/nmol 177Lu) to a vial containing all the 
necessary excipients, e.g. buffer, anti-oxidants and peptide, subsequently this 
was heated at 85°C for 7 and 20 min, respectively. To measure radiometal incor-
poration, quality control was performed by instant thin layer chromatography 
on silica gel using 0.1 M citrate (pH 5) or 1 M ammonium acetate/methanol 
(30/70 v/v) as buffers. High-performance liquid chromatography was performed 
with a gradient of methanol and 0.1% trifluoroacetic acid to determine radio- 
chemical purity. Both 68Ga-NeoBOMB1 and 177Lu-NeoBOMB1 were diluted in 
phosphate-buffered saline plus a tensioactive agent to prevent sticking of the 
peptide, before injection in animals.
Animal Model
All animal studies were conducted in agreement with the Animal Welfare 
Committee requirements of Erasmus MC and in accordance with accepted guide-
lines. Male Balb c nu/nu animals (6-8 wks) (Janvier) were subcutaneously (right 
shoulder) injected with 150 μL inoculation medium (1/3 Matrigel high concentra-
tion (Corning) and 2/3 HBSS (Thermofisher scientific)) containing 5×106 cells of 
the GRPR-expressing human derived prostate cancer cell line, PC-3 (American 
Type Culture Collection). In vivo imaging and biodistribution studies were 
performed 3-4 weeks post tumor cell inoculation, when tumor size was 340±114 
mm3.
Figure 1. Chemical structure of NeoBOMB1. Green=DOTA chelator, Orange=spacer, 
Purple=binding domain.
Imaging Studies
Mice (n=2 per radiotracer) were injected with 50 μL ~11.5 MBq/230 pmol 
68Ga-NeoBOMB1 or 200 μL 20 MBq/200 pmol 177Lu-NeoBOMB1 after which 
PET/computed tomography (CT) or SPECT/magnetic resonance imaging (MRI) 
was performed.
The PET/CT scans were performed 1 h post injection (p.i.) of 68Ga-NeoBOMB1 
in a small animal SPECT/PET/CT scanner (VECTor/CT, Milabs) under isoflu-
rane/O2 anesthesia. Whole body scans were acquired for 120 min (48 projec-
tions, 38 sec/projection) using a special collimator with clustered-pinholes for 
high-energy photons. The collimator contains 162 pinholes with a diameter of 0.7 
mm grouped in clusters of 4. Reconstruction was performed using a pixel-based 
Ordered Subset Expectation Maximization method (4 subsets, 30 iterations) and 
visualized with Vivoquant (InVicro). A post reconstruction 3D Gaussian filter was 
applied (1.2 mm full width half maximum).
Whole body SPECT images were obtained 4 h p.i. of 177Lu-NeoBOMB1 under 
isoflurane/O2 anesthesia, using a 4-head multipinhole system (NanoScan SPECT/
MRI, Mediso Medical Imaging). The images were acquired using 28 projec-
tions (40 sec/projection) and reconstructed using the Ordered Subset Expecta-
tion Maximization method and a voxel size of 0.25×0.25×0.25 mm and a scan 
time of 47 min. Coronal T2 weighted images were acquired with a 2D fast spin 
echo sequence on a 1 tesla permanent magnet (Mediso) with a 35 mm transmit/
receive solenoid coil. Scan parameters used were: TE/TR: 4500/39 ms; number 
of signals averaged: 4; field of view: 70 mm; resolution: 0.4×0.4×0.8 mm, with 0.1 
mm spacing between slices and a scan time of 10 min.
Biodistribution Studies
Biodistribution studies were performed to determine tumor and organ uptake of 
68Ga-NeoBOMB1. Animals (n=4 for each time point) were injected intravenously 
with an average of 13 MBq/250 pmol 68Ga-NeoBOMB1 (injected volume: 50 μL) 
at t=0. At 6 selected time points (15 min, 30 min, 1 h, 2 h, 4 h and 6 h) p.i. animals 
were euthanized, organs and tumors were excised and their radioactivity uptake 
was determined. For the 177Lu-NeoBOMB1 biodistribution studies, animals 
were injected with either 1 MBq/200 pmol or 1 MBq/10 pmol 177Lu-NeoBOMB1 
(injected volume: 200 μL) to determine the peptide amount with optimal tumor 
to background ratio. Four hours, 24 h, 48 h, 96 h and 168 h p.i. animals were 
euthanized, organs were collected and radiotracer uptake was determined 
(n=4 for each concentration per time point). For both the 68Ga-NeoBOMB1 and 
177Lu-NeoBOMB1 biodistribution studies the following organs were collected: 
blood, lungs, spleen, pancreas, kidneys, liver, organs of the GI-tract (stomach, 
intestine, caecum and colon), muscle, tail and tumor. To confirm receptor speci-
ficity of radiotracer uptake PC-3-xenografted mice were co-injected with either 
68Ga-NeoBOMB1 or 177Lu-NeoBOMB1 plus an excess (40 nmol) of unlabeled 
NeoBOMB1 (n=2 and n=4, respectively), after which tumor and organ uptake 
was determined 2 h and 4 h p.i., respectively.
After collecting tumor and organs, the samples were weighed and counted in a 
γ-counter (1480 WIZARD automatic γ-counter, PerkinElmer) to determine the 
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percentage of injected dose per gram tissue (%ID/g tissue). For γ-counter measure- 
ments an isotope specific energy window, a counting time of 60 sec and a counting 
error ≤5% was used. 
Radioactivity uptake in tumor and organs was corrected for the percentage of 
radioactivity measured in the tail.
Dosimetry
Kinetic analysis of the biodistribution data was performed to determine uptake 
and clearance characteristics of the radiotracers. For 177Lu-NeoBOMB1, 
the resulting time-activity concentration curves through the uptake data 
were used to calculate the absorbed doses to the organs and tumor. The 
mouse dosimetry was performed using the RAdiation Dose Assessment 
Resource realistic mouse model (23). The absorbed dose to an organ Dorgan 
was calculated according to the Medical Internal Radiation Dose scheme (24): 
 
 with TIACsrc the time-integrated 
 
activity concentration , S(organ�src) the absorbed 
 dose rate per unit activity in the source src for all source and organ combinations. 
The organ mass morgan is taken from a reference mouse phantom of 25 g to obtain 
invariance to the measured organ weights. Tumor dosimetry was performed in 
the same way with the S-values from Stabin et al. (25).
Extrapolation of the mouse biodistribution data to estimate human dosimetry was 
performed according to the methods by M. Stabin (26). Only organ uptake values 
were extrapolated and time-scaling was not applied. Two methods were applied 
for translation of the mice TIAC to human TIAC for each organ:
, by the ratio in body weights: Mmouse=25 g and 
  
Mhuman=70 kg
, by the ratio in organ weights of mouse and 
 
human, e.g. for pancreas: mmouse=0.305 g and mhuman=94.3 g.
The extrapolated TIAChuman, multiplied by the reference man organ weight, was 
used as input to the dosimetry software OLINDA/EXM (27). Absorbed doses to 
the organs were derived for the reference male phantom. Fifty percent of the 
activity was considered to be distributed in the whole body (remainder) and the 
dynamic bladder model was used to derive the urinary bladder dose with 5 voids 
per day.
Statistics
Least-square fits with exponential curves were performed with the Graphpad 
Prism software (version 5.01). Decisions on the number of exponentials and 
plateau values were based on the Aikake information criterion, thereby balancing 
better fit correlation and degrees of freedom for the fit. A correlation coefficient 
R2>0.7 was used as lowest allowable goodness of fit criterion. Time-activity 
curves below this criterion were piece-wise integrated by the trapezoidal method.
RESULTS
Biodistribution of 68Ga-NeoBOMB1
The results of the biodistribution studies with ~13 MBq/250 pmol 68Ga-NeoBOMB1 
are presented in Figure 2. The highest tumor uptake of 12.4±2.3 %ID/g tissue 
was measured at 120 min p.i. (Figure 2A). At that time point uptake in the 
pancreas was 22.7±3.3 %ID/g tissue. As a consequence of renal and hepatobiliary 
excretion, uptake values in the kidney and liver were 5.7±2.4 %ID/g tissue and 
8.3±1.8 %ID/g tissue, respectively. When receptors were blocked by co-injection 
with an excess of unlabeled NeoBOMB1, uptake in GRPR-expressing tissues, 
such as tumor and pancreas decreased to 1.0±0.1 %ID/g tissue and 0.7±0.1 %ID/g 
tissue, respectively. Pharmacokinetic calculations resulted in a tumor clearance 
half-life of 6.9±2.8 h and a pancreas clearance half-life of 12.9±4.0 h (Figure 2B+C). 
Clearance from blood proceeded according to a bi-phasic pattern: 66±9% with 
T1/2=8±5 min and 34% with T1/2=50±15 min.
PET/CT scans of animals injected with 11.5 MBq/230 pmol resulted in good visuali- 
zation of the tumor tissue. As expected, uptake was also seen in the abdominal 
area as a consequence of uptake in the GI-tract and/or pancreas. Images are 
presented in Figure 2D. 
Biodistribution of 177Lu-NeoBOMB1 
Injection of 1 MBq/10 pmol or 1 MBq/200 pmol 177Lu-NeoBOMB1 in PC-3- 
xenografted mice resulted in a higher tumor uptake with 200 pmol 177Lu-NeoBOMB1 
compared to that obtained after injection of 10 pmol 177Lu-NeoBOMB1 
(17.9±3.3 %ID/g tissue 4 h. p.i. vs. 11.6±1.3 %ID/g tissue 4 h p.i.). Figure 3 
shows the results of the 177Lu-NeoBOMB1 biodistribution studies with 200 pmol 
(Figure 3A) and with 10 pmol (Figure 3B). Next to the tumor, high uptake was 
seen in the pancreas. However, in contrast to the tumor uptake, pancreas uptake 
was lower after injection of 200 pmol 177Lu-NeoBOMB1 (19.8±6.9 %ID/g tissue 4 
h p.i.) compared to injection of 10 pmol 77Lu-NeoBOMB1 (105±13 %ID/g 4 h p.i.), 
resulting in a significant increase of the tumor to pancreas ratio with the higher 
peptide amount. Apart from the tumor and pancreas, the difference in peptide 
amount injected did not affect uptake in other non-GRPR-expressing organs (e.g. 
kidney uptake was 2.8±0.4 vs. 2.5±0.6 %ID/g tissue 4 h p.i. of 200 pmol and 10 
pmol 177Lu-NeoBOMB1, respectively). 
Uptake in tumor and pancreas was receptor-specific, since co-injection with an 
excess of unlabeled NeoBOMB1 resulted in a significant decrease of both tumor 
uptake (0.50±0.02 %ID/g tissue and 0.39±0.06 %ID/g tissue using 200 pmol and 
10 pmol 177Lu-NeoBOMB1 respectively) and pancreas uptake (0.13±0.01 %ID/g 
tissue and 0.10±0.01 %ID/g tissue using 200 pmol and 10 pmol 177Lu-NeoBOMB1 
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Figure. 2. 68Ga-NeoBOMB1 biodistribution and imaging. A) Biodistribution of ~13 MBq/250 
pmol 68Ga-NeoBOMB1. Tumor to organ ratios are displayed in the upper bar graph. B+C) 
Pharmacokinetic modeling of the 68Ga-NeoBOMB1 tumor and pancreas uptake, respectively. 
D) PET/CT images acquired 1 h post injection of 11.5 MBq/230 pmol 68Ga-NeoBOMB1. 
Tumor is located on the right shoulder. Mu=muscle, Lu=lungs, Sp=spleen, GI=GI-tract, 
Bl=blood, Ki=kidney, Li=liver, Pa=pancreas and Tu=PC-3 tumor.
Figure 3. 177Lu-NeoBOMB1 biodistribution and imaging. A+B) Biodistribution of 200 pmol 
and 10 pmol 177Lu-NeoBOMB1 in PC-3-xenografted animals, respectively. Tumor to organ ratios 
are displayed in the upper bar graph. C) Pharmacokinetic modeling of the 177Lu-NeoBOMB1 
tumor uptake. D) Pharmacokinetic modeling of the 177Lu-NeoBOMB1 pancreas uptake. E)
SPECT/MR images 4 h post injection of 20 MBq/200 pmol 177Lu-NeoBOMB1. Tumor is 
located on the right shoulder. Mu=muscle, Lu=lungs, Sp=spleen, GI=GI-tract, Bl=blood, 
Ki=kidney, Li=liver, Pa=pancreas and Tu=PC-3 tumor.
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respectively), independent of the peptide amount used. Although initial radio-
activity uptake in the pancreas was high, pancreas uptake decreased relatively 
rapidly, while tumor radioactivity was retained longer. The pharmacokinetic 
calculations resulted in a tumor clearance half-life of 28.6±2.7 h and in a pancreas 
clearance half-life of 11.0±2.9 h when animals were injected with 200 pmol 
177Lu-NeoBOMB1 (Figure 3C+D). The tumor clearance half-life was 36.1±2.8 h 
after injection of 10 pmol of the radiotracer. The clearance from the pancreas 
showed a bi-exponential pattern after injection of 10 pmol 177Lu-NeoBOMB1: 63% 
with a half-life of 4.5±1.6 h and 37% with 13.7±6.2 h. After injection of 200 pmol 
177Lu-NeoBOMB1, only a single-exponential curve could be fitted. Clearance from 
blood proceeded according to a single-phase pattern with T1/2=63±32 min after 
injection of 10 pmol 177Lu-NeoBOMB1 and withT1/2=48±12 min after injection of 
200 pmol of the radiotracer.
SPECT/MR images acquired 4 h p.i. of ~20 MBq/200 pmol of 177Lu-NeoBOMB1 
resulted in good visualization of the tumor (Figure 3E). In line with the results of 
the biodistribution study minimal uptake was observed in the GI-tract.
Dosimetry
Dosimetry calculations resulted in a higher tumor dose (581 mGy/MBq vs. 435 
mGy/MBq) and a lower dose to the pancreas (265 mGy/MBq vs. 1393 mGy/
Mbq) after injection of 200 pmol 177Lu-NeoBOMB1 vs. 10 pmol 177Lu-NeoBOMB1 
(Table 1). When animal data were used to predict human dosimetry according to 
method 2 (ratio of organ weights), we found a kidney, pancreas and liver exposure 
of 0.10, 0.65 and 0.06 mGy/MBq respectively (Table 2). Method 1 (ratio of body 
weights) yielded lower absorbed dose estimates.
Table 1. Absorbed dose per administered activity (mGy/MBq) in 340±100 mm3 PC-3-tumor 
xenografts and organs for 177Lu-NeoBOMB1
Organs 10 pmol 200 pmol D (tumor)/D (organ)
10 pmol 200 pmol
Tumor 435 570 - -
Kidneys 58 57 7.5 10
Pancreas 1393 265 0.31 2.15
DISCUSSION
Since overexpression of the GRPR is reported in various cancer types, targeting 
this receptor with radiolabeled peptide analogs for imaging and therapy might 
have a significant impact on patient care. In this study we explored the use 
of a novel radiolabeled GRPR antagonist, NeoBOMB1, for tumor targeting by 
performing imaging and biodistribution studies in a prostate cancer mouse 
model. NeoBOMB1 is linked to a DOTA-chelator and can be labeled with 
different radionuclides enabling the theranostic use of the peptide analog. We 
evaluated the biodistribution of both 68Ga-NeoBOMB1, for imaging purposes, and 
177Lu-NeoBOMB1, for therapy purposes in a mouse model in order to generate 
information for theranostic use of the radiotracer.
Biodistribution studies with 68Ga-NeoBOMB1 resulted in high tumor uptake, 
leading to clear visualization of the tumor on PET/CT scans. Furthermore, rela-
tively high uptake of 68Ga-NeoBOMB1 was observed in the GRPR-expressing 
pancreas, resulting in a tumor to pancreas ratio of 0.6 (1 h p.i.). Clearance half-
lives demonstrated a lower clearance half-life for the tumor (6.9±2.8 h) compared 
to the pancreas (12.9±4.0 h). Presumably, this is a consequence of the limited 
time points studied in the 68Ga-NeoBOMB1 biodistribution studies. Furthermore, 
tumor uptake was slower than pancreas uptake. Because of the short half-life of 
68Ga in combination with the slower tumor kinetics, biodistribution studies could 
Table 2. Extrapolated human dosimetry (mGy/MBq) for 177Lu-NeoBOMB1
10 pmol 200 pmol
Organs Method 1 Method 2 Method 1 Method 2
Lower large intestine wall 0.18 0.32 0.17 0.18
Small intestine 0.17 0.19 0.15 0.16
Stomach wall 0.16 0.19 0.15 0.17
Upper large intestine wall 0.23 0.34 0.17 0.21
Heart wall 0.02 0.02 0.01 0.01
Kidneys 0.03 0.09 0.03 0.10
Liver 0.15 0.03 0.03 0.06
Lungs 0.02 0.01 0.01 0.01
Muscle 0.01 0.01 0.01 0.01
Pancreas 0.54 3.37 0.11 0.65
Red Marrow 0.11 0.10 0.11 0.11
Osteogenic cells 0.44 0.42 0.45 0.44
Spleen 0.02 0.03 0.01 0.02
Urinary bladder wall 0.75 0.74 0.75 0.75
Total Body 0.15 0.14 0.15 0.15
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not be performed at later time points. Nevertheless, the presented data indicates 
that NeoBOMB1 has excellent pharmacokinetic properties for imaging. 
In the 177Lu-NeoBOMB1 biodistribution studies, we compared organ and tumor 
uptake of 2 different peptide amounts, 1 MBq/10 pmol and 1 MBq/200 pmol. 
Injection of 1 MBq/200 pmol 177Lu-NeoBOMB1 resulted in a higher tumor uptake 
and a lower pancreatic uptake compared to the uptake observed after adminis-
tration of 1 MBq/10 pmol 177Lu-NeoBOMB1, resulting in a favorable tumor to 
pancreas ratio (0.9 vs. 0.11, based on radioactivity uptake 4 h p.i.) with the high 
peptide amount used. In contrast to the GRPR-positive pancreas, the uptake in 
other organs was not influenced by the injected peptide amount. The observed 
peptide amount dependent uptake in the pancreas is likely due to partial receptor 
saturation of the pancreas when 200 pmol of the radiotracer is administered. Our 
results are in line with previous observations (8,28) for the GRPR agonist AMBA, 
and emphasize the need for careful optimization of protocols for nuclear imaging 
and therapy.
Furthermore, dosimetry calculations resulted in a 1.3 times higher tumor dose 
and a 5 times lower pancreas dose with 200 pmol 177Lu-NeoBOMB1 compared 
to 10 pmol 177Lu-NeoBOMB1. When comparing dosimetry data with other radio-
labeled GRPR antagonists, such as 177Lu-JMV4168 (29), estimated absorbed 
radiation doses to the tumor were higher for 177Lu-NeoBOMB1 (29 Gy/50 MBq 
vs. 11 Gy/50 MBq) even when 177Lu-JMV4168 was stabilized by co-injection of an 
enzyme inhibitor (29 Gy/50 MBq vs. 20 Gy/MBq). When we compared the dose 
to the kidneys and pancreas of the radiotracers, we found a more favorable tumor 
to kidney ratio for 177Lu-NeoBOMB1 (10 vs. 1.5) and a similar tumor to pancreas 
ratio (2.2 vs. 2.5).
As expected, comparing the biodistribution of the 68Ga-NeoBOMB1 or 
177Lu-NeoBOMB1, with the uptake of radiolabeled GRPR agonists, e.g. 99mTc-
Demobesin4 or 177Lu-AMBA, a lower uptake was observed in GRPR-expressing 
organs, namely the pancreas and the gastrointestinal tract (8,13).
Comparing uptake and dosimetry of radiolabeled NeoBOMB1 with other radio-
labeled GRPR antagonists mentioned in literature is difficult because of the differ-
ences between experimental conditions, such as the peptide amount used and the 
radionuclide bound to the peptide. However, we can report that in vivo tumor to 
pancreas ratio in mouse models are more favorable for 68Ga-NeoBOMB1 (0.6) 
compared to other GRPR antagonists such as 67Ga-SB3 (0.2) reported by Maina 
et al. (16) and 99mTc-Demobesin 1 (0.2) reported by Cescato et al. (13) (numbers 
are based on biodistribution results 1 h p.i. of the radiotracers). However, lower 
peptide amounts were used in these studies which could lead to less favorable 
results as demonstrated in the 177Lu-NeoBOMB1 biodistribution studies. Never-
theless, the mentioned radiotracers have successfully been used in clinical trials 
for the visualization of both breast and newly diagnosed prostate cancer lesions, 
emphasizing the potential of 68Ga-NeoBOMB1 for tumor visualization in humans.
Comparing extrapolated human dosimetry data of 177Lu-NeoBOMB1 with extra-
polated dosimetry data of 177Lu-DOTA-Tyr3-octreotate, which is currently 
successfully used for treatment of patients with neuroendocrine tumors, we 
found similar values (Table 3). This was expected since excretion patterns of 
the two radiotracers are comparable. Although the extrapolated dosimetry data 
of 177Lu-DOTA-Tyr3-octreotate does not completely fit the dosimetry values 
obtained from patients studies (Table 3), based on the extrapolated data of 
177Lu-NeoBOMB1 we expect similar values. 
Concerning imaging, patient studies by Maina et al. (16) in which prostate cancer 
lesions were successfully visualized using a GRPR radioligand showed a biodis-
tribution pattern in physiological organs similar to what was found in mice. 
Although the authors did not report on limitations of their imaging studies, more 
clinical studies are needed.
Very promising prostate-specific membrane antigen (PSMA)-targeting ligands 
are currently also under investigation for the same purpose. In a recent study 
Minamimoto et al. (30) compared PSMA and GRPR-targeted imaging in prostate 
cancer and found no significant differences. Furthermore, Perera et al. (31) 
reported on a relatively low sensitivity of PSMA-targeted imaging in patients 
with low prostate-specific antigen levels and patients with primary disease (40% 
and 50%, respectively). Especially in these patient groups the application of 
GRPR radioligands may be of benefit.
Based on the presented data we conclude that both 68Ga-NeoBOMB1 and 
177Lu-NeoBOMB1 have excellent tumor uptake and favorable pharmacokinetics 
for theranostic use. Clinical studies using this radiotracer in GRPR-expressing 
cancer, e.g. prostate cancer and breast cancer, have yet to be performed, but 
expectations are high.
Table 3. Comparison between extrapolated and determined absorbed doses per injected activity 
for 177Lu-DOTA-Tyr3-octreotate
* Data based on published data by S. Bison et al. (32).
† Data published by Sandström et al. (33).
Organs Method 1* Method 2† 177Lu-DOTA-Tyr3-octreotate in patients†
Kidneys 0.06 0.16 0.62 (0.49-0.75)
Liver 0.01 0.01 0.29 (0.21-0.49)
Red Marrow 0.11 0.11 0.016 (0.012-0.022)
Spleen 0.01 0.02 0.68 (0.51-0.92)
Total Body 0.14 0.14
Chapter 9 GRPR Radioligand for Theranostic Use
169168
9
REFERENCES
1. Guo M, Qu X, Qin XQ. Bombesin-like Peptides and their Receptors: Recent Findings in Phar-
macology and Physiology. Curr Opin Endocrinol Diabetes Obes. 2015;22:3-8.
2. Gonzalez N, Moody TW, Igarashi H, Ito T, Jensen RT. Bombesin-related Peptides and their 
Receptors: Recent Advances in their Role in Physiology and Disease States. Curr Opin Endo-
crinol Diabetes Obes. 2008;15:58-64.
3. Gugger M, Reubi JC. Gastrin-releasing Peptide Receptors in Non-neoplastic and Neoplastic 
Human Breast. Am J Pathol. 1999;155:2067-2076.
4. Markwalder R, Reubi JC. Gastrin-releasing Peptide Receptors in the Human Prostate: Relation 
to Neoplastic Transformation. Cancer Res. 1999;59:1152-1159.
5. Brabander T, Kwekkeboom DJ, Feelders RA, Brouwers AH, Teunissen JJ. Nuclear Medicine 
Imaging of Neuroendocrine Tumors. Front Horm Res. 2015;44:73-87.
6. Kwekkeboom DJ, Krenning EP. Peptide Receptor Radionuclide Therapy in the Treatment of 
Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2016;30:179-191.
7. Yu Z, Ananias HJ, Carlucci G, et al. An Update of Radiolabeled Bombesin Analogs for Gastrin-
releasing Peptide Receptor Targeting. Curr Pharm Des. 2013;19:3329-3341.
8. Lantry LE, Cappelletti E, Maddalena ME, et al. 177Lu-AMBA: Synthesis and Characterization 
of a Selective 177Lu-labeled GRP-R Agonist for Systemic Radiotherapy of Prostate Cancer. J 
Nucl Med. 2006;47:1144-1152.
9. Schroeder RP, Muller C, Reneman S, et al. A Standardised Study to compare Prostate Cancer 
Targeting Efficacy of Five Radiolabelled Bombesin Analogues. Eur J Nucl Med Mol Imaging. 
2010;37:1386-1396.
10. Nock B, Nikolopoulou A, Chiotellis E, et al. [99mTc]Demobesin 1, a Novel Potent Bombesin 
Analogue for GRP Receptor-targeted Tumour Imaging. Eur J Nucl Med Mol Imaging. 
2003;30:247-258.
11. Mather SJ, Nock BA, Maina T, et al. GRP Receptor Imaging of Prostate Cancer using [(99m)Tc]
Demobesin 4: a First-In-Man Study. Mol Imaging Biol. 2014;16:888-895.
12. Mansi R, Wang X, Forrer F, et al. Development of a Potent DOTA-conjugated Bombesin Antago-
nist for targeting GRPr-positive Tumours. Eur J Nucl Med Mol Imaging. 2011;38:97-107.
13. Cescato R, Maina T, Nock B, et al. Bombesin Receptor Antagonists may be preferable to 
Agonists for Tumor Targeting. J Nucl Med. 2008;49:318-326.
14. Ginj M, Zhang H, Waser B, et al. Radiolabeled Somatostatin Receptor Antagonists are Prefer-
able to Agonists for in vivo Peptide Receptor Targeting of Tumors. Proc Natl Acad Sci U S A. 
2006;103:16436-16441.
15. Bodei L, Ferrari M, Nunn AD, et al. 177Lu-AMBA Bombesin Analogue in Hormone Refrac-
tory Prostate Cancer Patients: a Phase I Escalation Study with Single-cycle Administrations 
[abstract]. Eur J Nucl Med Mol Imaging. 2007;34:S221 
16. Maina T, Bergsma H, Kulkarni HR, et al. Preclinical and First Clinical Experience with the 
Gastrin-releasing Peptide Receptor-antagonist [Ga]SB3 and PET/CT. Eur J Nucl Med Mol 
Imaging. 2016;43:964-973.
17. Heimbrook DC, Saari WS, Balishin NL, et al. Gastrin Releasing Peptide Antagonists with 
Improved Potency and Stability. J Med Chem. 1991;34:2102-2107.
18. Nock B, Kaloudi A, Lymperis E, et al. [68Ga]NeoBomb1, a New Potent GRPR-antagonist for 
PET Imaging-Preclinical and First Clinical Evaluation in Prostate Cancer. J Nucl Med. 2016;57 
(Suppl 2):583.
19. Dalm S, Bakker I, de Blois E, et al. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR 
Antagonist for Theranostic Use. J Nucl Med. 2016;57 (Suppl 2):331.
20. Maina-Nock T, Nock BA, de Jong M. Grpr-antagonists for detection, diagnosis and treatment 
of grpr-positive cancer. Google Patents; 2014.
21. Breeman WA, de Zanger RM, Chan HS, de Blois E. Alternative Method to Determine Specific 
Activity of (177)Lu by HPLC. Curr Radiopharm. 2015;8:119-122.
22. Castaldi E, Muzio V, D'Angeli L, Fugazza L. 68GaDOTATATE lyophilized Ready to use Kit for 
PET Imaging in Pancreatic Cancer Murine Model. J Nucl med. 2014;(Supplement 1):55.
23. Keenan MA, Stabin MG, Segars WP, Fernald MJ. RADAR Realistic Animal Model Series for 
Dose Assessment. J Nucl Med. 2010;51:471-476.
24. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD Pamphlet No. 21: a Generalized 
Schema for Radiopharmaceutical Dosimetry -Standardization of Nomenclature. J Nucl Med. 
2009;50:477-484.
25. Stabin MG, Konijnenberg MW. Re-evaluation of Absorbed Fractions for Photons and Electrons 
in Spheres of Various Sizes. J Nucl Med. 2000;41:149-160.
26. Stabin MG. Fundamentals of Nuclear Medicine Dosimetry. 1 ed: Springer-Verlag New York; 
2008.
27. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the Second-generation Personal Computer 
Software for Internal Dose Assessment in Nuclear Medicine. J Nucl Med. 2005;46:1023-1027.
28. De Blois E, Schroeder RJ, De Ridder CA, Van Weerden WM, Breeman WP, De Jong M. Improving 
Radiopeptide Pharmacokinetics by adjusting Experimental Conditions for Bombesin Receptor-
mediated Imaging of Prostate Cancer. Q J Nucl Med Mol Imaging. 2013 [epub].
29. Chatalic KL, Konijnenberg M, Nonnekens J, et al. In Vivo Stabilization of a Gastrin-Releasing 
Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate 
Cancer in Preclinical Studies. Theranostics. 2016;6:104-117.
30. Minamimoto R, Hancock S, Schneider B, et al. Pilot Comparison of 68Ga-RM2 PET and 
68Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 
2016;57:557-562.
31. Perera M, Papa N, Christidis D, et al. Sensitivity, Specificity, and Predictors of Positive 
68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced 
Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016 [epub].
32. Bison SM, Konijneberg MW, Koelewijn SJ, Melis ML, de Jong M. Influence of Specific Activity 
on Tumour Dosimetry and Response to Therapy in a Nude Mouse Small Cell Lung Cancer 
Model. 2014;41 (Suppl 2):S151-S705.
33. Sandstrom M, Garske-Roman U, Granberg D, et al. Individualized Dosimetry of Kidney 
and Bone Marrow in Patients undergoing 177Lu-DOTA-octreotate Treatment. J Nucl Med. 
2013;54:33-41.
Epilogue
Part 5
Summary, Discussion  
and Future Perspectives
Summary
175174
SUMMARY
Breast cancer (BC) is the 2nd most common cancer worldwide and the most 
frequent cancer type occurring in women. The disease is highly heterogeneous 
consisting of various subtypes; and therapy and prognosis varies dependent on 
the BC subtype (1,2). Over the years different detection techniques and novel 
therapies for BC have been introduced, which had a positive impact on BC care 
and outcome (3). However, the currently used imaging methods still have limi-
tations and current treatments for metastatic disease are unfortunately not asso-
ciated with cure. As a result the mortality rate is still too high. The aim of the 
studies described in this thesis was to investigate radiotracers for theranostic 
purposes in BC. Figure 1 shows an overview of the main findings.
Chapter 1 of this thesis provides an introduction on BC characteristics and current 
imaging and therapy options. Next, nuclear medicine-based imaging techniques and 
therapeutic options are explained, and examples of commonly used radionuclides 
for these purposes are mentioned. Subsequently, the currently used nuclear 
medicine-based imaging methods for BC and their limitations are portrayed, 
followed by an introduction of a more specific approach for nuclear medicine 
based imaging, in which biomarkers overexpressed on cancer cells are targeted 
with radiotracers. These radiotracers can also be used for therapeutic purposes 
when labeled with therapeutic radionuclides. In this regard, the concept of thera- 
nostics is explained including a list of radionuclides suitable for this purpose. Three 
biomarkers, SSTR, GRPR and CXCR4, interesting for targeting of BC for thera-
nostic purposes are described. Finally, the potential benefits of targeted nuclear 
imaging and treatment of BC are discussed. Chapter 2 provides an overview of 
all biomarkers currently under investigation in preclinical and/or clinical studies 
for targeted nuclear imaging. These biomarkers are differentially expressed in the 
different BC subtypes and information gained from nuclear imaging is dependent 
on the biomarker targeted. The heterogeneity of BC requires a more personalized 
approach of the disease; one size does not fit all, and thus careful selection of the 
right radiotracer for the right purpose and the right patient is needed. In order to 
achieve a successful personalized approach, important benefits and limitations of 
the radiotracers should be considered.
Figure 1. Overview of the main findings of the studies described in this thesis. PBC=primary 
breast cancer, MBC=metastatic breast cancer.
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The second part of the thesis focuses on the clinical relevance of targeting 
SSTR2, GRPR and CXCR4 in BC with the goal of identifying patient groups and 
applications of radiotracers targeting these receptors. In Chapter 3, we describe 
measurements of SSTR2, GRPR and CXCR4 mRNA expression levels of 915 
primary BCs by RT-qPCR and correlation with known clinicopathologic factors, 
biological factors and prognosis. First, in vitro autoradiography was performed 
using both a GRPR and a SSTR2 radioligand on a small panel of BC specimens 
to determine whether mRNA expression of the 2 receptors could be used as a 
surrogate for radiotracer binding; this resulted in a significant positive correla-
tion. Although autoradiography studies with CXCR4 radioligands could not be 
performed, prior studies reported that CXCR4 mRNA and protein expression 
correlated significantly as well. Associating SSTR2, GRPR and CXCR4 mRNA 
expression levels with BC characteristics identified ER-positive tumors (luminal 
A and B BCs) as potential candidates for SSTR2 and GRPR-mediated imaging 
and therapy, while targeting of CXCR4 might be more suited for ER-negative 
tumors (including basal-like tumors). Moreover, high CXCR4 mRNA levels were 
associated with a prolonged prognosis in terms of disease-free, metastases-
free and overall survival. This finding was unexpected, because high CXCR4 
mRNA expression levels were associated with ER-negative tumors, which are 
usually more aggressive. This could be explained by a factor independent of ER 
expression that determines good outcome in this patient group. SSTR2 expres-
sion showed no significant association with prognosis, while high GRPR mRNA 
expression levels were associated with prolonged progression-free survival after 
first-line tamoxifen treatment.
Since metastatic BC is incurable and the main reason for BC-related death, better 
detection and better treatment of advanced disease is very important. Therefore, 
we studied the expression of SSTR2, GRPR and CXCR4 mRNA expression in 60 
paired primary BCs as well as in the corresponding locoregional or distant metas-
tases as described in Chapter 4. The comparison of matched primary tumors 
and metastases demonstrated that there were no significant differences in GRPR 
and CXCR4 mRNA levels between primary tumors and corresponding metas-
tases. Regarding SSTR2, the mRNA expression was lower in liver and ovarian 
metastases compared to the matched primary tumor (P=0.02 and P=0.03, 
respectively). Furthermore, similar to data reported in Chapter 3 high GRPR 
and SSTR2 mRNA expression was mainly associated with ER-positive tumors. 
In only few tumors ER status between primary tumors and metastases was 
discordant, which also affected GRPR and SSTR2 expression in the majority of 
these lesions: in ER-negative metastases that had matched ER-positive primary 
breast tumors, a significant lower expression of GRPR and SSTR2 was observed 
as well. A switch in ER expression between primary tumors and metastases is 
observed in approximately 14% of BCs (4), and hence the associated change 
in GRPR and SSTR2 expression should be kept in mind if GRPR- and SSTR2-
targeting is considered. Based on these findings we concluded that targeting of 
SSTR2, GRPR and CXCR4 for theranostic purposes might be beneficial for both 
primary and advanced disease.
In the next section of the thesis the focus is on SSTR-mediated imaging of BC. 
Chapter 5 is a review of all previously performed clinical studies on SSTR- 
mediated nuclear imaging, of which the majority was performed over a decade 
ago. The aim of the review was to critically assess the methods, findings and limi-
tations of the clinical studies in order to determine whether recent developments 
made in the field of nuclear medicine, both related to better imaging methods 
as well as improved radiotracers, could improve SSTR2 radiotracer-based BC 
imaging. A sensitivity and specificity ranging between 36-100% and 22-100%, 
respectively, was reported from the different studies. Low and heterogeneous 
target expression were identified as the main limiting factors. In the performed 
studies, planar imaging was the main imaging method, octreotide or depreo-
tide were the SST analogs applied, and no discrimination between different BC 
subtypes was made. With the currently available and approved nuclear medicine 
imaging techniques (SPECT, PET and dedicated breast imaging platforms), the 
novel SST analogs (receptor agonists as well as antagonist) with higher receptor 
affinity available, as well as the knowledge of SSTR-expression in relation to BC 
subtypes, it seems worth to reinvestigate the value of SSTR-mediated imaging of 
BC, both in primary and advanced disease. In case imaging is successful, SSTR2 
radioligands coupled to therapeutic radionuclides might be considered for thera-
peutic purposes.
One recent development is the use of SSTR2 antagonists for tumor targeting. 
It has been reported in preclinical and clinical studies that radiolabeled SSTR2 
antagonists are superior to SSTR2 agonists for imaging purposes in neuro-
endocrine tumors, despite the accumulation of radioactivity in tumor cells as 
a consequence of radio-agonist internalization. The enhanced binding of the 
antagonist was explained by the ability to bind more binding sites/receptors than 
the agonist. Since low and heterogeneous SSTR2 expression was identified as a 
limiting factor for SSTR-mediated BC imaging, application of radiolabeled SSTR2 
antagonists might increase radiotracer accumulation and as a consequence 
result in better tumor targeting. In Chapter 6 we compared the binding of a 
radiolabeled SSTR2 agonist, DOTA-Tyr3-octreotate, and an SSTR2 antagonist, 
DOTA-JR11, in 40 human BC specimens as well as the biodistribution of the 2 
compounds in a patient-derived orthotopic BC xenograft mouse model. Binding of 
111In-DOTA-Tyr3-octreotate and 111In-DOTA-JR11 to the BC specimens analyzed 
by in vitro autoradiography was significantly higher (P<0.001) for the receptor 
antagonist compared to the agonist. The ratio of antagonist to agonist binding 
ranged from 1 (in only 1 case) -57 (median (interquartile range)=3.39 (2-5)). 
SPECT/MR imaging in a patient-derived orthotopic BC mouse model (T126) 
resulted in much better visualization of the tumor after injection of 177Lu-DOTA-
JR11 vs. 177Lu-DOTA-Tyr3-octreotate. Biodistribution studies performed after 
imaging confirmed the higher tumor uptake of the antagonist. It was concluded 
that the use of SSTR2 antagonists such as DOTA-JR11, could improve BC 
targeting, shedding new light on SSTR-targeted nuclear imaging and potentially 
also SSTR-targeted therapy.
Since the superiority of SSTR2 radiotracers was only demonstrated for imaging 
purposes and a major benefit of radiotracers is the application for treatment as 
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well, we compared 177Lu-DOTA-JR11 and 177Lu-DOTA-Tyr3-octreotate for thera-
peutic purposes in a preclinical setting (both in vitro and in vivo) in Chapter 7. 
To deliver proof of principle these experiments were performed in vitro in cells 
transfected with SSTR2 (U2OS+SSTR2) and in vivo in mice bearing SSTR-
expressing H69 xenografts. In vitro, tracer uptake and DNA damage (indirectly 
measured by 53BP1 foci) were determined after incubation with 177Lu-DOTA-
JR11 and 177Lu-DOTA-Tyr3-octreotate. This resulted in a 5 times higher uptake 
and 2 times more DNA damage after incubation with the radio-antagonist vs. the 
radio-agonist. In vivo therapy studies, performed after determining the optimal 
peptide amount for tumor targeting in biodistribution studies, resulted in a longer 
growth delay and a better median survival time after 177Lu-DOTA-JR11 treatment 
compared to those observed after 177Lu-DOTA-Tyr3-octreotate treatment. These 
findings led to the conclusion that the use of SSTR2 antagonists is not only 
superior for imaging, but also for therapeutic purposes and could thus improve 
the theranostic use of SSTR2 radiotracers. This is especially interesting for 
tumor types with lower SSTR2 expression, including BC
The last section of the thesis focusses on the use of GRPR radiotracers for tumor 
targeting. In Chapter 8 the application of GRPR radioligands in BC was studied 
in a preclinical setting. First, in vitro autoradiography using a radiolabeled GRPR 
agonist, 111In-AMBA, was used to determine GRPR expression in 50 human BC 
specimens. The majority of the tumors (96%) expressed the receptor and GRPR 
expression was positively associated with ER expression. Next, a panel of BC 
cell lines was screened for their ability to bind 111In-AMBA and the cell lines with 
the highest uptake, T47D and MCF7 (both ER-positive cell lines), were used 
for further studies. In vitro therapy of T47D cells with 177Lu-AMBA resulted in 
a significant reduction (up to 80%) of viable cells compared to untreated cells, 
while treatment with 177Lu-DTPA and unlabeled AMBA had no significant effect 
on cell viability. Mice with subcutaneous and orthotopic T47D or MCF7 xeno-
grafts scanned by SPECT after injection of an in situ stabilized radiolabeled GRPR 
antagonist, 111In-JMV4168 + phosphoramidon (an enzyme inhibitor preventing 
degradation of the peptide), showed good visualization of the tumors. In line with 
the in vitro studies, T47D xenografts were visualized better than MCF7 xeno-
grafts. This was also confirmed in the biodistribution studies. The application of 
GRPR radioligands proofed to be promising for nuclear imaging and treatment of 
GRPR-positive breast lesions. Since high GRPR expression is associated with 
ER-positive BC and ~70% of BCs are ER-positive, targeting the GRPR for thera-
nostic purposes holds promise for the majority of BCs.
In the final chapter (Chapter 9) a novel GRPR radiotracer, NeoBOMB1 was inves-
tigated for theranostic use. In vivo studies were performed comparing the use of 
177Lu and 68Ga labeled NeoBOMB1 in vivo in a prostate cancer (PC3) xenograft 
mouse model. Biodistribution and imaging studies (SPECT and PET) were 
performed at different time points after injection of the radiotracers. Data was 
used to determine pharmacokinetics, dosimetry and to predict patient dosimetry. 
For the 177Lu-NeoBOMB1 studies, two different peptide amounts (10 pmol vs. 
200 pmol) were compared to find the best tumor to background ratio for tumor 
targeting. Both 68Ga-NeoBOMB1 and 177Lu-NeoBOMB1 uptake in tumors was 
high and tumors were successfully visualized in SPECT and PET imaging studies. 
Notable uptake was also observed in the GRPR-expressing pancreas and the 
kidneys, the latter due to renal excretion and partial reabsorption of the radio-
tracers. However, clearance from the pancreas and kidneys was relatively fast, 
while in the tumor the radiotracer was retained better. When 2 peptide amounts 
of 177Lu-NeoBOMB1 were compared, the highest peptide amount appeared to be 
the preferred one, as higher tumor uptake and a lower background uptake were 
observed. As expected, this resulted in a higher tumor dose and lower dose in 
normal organs that showed radiotracer uptake after the highest amount, 200 pmol 
NeoBOMB1 labeled with 177Lu, was injected. Concerning the predicted patient 
dosimetry, the calculated values were similar to those reported for the clinically 
successfully used SSTR2 radiotracer 177Lu-DOTA-Tyr3-octreotate. Based on the 
acquired data it was concluded that both 68Ga-NeoBOMB1 and 177Lu-NeoBOMB1 
had excellent tumor uptake and pharmacokinetics for theranostic use. Although 
these studies were performed in a prostate cancer mouse model, our findings 
indicate the potential of this radiotracer for theranostic purposes in BC as well. 
DISCUSSION AND FUTURE PERSPECTIVES
The studies described in this thesis demonstrated the potential of SSTR, GRPR 
and CXCR4 (with the majority of studies focused on SSTR2 and GRPR) as 
targeting radiotracers for theranostic use in BC. Application of targeted nuclear 
medicine can potentially offer a non-invasive, sensitive, specific and personalized 
method for imaging and treatment of the disease. Based on the results of the 
preclinical studies, it is suggested that there are specific BC patient groups that 
may benefit from SSTR2, GRPR or CXCR4 targeting. There are still many chal-
lenges, however, that need to be addressed. 
BC Subtypes
ER-positive BC subtypes were identified as the most suitable BCs for GRPR- and 
SSTR2-targeting, while ER-negative BC showed higher expression of CXCR4, 
making the latter target more suitable for ER-negative tumors. However, it is 
necessary to mention that GRPR, SSTR2 and CXCR4 expression was not limited 
to ER-positive and -negative tumors, respectively, and thus in some cases radio-
tracers targeting these receptors might also be applied to the other BC subtypes. 
The other way around, although the majority of ER-positive BCs express the 
GRPR, not all tumors showed (sufficient) expression for targeting. This was also 
the case for SSTR2 and CXCR4, the latter in the case of ER-negative tumors. 
Furthermore, the difference in target expression observed between ER-positive 
and ER-negative tumors was less pronounced for CXCR4 than for GRPR and 
SSTR2.
The high correlation between ER expression and GRPR and SSTR2 expres-
sion suggests a connection between the receptors. Various studies reported an 
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estrogen dependent regulation of SSTR2 expression via ER in human derived BC 
cell lines (5-7). In some studies it was reported that incubation with tamoxifen led 
to an increase in SSTR2 expression, while incubation with “pure” anti-estrogens 
caused a decrease in SSTR2 expression. Concerning GRPR expression, to our 
knowledge there are no studies describing a connection between ER signaling 
and GRPR expression or vice versa. If SSTR2 and GRPR-mediated imaging and/
or treatment is to be used in patients treated with anti-estrogen treatment, it 
is important to be aware of the potential effect of anti-estrogens on SSTR2 and 
GRPR expression and to understand the mechanisms underlying SSTR2 and 
GRPR expression in relation to ER. The latter is also important in tumors that 
show resistance against anti-estrogen treatment. In the metastatic setting, in 
which response can be assessed, approximately 20% of patients show intrinsic 
resistance against first line anti-estrogen treatment, and only 30-40% of patients 
respond to second and third line endocrine therapy (8). Especially in patients who 
have been treated with multiple lines of endocrine treatment, the use of SSTR2 
or GRPR radioligands for therapeutic purposes might be considered, if SSTR2 
and GRPR expression in these patients is retained. There are a few mechanisms 
described regarding anti-estrogen resistance including down regulation of ER, 
genetic mutations in ESR1, loss of ER, impaired co-activator signaling and activa-
tion of the growth factor signaling pathway (9-11). The question remains whether 
and how these factors negatively influence SSTR2 and GRPR expression. In a 
substantial percentage of breast tumors hormone receptor expression and/or 
HER2 expression changes during disease progression, resulting in discordance 
of receptor expression between primary BC and metastases (12). In one of the 
described studies (Chapter 4) we investigated the effect of ER and HER2 discor-
dance on SSTR2, GRPR and CXCR4 expression in a small number of primary 
tumors and metastatic lesions. Although we found preliminary evidence that a 
change in ER expression influenced GRPR and SSTR2 expression as well, the 
studied sample size was too small for reliable conclusions and larger studies are 
needed.
It is currently recommended by both the national and international societies to 
biopsy metastatic disease as much as possible to determine hormone receptor 
and HER2 expression of the metastatic lesions in order to administer the appro-
priate therapy, and to prevent ineffective treatment when considering biomarker 
expression of the primary tumor only (13). On the other hand, it is not always 
possible to biopsy all the metastatic lesions, and it is theoretically possible that 
biomarker expression varies with the location of the metastases. With regard 
to SSTR2, GRPR and CXCR4, the theranostic use of radiotracers offers the 
opportunity to evaluate target expression of metastases or recurrent disease in 
a non-invasive way by performing imaging studies and therefore biopsy is not 
necessary. The results of these imaging studies might indicate whether targeted 
radionuclide treatment is recommended in a specific patient.
Targets and Radioligands
A number of targets are currently under investigation for BC imaging. If we limit 
our discussion to the targets investigated in this thesis, both SSTR2 and GRPR 
seem to be suitable for application in ER-positive BCs. However, according to our 
studies and other published papers, SSTR2 expression was reported to be less 
frequent, of low density and heterogeneously distributed over the tumor, while 
GRPR was found to be expressed frequently, abundantly and homogenously in 
the majority of breast tumors (14). Based on this information targeting of GRPR 
seems more promising for ER-positive BC than targeting of SSTR2. Neverthe-
less, BC is a very heterogeneous disease; there is not one specific target suitable 
for all ER-positive BCs and when GRPR targeting is not possible, targeting of 
SSTR2 might be a good second option. In order to select the best biomarker for 
tumor targeting, expression of potential targets should be determined on biopsy 
material (as is currently done for ER, PR and HER2 expression) or by performing 
SPECT or PET imaging studies using radioligands targeting these biomarkers, 
which is less invasive but comes with the cost of radiation burden. Furthermore, 
physiological uptake of radiotracers in healthy organs might be dose-limiting 
when radiotracers are applied for therapeutic purposes, and dosimetry calcula-
tions should be performed based on imaging and pharmacokinetic data. So, high 
SSTR2 radiotracer uptake was reported in spleen, adrenals, liver, kidneys and the 
bladder of patients with neuroendocrine tumors (15,16). Furthermore, next to 
the kidneys, bone marrow has been identified as the dose-limiting organ because 
of the high exposure of this organ to radioactivity that is in the blood (17). For 
GRPR radiotracers, high uptake was reported in the pancreas, kidneys, bladder 
and gastrointestinal sphincters (18,19).
Furthermore, as was described in our second chapter, other biomarkers are 
currently under investigation for targeting with radiotracers mainly for imaging 
purposes, including ER and PR. Limitations of these biomarkers include difficulty 
to target lesions when treated with anti-estrogens that bind to the ER since this 
makes the receptor unavailable for radiotracer binding. Besides, down regulation 
or loss of the ER/PR has been observed during anti-estrogen resistance, which 
also hampers the use of ER-targeted radiotracers.
Concerning CXCR4, ER-negative tumors showed the highest expression. In view 
of the limited therapeutic options for this BC subtype, the use of radiotracers 
targeting this receptor might offer new options for this patient group, particu-
larly in patients progressing on standard of care therapies (usually only chemo-
therapy). However, studies using CXCR4 radiotracers for BC targeting are scant. 
A recent clinical study by Vag et al. (20) reported low to moderate uptake of 68Ga- 
pentixafor in BC lesions. Multiple explanations were given for this observation, such 
as low cell surface expression of the receptor (even though CXCR4 expression in BC 
cells is high, the majority of the receptors might be present inside the cell where they 
are inaccessible for the radiotracer) and high expression of CXCR4 on cancer stem 
cells of which the number present in a tumor seems to differ between BC subtypes. 
Only 3 BC patients were included in this study and no information regarding hormone 
receptor status was provided. More investigations are therefore needed to determine 
the true value of targeting CXCR4 for theranostic purposes.
Once a suitable target has been selected, the question remains which radioligand 
to choose. Although the studies in this thesis did not primarily focus on selecting 
the best radioligand for targeting the studied biomarkers, it is worthwhile to 
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make a few remarks. A successful radioligand should have high affinity for its 
target, good in vivo stability, good tumor retention, as well as low uptake in and 
fast clearance from healthy organs. SSTR2 radioligands have been tested widely 
in the clinic for their application in neuroendocrine tumors. Currently several 
SSTR2 ligands, including DOTATATE, DOTANOC, DOTATOC and DTPA- 
octreotide, that can be labeled with different radionuclides are being applied (21). 
Concerning BC, our studies demonstrated that SSTR2 radioligands with anta-
gonistic properties are more suitable, but these radioligands are not approved 
for clinical use yet. DOTATATE has the highest affinity for SSTR2 and can be 
labeled with 68Ga for PET imaging (Somakit). Since PET imaging is currently the 
most sensitive nuclear based imaging method and high sensitivity is necessary 
to increase the chance of detecting tumors with low and heterogeneous target 
expression, 68Ga-DOTATATE is the best radiotracer for SSTR2 targeted imaging. 
Furthermore, DOTATATE can also be labeled with 177Lu for therapeutic purposes. 
For GRPR radioligands the situation is more complicated. Even though a number 
of radioligands are being explored, currently no GRPR radioligand is approved for 
clinical use. In this thesis 3 GRPR radioligands were used: radio-labeled AMBA, 
JMV4168 and NeoBOMB1. AMBA is a GRPR agonist, while JMV4168 and 
NeoBOMB1 are receptor antagonists. Since radiolabeled agonists might cause 
side effects when used for therapeutic purposes, it was reported that GRPR 
antagonists are more suited for therapy and theranostic purposes. In Chapter 
9, we described the use of a novel GRPR antagonist, NeoBOMB1, which has 
excellent tumor targeting capacity, good tumor to background ratio and favorable 
pharmacokinetics making this radiopharmaceutical promising for theranostic 
applications. Application of this GRPR radioligand in BC patients has not been 
described, but results obtained in prostate cancer patients are promising (22). 
When results of preclinical studies using 177Lu-NeoBOMB1 and 177Lu-JMV4168 
were compared, tumor dose and tumor to kidney ratio were more favorable for 
NeoBOMB1. Recently, another radiolabeled GRPR antagonist, 68Ga-RM2, was 
applied for imaging purposes in BC patients, which resulted in successful visuali-
zation of primary tumors, lymph node lesions and bone metastasis (23). 
Prospects Regarding Targeted Radionuclide Therapy of BC
The studies described in this thesis highlight the potential of targeted radio-
nuclide therapy for treatment of BC in a preclinical setting. According to our 
studies GRPR and SSTR2 are expressed in 96% and 49% of breast tumors, 
respectively, emphasizing that targeting these receptors with radiotracers might 
be beneficial for a large group of BC patients in specific settings.
Targeted radionuclide therapy has not been studied in patients with BC yet. 
However, studies on treatment of neuroendocrine tumors treated with SSTR-
targeting radiotracers reported stable disease and partial remissions in the 
majority of cases (24). Radionuclide therapy should first be tested in BC patients 
with refractory disease and if successful this method can also be considered 
for other patient groups. Also, the combination of targeted radionuclide therapy 
with another form of systemic therapy (either endocrine therapy, HER2-targeted 
therapy, or chemotherapy) might be beneficial. Although, combination treatment 
with SSTR2 or GRPR radiotracers and endocrine therapy, HER2-targeted 
or chemotherapy has not been investigated yet, studies in other cancer types 
showed promising results. One example is treatment with a combination of 177Lu- 
DOTATATE and Capecitabine or Temozolomide, which resulted in an enhanced 
anti-tumor effect in neuroendocrine tumors (25). 
Also, studies on radioresistance of BC cells have identified a few key players in 
this mechanism such as HER2 and the EGFR/PI3K/Akt pathways (26). These 
molecules exhibit at least a part of their radioresistance by facilitating DNA 
repair, enabling cells to survive DNA damage caused by radiation. These studies 
were mostly based on external beam radiation, but the acquired knowledge can be 
used in an attempt to avoid resistance against radionuclide therapy by combining 
the use of radiotracers with radiosensitizers such as lapatinib, a dual inhibitor of 
EGFR and HER2. A recent study by Nonnekens et al. (27) successfully combined 
177Lu-DOTATATE therapy with a DNA repair inhibitor, Olaparib, demonstrating 
the potential of this approach.
Concluding Remarks
To summarize, the studies described in this thesis identified BC subtypes suited 
for targeting of GRPR, SSTR2 and CXCR4, showed feasibility of targeting SSTR2 
and GRPR in BC with radioligands in a preclinical setting and demonstrated 
the potential of radiolabeled SSTR2 antagonists for theranostic use of cancer 
including low SSTR-expressing cancers such as BC. Moreover, important in vivo 
characteristics of a novel GRPR radioligand were studied preclinically, delivering 
a basis for future clinical studies using this radiotracer. 
In the section above we discussed that GRPR might be the more suitable target 
for ER-positive BC, since receptor expression is seen more frequently, at higher 
density, and more homogenously compared to that of SSTR2. One target does not 
serve all however and thus SSTR-targeting can still be beneficial in BC cases that 
lack GRPR. More studies are needed to determine whether there is sufficient cell 
surface expression of CXCR4 for tumor targeting, but if so this method can best 
be applied in ER-negative BCs. Since biomarker expression may change during 
treatment and disease progression, more research is needed to investigate the 
role of these events on target expression. Except for the studied biomarkers, 
other targets are being investigated for targeted-nuclear imaging and treatment. 
These radiotracers are suited for targeting of different BC subtypes and can be 
used for different purposes (e.g. disease monitoring and assessing of treatment 
response), depending on the target. A critical evaluation is needed to select the 
best target for a specific BC subtype and a specific purpose. Concerning therapy, 
future research should explore the use of therapeutic radioligands alone, as well 
as in combination with other treatment modalities currently used (e.g. endocrine 
treatment or chemotherapy) or radiosensitizers. 
Using the theranostic approach in a personalized setting, targeting of GRPR, 
SSTR2 and CXCR4 with radioligands has the potential to play an important role in 
BC care, offering new possibilities for disease monitoring, pre-operative imaging, 
monitoring of therapy response, visualization of regional and distant metastases, 
intra-operative guidance and radionuclide therapy.
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Borstkanker is op één na de meest voorkomende kanker in de wereld en de meest 
voorkomende kankersoort bij vrouwen. De ziekte is erg heterogeen en bestaat 
uit verschillende subtypen, die bepalend zijn voor de behandeling en prognose. 
Verschillende beeldvormingstechnieken (zoals mammografie) en behandelings-
methoden (zoals chirurgie, radiotherapie, hormoon behandeling en chemothe-
rapie) voor borstkanker zijn ontwikkeld en beschikbaar, deze hebben een positief 
effect gehad op het ziekteverloop. De beeldvormingstechnieken en behande-
lingsmethoden die momenteel gebruikt worden in de kliniek hebben echter nog 
steeds een aantal beperkingen en het sterftecijfer als gevolg van de ziekte is 
helaas nog steeds hoog. Het doel van de studies beschreven in dit proefschrift 
is het bestuderen van het gebruik van nieuwe radiofarmaca (radiotracers) voor 
beeldvorming (imaging) en behandeling (radionuclidentherapie) van borstkanker.
In Hoofdstuk 1 van het proefschrift wordt borstkanker beschreven, inclusief de 
karakteristieken van de ziekte en de momenteel toegepaste beeldvormingstech-
nieken en behandelingsmethoden. Vervolgens worden nucleair geneeskundige 
beeldvormingstechnieken en therapieën beschreven. De nucleaire beeldvor-
mingstechnieken die momenteel klinisch worden toegepast voor het in beeld 
brengen van borstkanker (bijvoorbeeld 18F-FDG PET) worden eerst genoemd, 
gevolgd door de introductie van een specifiekere methode die toegepast kan 
worden voor borstkanker imaging. Deze specifiekere methode is gebaseerd op 
het gebruik van radiogelabelde tracers die specifiek gericht zijn tegen molecu-
laire eiwitten die tot (over)expressie komen op kankercellen en niet of in veel 
mindere mate op gezonde/normale cellen. Afhankelijk van het radionuclide 
waarmee deze tracers gelabeld zijn, kunnen de radiotracers ook gebruikt worden 
voor therapeutische doeleinden. Met betrekking tot het laatstgenoemde, wordt 
het theranostisch concept (het gebruik van dezelfde tracer voor zowel beeld-
vorming als therapie) uitgelegd en wordt er een lijst gegeven van radionucliden 
die hiervoor gebruikt kunnen worden. Moleculaire eiwitten die kunnen dienen 
als doelwitten voor radiotracers worden besproken met de nadruk op de “soma-
tostatine receptor subtype 2 (SSTR2)”, de “gastrin releasing peptide receptor 
(GRPR)” en de “C-X-C chemokine receptor type 4 (CXCR4)”. Tenslotte worden 
de potentiele voordelen van deze doelwit-gemedieerde nucleaire beeldvor-
mingstechnieken en radionuclidentherapie besproken. Hoofdstuk 2 geeft een 
overzicht van de moleculaire eiwitten die momenteel worden onderzocht in 
preklinische en klinische studies voor doelwit-gemedieerde nucleaire beeldvor-
ming en bespreekt de (potentiele) voordelen van de verschillende benaderingen. 
Een aantal moleculaire eiwitten wordt bestudeerd als potentieel doelwit, inclusief 
de eerder genoemde SSTR2, GRPR en CXCR4, maar ook hormoonreceptoren en 
de “human epidermal growth factor receptor 2”. Deze doelwitten komen niet 
voor op alle borstkanker subtypen en radiotracers gericht tegen deze moleculaire 
eiwitten kunnen gebruikt worden voor verschillende doeleinden. De heterogeni-
teit van borstkanker vraagt om een persoonsgerichte benadering, waarbij indien 
doelwit-gemedieerde nucleaire middelen hun toepassing vinden in de dagelijkse 
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praktijk er een zorgvuldige afweging moet worden gemaakt voordat een radio-
tracer gericht tegen een specifiek doelwit wordt gekozen. Hierbij moeten de 
voordelen en beperkingen van de verschillende methoden goed in acht worden 
genomen.
In het tweede gedeelte van het proefschrift ligt de focus op de klinische rele-
vantie van SSTR2, GRPR en CXCR4-gemedieerde imaging en therapie bij borst-
kanker patiënten met als voornaamste doel het identificeren van borstkanker 
patiëntengroepen en doeleinden geschikt voor de applicatie van deze methoden. 
In Hoofdstuk 3 worden SSTR2, GRPR en CXCR4 mRNA expressie levels van 
915 primaire borsttumoren gecorreleerd aan klinisch-pathologische factoren, 
biologische factoren en prognose. Om aan te tonen dat mRNA expressie repre-
sentatief is voor radiotracer binding aan tumor celen, is voorafgaand in een kleine 
set borsttumoren eiwitexpressie van SSTR2 en GRPR gemeten door middel van 
autoradiografie studies. De resultaten van de autoradiografie studies zijn gecor-
releerd aan mRNA expressie, resulterend in significante correlaties. Hieruit 
hebben wij geconcludeerd dat SSTR2 en GRPR mRNA expressie representa-
tief was voor SSTR2 en GRPR eiwitexpressie. Helaas was het voor CXCR4 niet 
mogelijk een dergelijke correlatie aan te tonen door gebrek aan een geschikte 
radiotracer, maar eerder gepubliceerde studies toonden aan dat CXCR4 mRNA 
expressie ook representatief is voor CXCR4 eiwitexpressie. De correlatie van 
SSTR2, GRPR en CXCR4 mRNA expressie met borstkanker karakteristieken 
toonde aan dat oestrogeen receptor (ER)-positieve tumoren het meest geschikt 
zijn voor SSTR2 en GRPR-gerichte imaging en therapie, terwijl CXCR4 juist 
in ER-negatieve tumoren een toepassing zal hebben omdat het in deze borst-
kanker subgroep op mRNA niveau het hoogst tot expressie komt. Met betrek-
king tot prognose, was een hoge CXCR4 expressie geassocieerd met een betere 
ziektevrije- , metastasevrije- en totale overleving. Deze laatste bevinding was 
onverwacht omdat hoge CXCR4 expressie geassocieerd is met ER-negatieve 
tumoren, de meeste agressieve borsttumoren. Een mogelijke verklaring is dat 
er een andere factor is, onafhankelijk van ER expressie, die bepalend is voor een 
goede prognose van deze patiënten groep. SSTR2 expressie was niet significant 
geassocieerd met prognose terwijl hoge GRPR mRNA expressie levels waren 
geassocieerd met een verlengde progressie vrije overleving na behandeling met 
hormoon therapie met tamoxifen. Uitgezaaide borstkanker is ongeneeslijk, de 
uitzaaiingen vormen de voornaamste reden voor sterfte als gevolg van de ziekte. 
Derhalve zijn betere visualisatie en betere behandelingsopties van borstkanker-
metastasen heel belangrijk om de kwaliteit van leven ten gevolge van de ziekte 
te verbeteren. In Hoofdstuk 4 hebben wij SSTR2, GRPR en CXCR4 mRNA 
expressie van 60 primaire borsttumoren en bijbehorende metastasen (zowel 
metastasen in regionale lymfeklieren als afstandsmetastasen in onder andere 
de hersenen, longen, lever en eierstokken) onderzocht. mRNA expressie levels 
van primaire tumoren en gepaarde metastasen zijn met elkaar vergeleken, wat 
resulteerde in vergelijkbare GRPR en CXCR4 mRNA expressie niveaus van 
primaire tumoren en bijbehorende metastasen. Echter, SSTR2 mRNA expressie 
in lever- en eierstok metastasen was significant lager dan dat in de primaire 
tumoren (P=0.02 en P=0.03, respectievelijk). Bovendien was hoge SSTR2 
en GRPR expressie geassocieerd met ER-positieve tumoren en hoge CXCR4 
expressie met ER-negatieve tumoren. Dit is in overeenstemming met hetgeen 
gevonden in Hoofdstuk 3. In een enkele gevallen was ER-status van de primaire 
tumor niet gelijk aan de ER-status van de gepaarde metastase. Dit verschil in 
ER-status was van invloed op de SSTR2 en GRPR expressie, waarbij de SSTR2 
en GRPR expressie de ER-status van de metastase lijkt te volgen. Een discre-
pantie in ER-expressie tussen primaire tumoren en metastasen komt in ongeveer 
14% van de borstkanker patiënten voor en de daarmee gepaarde verandering in 
GRPR expressie moet in gedachte worden gehouden als GRPR als doelwit wordt 
gebruikt voor imaging en/of therapie. Op basis van deze bevindingen hebben wij 
geconcludeerd dat SSTR2, GRPR en CXCR4 goede doelwitten zijn voor thera-
nostische doeleinden in zowel primaire als uitgezaaide borstkankers, waarbij 
gezegd moet worden dat het borstkankersubtype in acht moet worden genomen 
bij de keuze van het doeleiwit.
In het volgende gedeelte van het proefschrift ligt de focus op SSTR2-gemedieerde 
imaging van borstkanker. Hoofdstuk 5 is een review van eerder gepubliceerde 
klinische studies over SSTR2-gemedieerde imaging van borstkanker, waarvan 
het merendeel van de studies meer dan 10 jaar geleden is uitgevoerd. Het doel 
van de review was het kritisch analyseren van de methoden, bevindingen en 
beperkingen van deze klinische studies, om zodoende te bepalen of de recentere 
ontwikkelingen op het gebied van nucleaire geneeskunde kunnen leiden tot 
verbetering van de resultaten. Samenvoeging van de resultaten van de geanaly-
seerde studies resulteerde in een sensitiviteit van 36-100% en een specificiteit 
van 22-100% voor SSTR2-gemedieerde borstkanker imaging. De voornaamste 
beperking van eerder gerapporteerde studies was een lage en heterogene SSTR2-
expressie in de tumoren. Planaire beeldvorming was de voornaamste beeldvor-
mingstechniek gebruikt in deze vroege studies, octreotide of depreotide werd 
gebruikt als somatostatine analoog en er werd geen onderscheid gemaakt tussen 
de verschillende borstkanker subtypen. Er is veel ontwikkeling geweest op het 
gebied van beeldvormingstechnieken (bijvoorbeeld SPECT, PET of de daarvan 
afgeleide toegewijde mamma camera’s) en somatostatine-analoga (receptor-
agonisten en receptor-antagonisten met hogere affiniteit voor de SSTR2). Voorts 
is de kennis over SSTR2-expressie in relatie tot de verschillende borstkanker 
subtypen toegenomen. Deze ontwikkelingen kunnen SSTR2-gemedieerde borst-
kanker-imaging gunstig beïnvloeden. Derhalve is nieuw onderzoek nodig met 
toepassing van de nu beschikbare kennis en technieken. Als SSTR2-gemedieerde 
imaging van borstkanker succesvol blijkt, kan deze methode ook gebruikt worden 
voor therapie. Één van de ontwikkelingen op het gebied van SSTR2-gemedieerde 
imaging is het gebruik van SSTR2 antagonisten. Uit recente preklinische en 
klinische studies blijkt dat SSTR2 antagonisten beter zijn dan SSTR2 agonisten 
voor het in beeld brengen van SSTR2-positieve tumoren, ondanks de accumu-
latie van SSTR2 agonisten in kankercellen. Dit verschijnsel wordt verklaard door 
het vermogen van de antagonist om te binden aan meer bindingsplaatsen/recep-
toren dan de agonist. Omdat lage en heterogene SSTR2 expressie een beper-
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kende factor is voor succesvolle SSTR2-gemedieerde imaging kan de applicatie 
van radiogelabelde SSTR2 antagonisten gunstig zijn. In Hoofdstuk 6 hebben 
we het gebruik van een SSTR2-agonist, Tyr3-DOTA-octreotate, en een SSTR2-
antagonist, DOTA-JR11, vergeleken in 40 humane borstkankerweefsels en in een 
orthotoop borstkankermuismodel. Binding van 11In-DOTA-JR11 aan de borst-
kankerweefsels was significant hoger (P<0.001) dan dat van 111In-DOTA-Tyr3-
octreotaat. De verhouding antagonist- vs. agonist-binding verhield zich van 1 
(slechts in 1 geval aangetoond) staat tot 57. SPECT/MR imaging studies in het 
muismodel resulteerde in een betere tumor visualisatie na injectie van de antago-
nist 177Lu-DOTA-JR11 vs. de agonist 177Lu-DOTA-Tyr3-octreotaat. De resultaten 
van biodistributie studies, uitgevoerd na het scannen, bevestigde een hogere 
opname van de antagonist in de tumorweefsel. Deze resultaten leidden tot de 
conclusie dat SSTR2 antagonisten zoals DOTA-JR11, SSTR2-gemedieerde borst-
kanker-imaging kunnen verbeteren en potentieel ook gebruikt kunnen worden 
voor therapie doeleinden. Studies hebben bewezen dat radiogelabelde SSTR2-
antagonisten beter zijn voor imaging doeleinden, maar over de toepassing van 
SSTR2-antagonisten voor therapie is nog weinig bekend. Een groot voordeel 
van deze radiotracers is dat ze voor zowel imaging en therapie gebruikt kunnen 
worden. Daarom hebben wij in Hoofdstuk 7 het gebruik van 77Lu-DOTA-JR11 
en 177Lu-DOTA-octreotaat voor therapie doeleinden vergeleken in een prekli-
nische setting. Hiervoor hebben wij in vitro opname studies en DNA schade-
analyses (53BP1 is gebruikt als indirecte meting voor DNA schade) gedaan in een 
cellijn getransfecteerd met de SSTR2 (U2OS+SSTR2). Verder hebben wij in vivo 
therapie experimenten gedaan in Balb c muizen met H69 (een SSTR2-positieve 
long kanker cellijn) xenograft tumoren. De gemeten opname van de antagonist in 
U2OS+SSTR2 cellen was 5 keer hoger dan die van de agonist en de DNA schade 
veroorzaakt door 177Lu-DOTA-JR11 was 2 keer hoger dan die veroorzaakt door 
177Lu-DOTA-Tyr3-octreotaat. In vivo therapie studies na injectie van de optimale 
peptide hoeveelheid van de radiotracers resulteerde in een langere tijd tussen 
de start van de therapie en tumor hergroei. Voorts was er een betere mediane 
overleving na therapeutische injectie van177Lu-DOTA-JR11 in vergelijking met 
177Lu-DOTA-Tyr3-octreotaat. De bovengenoemde bevindingen leidden tot de 
conclusie dat SSTR2-antagonisten beter zijn dan SSTR2-agonisten voor zowel 
imaging als behandeling. Dit is vooral interessant voor kankersoorten met een 
relatief lage SSTR2-expressie zoals borstkanker.
De laatste sectie van het proefschrift heeft als focus de applicatie van GRPR-
radiotracers voor theranostische doeleinden. In Hoofdstuk 8 is de applicatie 
van GRPR-radioliganden voor imaging en therapie van borstkanker bestudeerd 
in een preklinische setting. Allereerst is de binding van een radiogelabeld 
GRPR-agonist, 11In-AMBA, aan 50 humane borstkanker weefsels geanalyseerd 
en geassocieerd met ER-expressie van de tumoren. De radiotracer kon aan de 
meerderheid (96%) van de tumoren binden, wat impliceert dat deze tumoren 
GRPR tot expressie brengen. De binding van de radiotracer was positief gecor-
releerd met ER-expressie. Vervolgens is dezelfde radiotracer gebruikt in in vitro 
opname studies voor het bepalen van GRPR-expressie van 10 borstkankercel-
lijnen. De meerderheid van de cellijnen lieten opname van de radiotracer zien. 
De 2 cellijnen met de hoogste radiotracer opname, T47D en MCF7 (beide ER 
positief) zijn gebruikt voor vervolg studies. T47D is gebruik voor in vitro studies, 
waarbij de cellijn is behandeld met verschillende concentraties 177Lu-AMBA, 
resulterend in een significante vermindering (tot aan 80%) van het aantal cellen 
na behandeling. Dit effect van de radiotracer op de cellen werd niet waargenomen 
na incubatie met het radionuclide alleen of met het niet radiogelabeld ligand. Ook 
zijn er in vivo biodistributie- en imaging studies gedaan bij muizen na subcutane 
en orthotope inoculatie met T47D- of MCF7-cellen. Na tumorvorming zijn de 
muizen geïnjecteerd met een GRPR antagonist, 111In-JMV4168 + phosphor-
amidon (een enzymremmer die afbraak van het radioligand tegen gaat), en is een 
SPECT scan gemaakt. Zowel T47D- als MCF7-tumoren waren duidelijk zichtbaar 
op de scan, maar opname was hoger in T47D- ten opzichte van MCF7-tumoren. 
De hogere opname in T47D-xenografts werd bevestigd in biodistributie studies. 
Op basis van bovengenoemde resultaten concluderen wij dat GRPR radioliganden 
veelbelovend zijn voor nucleaire beeldvorming en therapie van GRPR-positieve 
borsttumoren. In het laatste hoofdstuk (Hoofdstuk 9) is het gebruik van een 
nieuwe GRPR-radiotracer, NeoBOMB1, getest voor theranostische doeleinden. 
In 2 in vivo studies, uitgevoerd in een prostaatkanker (PC3) xenograft muismodel, 
is de biodistributie van 177Lu- en 68Ga-gelabeld NeoBOMB1 getest. Ook zijn er 
imaging studies (zowel SPECT en PET) uitgevoerd na injectie van de radio- 
tracers. De verworven data zijn gebruikt om de farmacokinetiek, muizendosime-
trie en patiëntendosimetrie te voorspellen. In het geval van 177Lu-NeoBOMB1 is 
het gebruik van 2 verschillende peptiden hoeveelheden (10 pmol en 200 pmol) met 
elkaar vergeleken om de peptide hoeveelheid te vinden met de ideale verhouding 
tussen tumor opname ten opzichte van opname in andere organen. De opname 
van zowel 68Ga-NeoBOMB1- als 177Lu-NeoBOMB1 in tumoren was goed. Radio-
tracer-opname was ook te zien in de GRPR-positieve pancreas en in de nieren. 
Het laatste als gevolg van renale uitscheiding van de radiotracers. Radiotracer 
klaring uit de pancreas en de nieren verliep relatief snel, terwijl de tumor-opname 
langer behouden bleef. Met betrekking tot de 2 verschillende hoeveelheden 
177Lu-NeoBOMB1 die getest werden, resulteerde de hogere peptide dosis in 
een betere biodistributie (een hogere tumor opname en een lagere opname in 
andere organen) dan de lage peptidemassa. Zoals verwacht op basis van boven-
staande resultaten, resulteerde dit in een hoge radionuclidedosis in de tumor 
en een lagere dosis in overige organen. De waarden verkregen na voorspelling 
van de patiëntendosimetrie waren vergelijkbaar met de waarden gerapporteerd 
voor de klinisch succesvol gebruikte 177Lu-DOTA-Tyr3-octreotaat. De SPECT 
en PET imaging studies resulteerden in goed zichtbare tumoren op de scans. 
Gebaseerd op de verkregen data concluderen we dat zowel 68Ga-NeoBOMB1 
en 177Lu-NeoBOMB1 uitstekende tumor-opname en goede farmacokinetische 
eigenschappen hebben voor theranostisch gebruik. Hoewel deze studies in een 
prostaatkanker-model zijn uitgevoerd, zijn de bevindingen ook veelbelovend voor 
applicatie van de radiotracer voor imaging en therapie van borstkanker.
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